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SOME hae meet, and canna eat, 
And some wad eat that want it, 
But we hae meat and we can eat, 
And sae the Lord be thankit. 
Robert Burns (1759-1796) 
Summary 
The mucosal regulation of the systemic immune response to cholera toxin 
was investigated in inbred adult BALB/c mice. 
Specific systemic humoral immunity to parenterally administered toxin 
and an immunopurified, formalinised, antigenically cross-reactive 
toxoid was measured using isotype-specific enzyme-linked immunosorbent 
assays. Systemic delayed-type hypersensitivity (DTH) was shown to 
occur under similar experimental conditions by direct skin testing and 
histological examination of the sites of antigenic challenge. The 
passive transfer of DTH with sensitised, draining, peripheral lymph 
node cells and the specific inhibition of the in vitro migration of 
these cells in the presence of antigen confirmed that systemic cell- 
mediated immunity had been induced. 
A single feed of either the toxin or toxoid was able to inhibit the 
induction of systemic DTH but did not tolerise specific systemic 
antibody levels. Oral tolerance to these antigens was found to be both 
antigen-specific and dose-dependant. The induction of tolerance was 
inhibited by the pretreatment of animals with a single dose of 
cyclophosphamid e two days before feeding. 
Splenic T lymphocytes, obtained 7 days after feeding, were able to 
transfer tolerance for systemic 0TH to syngeneic recipients. Cells 
with similar properties were also present in the mesenteric lymph nodes 
at 7 days but were not detected in either tissue 3 days after a single 
feed of antigen. Transferring these cells at various times after the 
immunisation of recipients revealed that they inhibited the afferent 
limb of the DTH response. Feeding mice did not suppress mature DTH 
effector cell function. 
Oral tolerance for DTH could also be transferred by serum obtained from 
animals fed one hour previously. This phenomenon could be abrogated by 
pretreating recipients with cyclophosphamide. The serum tolerogen did 
not induce the splenic suppressor T cells found earlier. 
These findings are discussed in the light of present knowledge and the 
methods used in this project are critically reviewed. 
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Introduction to Experiments 
Cholera toxin is the soluble exotoxin secreted by the enteric pathogen, 
Vibrio choleree. As a consequence of this, cholera toxin is normally 
only encountered via the gastrointestinal tract. However, cholera 
toxin is by no means a typical antigen. It has certain biochemical 
properties which separate it from other proteins and induce the profuse 
diarrhoea which characterises the disease it causes. 
The study of this toxin is therefore of great interest to immunologists 
for several reasons. Firstly, choleragen is an extremely potent 
antigen capable of evoking a marked immune response with only microgram 
quantities. Secondly, toxoids exist which are immunologically cross- 
reacive but lack the other properties of the holotoxin and so allow the 
examination of the role of its toxicity in the modulation of immune 
responses. Finally, although a vaccine has been recently developed 
which confers good protection, at least in the short term, the 
mechanism by which the onset of diarrhoea is prevented Is still 
uncertain. 
Antitoxin antibodies have not been shown to be protective except in the 
short term and there is evidence that other antigen-specific mechanisms 
may be responsible for the control of choleraic diarrhoea. 
Histopathological examination of infected Intestine, from both animals 
and humans, suggests that mucosal cell-mediated immunity (CMI) may be 
important in the long term protection against this disease but this 
limb of the potential immune reponse to choleragen has never been 
evaluated. By far the most common outcome of feeding soluble protein 
antigens is the induction of oral tolerance yet choleragen is a notable 
exception to this rule. If the mechanism(s) by which this disease is 
prevented is to be elucidated all potentially protective effector 
mechanisms must be evaluated and the regulation of such mechanisms must 
also be assessed. Accordingly, the aim of this thesis has been to 
examine both cell-mediated and humoral immune responses to choleragen, 
the role of choleragen's toxicity in immunity, the mucosal regulation 
of such responses and finally their comparison with the results 
obtained for more usual soluble protein antigens. 
Whet is the systemic immune response to cholera toxin? 
It has been established that choleragen can induce good systemic 
antitoxin antibody responses and, in addition to confirming this, 
experiments were designed to examine the capacity of this antigen to 
induce a delayed-type hypersensitivity (DTH) reaction. A simple 
protocol was employed where adult BALB/c mice were parenterally 
immunised with toxin in adjuvant and having been challenged 
intradermally with antigen were examined for DTH by direct skin 
testing. DTH was assessed in great detail and the ontogeny, histology 
and specificity of the swelling response was examined. 
Serum was obtained for antitoxin antibody analysis throughout the 
experiment so both effector limbs of the immune response to choleragen 
could be assessed simultaneously. This has never been done before. 
Is cholera toxoid antigenically distinct from the toxin? 
As both toxin and a forminalised immunopurified toxoid were used to 
immunise animals it seemed logical to measure both anti-toxoid and 
antitoxin antibody responses in these animals. Enzyme-linked 
immunosorbent assays were developed for this purpose using 
modifications of existing techniques. Despite the current availability 
of these assays, no experiments have been done to examine the effects 
of detoxification on antigenicity in this way and this novel approach 
has produced interesting findings about the effect of formalinisation 
on antigenicity. 
Does cholera toxin induce cell-mediated immunity? 
Besides DTH, other aspects of CMI were examined. Firstly, primed 
lymphocytes, obtained from the draining lymph nodes of immunised 
animals, were tested for their ability to transfer DTH to naive 
syngeneic recipients in the presence of antigen. These cells were also 
specifically depleted of certain lymphocyte subclasses to ascertain the 
lineage of the effector cell. Secondly, an in vitro assay was 
developed using primed lymphocytes to measure the production of certain 
lymphokines. 
Does cholera toxin induce oral tolerance? 
Varying doses of cholera toxin and toxoid were fed to examine their 
ability to induce oral tolerance. Using these two forms of the same 
antigen, the role of enterocyte binding and enzyme activation could be 
established in the mucosal regulation of systemic immunity. 
Furthermore, unrelated protein antigens were used to examine the 
specificty of observed responses. 
Does feeding cholera toxin induce regulatory cells? 
The cells regulating the systemic antibody response after feeding 
choleragen have been characterised elsewhere and experiments were 
designed to examine the regulation of specific DTH. In order to 
elucidate the mechanism(s) by which enterically encountered choleragen 
may alter the subsequent induction of systemic immunity, a series of 
studies were performed using both the transfer of lymphoid cells and 
the depletion of certain cell types by pharmacological and 
immunological means. 
Do several mechanisms operate in the induction of oral tolerance to 
choleragen? 
Recent evidence suggests that passage through the gastrointestinal 
tract may alter the immunogenicity of dietary proteins rendering them 
tolerogenic. Serum transfer experiments were used to investigate the 
intestinal 'processing' of choleragen. The relationship between this 
postprandial serum fragment and the induction of regulatory lymphocytes 
was also examined. 
Chapter 1 
IMMI RESPONSES TO CHOLERA TOXIN AND ITS DETOXIFIED DERIVATIVES 
2 
In this chapter I propose to review the literature on the effect of 
cholera toxin on the immune system. Some of these effects are due to 
Its antigenic nature but the toxin may also modulate immune responses 
by its ability to influence cyclic adenosine monophosphate (cAMP) 
levels within cells. As these actions are related to its structure and 
biochemical properties, these will also be reviewed. 
A number of attempts have been made to produce an immunologically 
cross-reactive toxoid either by isolating natural ly-occurring toxoid 
(choleragenoid) or by modifying the toxin to render it less toxic. I 
shall also review these detoxification procedures as well as comparing 
the immune responses to these toxoids with those to the native toxin. 
Ll The Structure of Cholera Toxin 
Cholera toxin is a protein of molecular weight 82,000. The holotoxin 
is composed of two different subunits, termed A and B. Each toxin 
molecule has five B subunits each weighing 11,500. The toxic A subunit 
component is secreted as a single polypeptide but is rapidly cleaved by 
a proteolytic enzyme into two peptides, Al and A2 (Mr 22,000 and 5,000 
respectively), which are covalently linked by a single disulphide bond. 
The A subunit is linked to the pentameric B subunit structure through 
the A2 peptide. 
Cross-linking studies, electron micrographs and preliminary x-ray 
diffraction data suggest that the B subunits form a symmetrical ring 
3 
with the A subunit in the midst of them. In this proposed structure 
the A2 linking peptide lies in the same plane as the B subunits with 
only the Al peptide protruding from the rest of the molecule (van 
Heyningen, 1983). 
L2 The Biochemical Action of Cholera Toxin 
Each of the subunits of cholera toxin serve different functions. The B 
subunit pentamer is responsible for binding the toxin to the surface of 
cells. Several workers have demonstrated that the B subunits bind 
preferentially to the GM1 ganglioside component of cell membranes 
(Cuatrecasas, 1973; Gill & King, 1975; King & van Heyningen, 1973; 
Moss, Fishman, Mangeniello, Vaughan & Brady, 1976). When this receptor 
is bound, the B subunits undergo a conformational change (Moss, 
Osborne, Fishman, Brewer, Vaughan & Brady, 1977). Furthermore, van 
Heyningen (1982) has shown that the conformational change that occurs 
in B subunits during binding is transmitted to the A subunit. 
The Al peptide is capable of activating adenylate cyclase on its own, 
but to do so it must penetrate the cell membrane. This process is 
probably facilitated by the B pentamer. There are several theories 
regarding the mechanism by which the cell membrane is penetrated. One 
is that a hydrophillic tunnel is formed between the B subunits and a 
pre-existing cellular carrier protein which allows entry of the Al 
peptide (Gill, 1978). Another is that the binding of the B subunits 
Increases the chance of random entry of the Al peptide. It has been 
4 
suggested that binding may release the peptide from the holotoxin by 
virtue of the conformational changes induced in the molecule. The most 
recent theory is that the A subunit may enter cells by endocytosis. 
Manuelidis and Manuelidis (1976) and Hansson, Holmgren and Svennerholm 
(1977) have shown that membrane-bound toxin is partly endocytosed. 
Other workers have shown that drugs inhibiting receptor internalisation 
and lysosomal processing also inhibit adenylate cyclase activation in 
intact HeLa cells and hepatocytes (Lin & Taniuchi, 1980; Houslay & 
Elliott, 1981). Unfortunately, there is no direct evidence to support 
any of the above ideas. 
During cell entry, or soon after it, the disulphide bond connecting the 
two fragments of the A subunit is split to generate the enzymatically 
active reduced Al fragment. This peptide catalyses the mono ADP- 
ribosylation of the protein Ns, which is a regulatory component of the 
adenylate cyclase system, present in the plasma membrane of most 
mammalian cells and displayed on the cytoplasmic surface. This 
reaction is essentially irreversible under physiological conditions and 
leads to a series of changes in the protein's properties. Of these, it 
is the reduced ability to hydrolyse guanine nucleotide triphosphate 
(GTP) that results in an elevated adenylate cyclase activity and an 
increase in intracellular cAW levels. In order for ADP ribosyletion 
to occur, GTP is required to bind to a separate site on the cell 
membrane, termed 'S', in a cooperative event that involves a soluble 
protein called cytosolic factor (Gill & Woolkalls, 1985). 
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The consequence of increased intracellular cAMP levels is determined by 
the type of cell in which the change occurs. This explains why toxin- 
treated fat cells release lipid, liver cells convert glycogen into 
glucose and adrenal cells produce steroid hormone (Greenough, Pierce & 
Vaughan, 1970; Zieve, Pierce & Greenough, 1970; Donta, 1974). In 
addition, these biochemical effects have been held responsible for 
alterations in lymphocyte function but these will be discussed in more 
detail later on in this chapter. 
In the enterocyte, raised cAMP levels, either directly or by the effect 
on intracellular Ca2* levels, affects electrolyte transport (Frizzell, 
Field & Schultz, 1979; Ilundain & Naftalin, 1979). In vitro data 
suggest that these mediators, via activation of protein kinases, have 
two principal effects on electrolyte transport. They inhibit the 
neutral NaCl absorption mechanism and they create anion conductance 
channels in the apical membrane of the crypt cell which allows chloride 
ions to go from the cell to the crypt lumen down an electrochemical 
gradient (Powell, Berschneider, Lawson & Martens, 1985). It is these 
processes that are thought to be ultimately responsible for the profuse 
diarrhoea typical of cholera. 
1.3 Immunological Response to Cholera Toxin 
In order to give an account of the development of the study of the 
immunology of cholera toxin, one must first describe how it was 
appreciated that the disease could be experimentally transferred 
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without the need for transfer of the causative microbe and that immune 
responses to the toxin were protective yet separate from the immune 
response to the vibrio. 
In 1883, Koch identified the Vibrio cholerae as the causative agent of 
cholera and a few years later proposed that the disease was toxin- 
mediated. The confirmation of an exotoxin was supplied independently 
by two Indian researchers, De and Dutta in 1959 (De, 1959; Dutte, Panse 
& Kulkarni, 1959). 
This disease was shown to cause an immune response in the host, one of 
the earliest reports being Metchnikoff's observation that there was a 
rise in the patient's bacteriolytic titre during convalescence 
(reviewed: Pollitzer & Burrows, 1959). Craig (1965a, 1965b, 1966) 
reported the presence of a factor in cholera stools and in filtrates of 
certain broth cultures of Vibrio choleree which produced induration, 
erythema and increased capillary permeability at the site of 
intradermal injection in Guinea-pigs or rabbits, reaching a peak at 18- 
24 hours. He observed that the convalescent sera from confirmed 
cholera cases were able to neutralise this factor but not human sera 
with high agglutination titres evoked by commercial cholera vaccine. 
Sera from rabbits, obtained after prolonged immunisation with agar- 
grown living vibrios, were also able to neutralise this toxic factor 
(Feeley, 1966). Furthermore, It had been noticed that in cholera cases 
not treated with antibiotics, the time at which antibody appeared in 
the blood seemed to correlate well with the time that symptoms abated 
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(Greenough, Gordon, Rosenberg, Davis & Benenson, 1964). Later work 
questioned whether this toxic factor was separate antigenically from 
the vibrio which produced it as high toxin-neutralisation titres were 
noted amongst children under 15 years of age without vibriocidal or 
agglutinating antibodies (Benenson, Saad, Mosely & Ahmed, 1968). Also, 
available whole cell vaccines which we re toxin-free did not stimulate 
antitoxin responses in recipients. 
The suggestion that antitoxin may play a role in recovery from disease 
has led to a number of workers examining the humoral responses to 
cholera toxin in humans and animal models of cholera infection. 
Central to this investigation has been the development of numerous 
assays of antitoxic immunity. 
1.4 The Measurement of Anti-Cholera Toxin Responses 
The plethora of tests of antitoxic immunity described in the literature 
makes it necessary for a brief summary to be mentioned here. 
Assays of the immune response to cholera toxin fall into two main 
categories: 
a. Bioassays of the response to cholera toxin 
Cholera toxin's ability to modulate intracellular levels of cAMP 
produces a number of different effects depending on the biological 
B 
system used. The inhibition of these effects by prior incubation of 
the toxin with antitoxin provides the basis for the measurement of 
neutralising antibody in an unknown system. This may be quantified 
either in terms of amount of toxin neutralised or more usually in 
comparison to a reference serum containing a known amount of antitoxic 
activity. 
This reasoning has been used in the skin permeability factor assay 
(also called the limit of blueing assay) (Craig, 1965a; Benenson 
et a1,1968; Craig, Eichner & Hornick, 1972), the isolated fat cell 
assay (Greenough, Pierce & Vaughan, 1970), the mouse adrenal tumour 
cell assay (Donta, 1974) and the S49-1 lymphocarcinoma cell assay 
(Ruch, Murphy, Graf & Field, 1978). In all these assays, serum from 
one animal is assayed using cells or tissues from another, either in 
vitro or in vivo. 
The intestinal loop assay is different from this. It depends on the 
measurement of fluid accumulation within a closed loop of bowel after 
challenge with either cholera toxin or live vibrios (De & Chatterje, 
1953; Kasai & Burrows, 1966; Pierce, Banwell, Sack, Mitra & Mondal, 
1970). It may be performed using jejunal or ileal loops of bowel and 
has been used in rabbits, rats and mice (Aziz, Moshin, Hare & Phillips, 
1968; Svennerholm, Lange & Holmgren, 1980). The Importance of this 
assay is that it may be performed as an inhibition test, like those 
above, measuring the antitoxin content of an unknown serum or It may be 
used as a measure of specific protection to toxin/vibrio challenge 
within the host animal. This test has several limitations. Firstly, 
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when used as an inhibition test (and this applies equally to the other 
inhibition assays) this method does not take into account the isotype 
or avidity of neutralising antibody and is thus a very indirect measure 
of humoral response. This assay is an appropriate measure of local 
protection in the host. However, to infer that the observed protection 
in vivo is a direct consequence of an antibody-mediated response should 
be exercised with caution. 
The footpad oedema model is another bioassay used to measure an 
antitoxic response in the host animal (Finkelstein & Hollingsworth, 
1970). 
The most recent assay of local protection at the gut level has been the 
introduction of an assay for mucosal adenylate cyclase activity 
(Liönnroth & Lange, 1981). This test measures the response of this 
enzyme to cholera toxin or other stimulants by the rate of manufacture 
of cAMP in vitro. 
b. bumunological assays of the response to cholera toxin 
These tests may be used to measure the humoral response directly. They 
can be broadly subdivided into two groups. 
(i) Those tests which measure the limits of antibody directly. 
Originally this was done by passive haemagglutination of sensitised 
sheep red blood cells (Hochstein, Feeley & Richardson, 1970; Hochstein, 
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Feeley & DeWitt, 1970; Finkelstein & Peterson, 1970) but is being 
increasingly replaced by radioimmunoassay (Hejtmancik, Peterson, Markel 
& Kurovsky, 1977) and enzyme-linked immunosorbent assays (Holmgren & 
Svennerholm, 1973; Young, Levine, Craig & Robbins-Browne, 1980; 
Svennerholm & Holmgren, 1978). 
(ii) Those test which measure antibody producing cells. 
This includes assays of isotype specific plaque-forming cells (Lycke, 
Lindholm & Holmgren, 1983), antitoxin-containing cells (Pierce & 
Gowans, 1975) or spot-forming cells (Czerkinsky, Nilsson, Nygren, 
Ouchterlony & Tarkwoski, 1983). 
The original antitoxin-containing cell assay employed successive 
incubations with purified cholera toxoid and then a fluorescein- 
labelled detecting antibody to detect positive cells. The authors 
realised that the ability of toxin to bind to most eukaryotic cells 
would lead to the detection of false positive results if it was used. 
More recent papers (Lange, LEnnroth & Nygren, 1984a; Lange, 
Lännroth & Nygren, 1984b; Lbnnroth, Lange & Hansson, 1984) have 
used purified cholera toxin in this test and thus their estimations of 
antitoxin-containing cells may be inaccurate. This same criticism 
applies to the spot-forming cell assay of Czerkinksy et al, 1983. 
The final test of humoral immunity is the assay of antigen-specific 
immunoglobulin production by lymphoid tissues in culture following 
their removal from an immunised host. This assay has been used in 
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rabbits (Svennerholm & Holmgren, 1977) and mice (Svennerholm, Lange & 
Holmgren, 1980) and has the advantage of localising the site of 
production of any particular antibody isotype. However, all in vitro 
tests must be applied to the In vivo situation with caution. 
1.5 kvvmne Responses in Humans after Enteric Exposure to Cholera Toxin 
As Vibrio cholerae is an intestinal pathogen, it is via the enteric 
route that cholera toxin is usually encountered. 
This section will 
deal with the antibody responses of humans after enteric exposure to 
cholera toxin as part of a clinical infection. Antitoxic responses in 
serum and at the mucosal level will both be considered. 
Benenson and his co-workers (1968) reported that serum antitoxin 
neutralisation titres were relatively high amongst Bangladeshi children 
even in the absence of vibriocidal and agglutinating antibodies. He 
noted that this titre increased with the presence of cholera infection. 
This report appears to be at variance with workers in Calcutta, who 
showed no change in serum IgG or IgA antibodies occurred during disease 
but a significant rise in IgA titres were seen during convalescence 
(Waldman, Bencik, Sakazaki, Sinha, Ganguly, Deb & Mukerjee, 1971). 
However, the antigen specificity of these antibodies was not determined 
so a rise in neutralisation titres is still possible in these patients. 
Later studies confirmed that IgG antitoxin titres, although no use in 
screening a Bangledeshi population for its cumulative exposure to V. 
cholerae, were a sensitive index in the detection of recent infection. 
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Serum IgA antitoxin titres were of little value in predicting 
colonisation or disease (Glass, Svennerholm, Khan, Huda, Huq & 
Holmgren, 1985). 
Levine and his co-workers pointed out that interpretation of 
seroepidemological studies of cholera varies greatly for populations in 
endemic or non-endemic areas (Levine, Young, Hughes, O'Donnell, Black, 
Clements, Robbins-Browne & Lim, 1981). Endemic areas have high 
background titres of antitoxin due both to the prevalence of infection 
(clinical and subclinical) and due to immunological cross-reactivity 
with the toxins of other organisms prevalent in those areas (Holmgren, 
Sdderlind & Wadstrom, 1973). In non-endemic areas few people have 
background titres of antitoxin. After challenge with V. cholerae or 
natural infection, most become ill and exhibit a rapid rise in 
antitoxin titres, often to high levels. Antitoxin titres return to 
baseline in 1 to 2 years. 
This is in agreement with a study of American volunteers who had had 
cholera between 4 and 12 months earlier. These people exhibited higher 
neutralisation titres than uninfected controls but their 
haemagglutination antibody levels were not significantly different. 
This study confirmed earlier reports that antitoxin levels did not help 
predict the clinical outcome of an oral challenge with live vibrios 
(Cash, Music, Libonati, Craig, Pierce & Hornick, 1974). 
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Early analysis of the immunoglobulin content of stools from 
convalescent patients showed the presence of IgA, IgG and IgM 
antibodies. Although some of the IgA was of the 11s size most of the 
IgA was 7s. Smaller fragments of IgA were also detected. In addition, 
IgG and IgM coproantibody showed signs of enzymatic degradation 
(Northrup, Bienstock & Tomasi, 1970). Improved enzymatic inhibition by 
the addition of a soy bean trypsin inhibitor, revealed that the 
predominant antibody in small intestinal secretions and stool was 
secretory IgA (Waldman et al, 1971). 
Sack and his co-workers analysed intestinal levage samples collected 
during the first three weeks after recovery from clinical cholera 
(Sack, Islam, Holmgren & Svennerholm, 1980). They detected antitoxin 
in all three classes, but IgA predominated once again, exceeding IgG 
levels at least 10 fold. IgA antitoxin appeared early and peaked 
between days 5 to 9 after illness. Levels then declined to a low level 
by day 17. Further studies revealed that the IgA antitoxin content in 
lavage samples from convalescent Bangladeshis were still higher than 
those from healthy age-matched controls 28 days after infection. 
Furthermore, intestinal challenge with a small dose of B subunit, at 
this time, caused a significant mucosal IgA antitoxin response in 7/9 
of convalescents compared with only 3/8 of controls (Svennerholm, 
Jetborn, Gothefors, Karim, Sack & Holmgren, 1984). 
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1.6 Antitoxic Responses to Enteral Toxin in Animal Models 
A number of models have been used to examine immune responses to 
cholera toxin. For the sake of clarity each species of animal model 
will be considered in turn. 
Much work in dogs has been done using Thiry-Vella loops. Intraloop 
administration of 2 doses of cholera toxin (CT) has been shown to 
increase systemic antitoxin by a factor of 4 and loop antitoxin titres 
by a factor of 30. Boosting increases the numbers of antitoxin- 
containing cells (ACC) in the lamina propria of this loop. The number 
of ACC in the lamina propria correlates well with the titres of 
antitoxin found in the loop fluids, and there appears to be an inverse 
relationship between the prechallenge antitoxin levels in loop fluids 
and the amounts of fluid secreted in response to toxin challenge 
(Pierce, Cray & Sircer, 1978). Oral immunisation has been shown to 
stimulate a serum antitoxin response and protect the animal from the 
lethal diarrhoea caused by oral administration of live vibrios (Pierce, 
Cray & Sacci, 1982). 
The rabbit model most commonly used also makes use of Thiry-Vella loops 
and provides very similar results to the canine model. Enteric 
administration of antigen has been shown to stimulate a systemic IgG 
and IgA antitoxin response. This procedure also induced a mucosal 
antibody response mainly of the IgA isotope although some IgG was 
detected. The capacity of loop fluids to neutralise toxin, in both 
skin permeability and ileal loop assays, correlated more closely with 
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IgA than IgG content in these fluids (Yardley, Keren, Hamilton & Brown, 
1978; Hamilton, Yardley & Brown, 1979). 
Intraduodenal priming of Wistar Lewis rats with CT produced a vigorous 
jejunal ACC response when the animals were challenged with crude toxoid 
by the same route. The magnitude of this response varied directly with 
primary dose used. Response to challenge was maximal by 2 weeks after 
priming and was maintained when the challenge interval was extended to 
16 weeks. By 32 weeks however, the local memory seemed to wane. 
Enterically administered toxin again produced a systemic antitoxin 
response but this did not relate to the magnitude of the local ACC 
response (Pierce, 1978). Similar findings were noted for Lewis strain 
(Lew/Crl Br) rats which responded best at 7 weeks of age and appeared 
to have a longer immunological memory (Pierce, 1984). Repeated peroral 
immunisations of CT in Sprague-Dawley rats stimulated serum and bile 
antitoxin responses in addition to an increased number of jejunal ACC. 
In the serum IgG antibodies predominated but IgA and IgM were 
detectable, if more transient. In the bile IgA was the predominant 
antitoxic isotope; IgG was present in lesser amounts but continued to 
increase in parallel with IgA. IgM concentrations remained fairly 
constant throughout (Lange at al, 1984b). 
Other workers have described the appearance of specific biliery IgA 
antitoxin following peroral, intraduodenal, or direct administration of 
CT into the Payer's patches. These workers have shown the ability of 
this biliary antitoxin to neutralise the effect of CT on ileal loop 
assays after 30 minutes preincubation. But in one report, non-immune 
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bile was also capable of doing this until bile salts were removed by 
passage through a AG1 x8 Biorad resin column (Vserman, Derijck- 
Langendris, Rits & Delacriox, 1985; Tamaru & Brown, 1985). 
The mouse model provided similar results to those found in other 
animals. Several workers have reported the presence of specific 
antitoxin (IgG, IgA and IgM) in the serum of mice fed CT (Svennerholm 
et al, 1980; Lycke et al, 1983; Elson & Ealding, 1984a). 
Furthermore, feeding CT has been shown to produce a local IgA antitoxin 
response in intestinal secretions (Lycke et al, 1983; Elson & 
Ealding, 1984a), the production of specific IgA and IgG antibody from 
cultured intestinal tissue (Svennerholm et al, 1980), an increase 
in the number of ACC in the intestinal lamina propria and the 
appearance of IgA, IgG and IgM antitoxin in bile (Lange et al, 
1984a). 
Protection against CT-induced secretion in a ligated loop assay 
appeared to correlate with in vitro synthesis of IgA antitoxin, IgA 
levels in gut secretions and the number of intestinal immunisations 
(Svennerholm et al, 1980; Lycke at al, 1983). As with the rat 
model above, the immunological memory for local antibody formation 
appeared to be dose-dependent (Svennerholm at all 1980). Recent 
studies have shown that CT-primed mice can produce a brisk, lamina 
proprial, IgA antitoxin response within 16 hours of antigenic challenge 
up to 2 years after the initial priming event. Workers have therefore 
concluded that the administration of choleragen leads to life-long 
persistence of memory B cells (and perhaps also T cells) in orally 
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immunised mice (Lycke & Holmgren, 1986a; Lycke & Holmgren, 1987). 
1.7 The Cellular Beds of the Antitoxin Response to Enterically 
Administered Toxin 
The ability to demonstrate ACC in various tissues has allowed 
investigators to follow the migration and isotype production of 
antigen-specific B cells and has enabled them to dissect tissue- 
dependent homing of lymphocytes from that which is dependent on the 
presence of antigen. Most importantly it has enabled workers to study 
antigenically reactive cells in syngeneic hosts without the need for 
labelling which may interfere with the very phemonena one is studying. 
Some of the experiments described below deal with the secondary 
response to an intraduodenal challenge with toxin of an intraperitoneal 
immunisation with toxoid. This has been found to be qualitatively, if 
not quantitatively similar to enteric priming and will be included 
below for the purpose of clarity. 
Rats primed intraperitoneally with toxoid were discovered to have ACC 
in their thoracic duct lymph (TDL) 5 to 21 days later, this preceeded 
the appearance of ACC in the jejunal lamina propria which occured 19 to 
90 days after priming. If these primed rats intraduodenally 
challenged, the response was profoundly increased and quickened. Large 
numbers of ACC appeared in TDL after only 3 days. These cells were 
shown to migrate to bowel, as cannulation of the thoracic duct 
prevented their normal appearance (4 to 6 days after challenge) in the 
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jejunal lamina propria. These ACC were predominantly of the IgA 
isotype. Immune thoracic duct lymphocytes appeared in the bowel when 
injected intravenously into naive syngeneic recipients. From this it 
was concluded that homing to gut of th ese cells was not antigen- 
dependent but their distribution within the gut was influenced by the 
presence of antigen (Pierce & Gowans, 1975). 
Elegant experiments using Thiry-Vella loops in the same rats showed the 
necessity of Peyer's patch (PP) as the source for these thoracic duct 
ACC, and confirmed that these cells homed to gut but were locally 
distributed according to the presence of antigen. Furthermore it was 
shown that the accumulation of ACC at the site of challenge was due 
both to specific migration of mature ACC (which then died in situ) and 
the local proliferation of ACC precursors (Husband & Gowans, 1978). 
Further studies in rats showed that mucosal priming at specific sites 
primed for a secondary response both at the site of priming and in 
other areas throughout the mucosa-associated lymphoid tissue (MALT). 
Challenge at the site of primary antigen exposure always produced the 
largest response which suggested that a resident population of antigen- 
responsive cells was induced in addition to the migratory population. 
However, experiments further subdivided the migratory population into 
two subgroups. One was shown to recirculate until attracted by the 
presence of antigen and the other was thought to undergo limited 
recirculation and then settle in distant MALT. The authors speculated 
that the first population were probably T cells but the cells which 
seeded the lymphoid tissue were thought to be B cells (Pierce & Cray, 
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1978). Experiments in mice showed that indraduodenal CT primed for aB 
cell response that was disseminated from the PP to the mesenteric lymph 
nodes (MLN), spleen and bronchial-associated lymphoid tissues (BALT). 
Using a modification of the Klinman clonal precursor assay, Fuhrman and 
Cebra (1981) also showed that immunisation with CT produced a 
preponderance of IgA +ve ACC. Although the frequency of IgM +ve cells 
declined initially, to be replaced by IgA-producing cells, IgM was once 
more expressed by 75% of clones after 12 weeks. Confirmation of this 
proposed migration was demonstrated by Lycke et al, 1983, who 
showed the sequential appearance of IgA plaque-forming cells in the PP, 
MLN and spleens of orally immunised mice, 3,5 and 7 days after 
challenge, respectively. 
Elson and Ealding (1984a) demonstrated B cells capable of producing IgA 
and IgG anti-CT in the lamina propria (LP), PP9 MLN and spleen of 
orally immunised mice. They also demonstrated that feeding induced 
helper T lymphocytes for IgG and IgA production in the PP9 MLN and 
spleens of these mice. It might be suspected that cells that migrate 
via the thoracic duct may be found in the peripheral blood of animals 
and antigen-specific B cells have indeed been discovered in the blood 
after oral cholera immuniseton in men and mice. But these cells 
required in vitro cultivation to fully develop into antibody-secreting 
cells (Lycke, Lindholm & Holmgren, 1985). These peripheral blood 
lymphocytes have been found to secrete IgA antitoxin when cultured from 
orally immunised hosts but generally produce IgG from parenterally 
primed subjects. This would appear to confirm the local origin of 
these cells. 
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Finally, humans who had been repeatedly orally immunised more than 12 
weeks earlier had a population of antigen-responsive cells which 
secreted IgM when cultured with mitogen (Lycke at al, 1985). These 
IgM +ve memory cells appear to agree with earlier studies (Fuhrman & 
Cebra, 1981) that demonstrated the appearance of IgM +ve clones 12 
weeks after oral immunisation with choleragen in mice. 
1.8 Immune Response to Parenterally Administered Cholera Toxin 
The immune response to parenteral choleragen initially stimulated 
interest because immunisations were originally given systemically. 
These regimes produced high titres of serum antibody but had an unknown 
effect on mucosal immunity. Furthermore, the role of humoral antibody 
in protection at mucosal surfaces had not been fully established 
(Pierce & Reynolds, 1975). These workers demonstrated that passive 
Immunisation with IgG antitoxin protected against cholera toxin-induced 
fluid accumulation in Thiry-Vella loops in mongrel dogs, even in the 
presence of repeated flushing of the loops. Using passive 
immunisation, the workers were able to protect intact mongrel dogs 
against orogastric challenge with live vibrios. 
The potential of this route for inducing protective immunity led to 
further studies on the immune response to parenterally administered 
cholera toxin. 
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Subcutaneous immunisation produced good serum antitoxin titres 
(Peterson, 1979) but also stimulated low levels of IgG and I9A 
antitoxin in the intestinal washings of rabbits (Holmgren, Svennerholm, 
Ouchterlony, Andersson, Wallenström dc Westerberg-Berndtsson, 1975; 
Svennerholm & Holmgren, 1975). Culture of tissue In vitro, revealed 
that immunisation increased synthesis of specific IgM and IgG by the 
spleen, IgG and especially IgA by the Peyer's patches, and IgA 
antitoxin by the intestine (Svennerholm & Holmgren, 1977). 
Repeated intravenous administration of choleragen produced a good serum 
antitoxin response on the rat. IgG antibody levels continued to rise 
with eac h successive boost but IgA and IgM peaked after 2 or 3 
injections and thereafter began to fa ll. No IgG or IgM was found in 
the bile of these animals, but a small transient IgA response was seen 
after the fourth immunisation (Lange et al, 1984b). 
Intravenous immunisation produced similar results in mice. The animals 
responded with increased systemic IgG, IgM and IgA antitoxin levels. 
IgG predominated. Administration of antigen by this route also led to 
some IgA, but particularly IgG antibody production by cultured 
intestinal tissue (Svennerholm at at, 1980). In addition, 
parenteral toxin stimulated plaque-forming cells (PFCs) in the Peyer's 
patches, MLNs and spleens of these animals. PFC responses were in all 
these immunoglobulin classes but paradoxically declined with repeated 
immunisations despite a continued rise in antitoxin titres. This 
unexplained phenomenon recurred after repeated feeds of cholergen in 
mice (Lycke at a1,1983). 
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The serum IgG antitoxin response appears to be under the control of the 
I-A region of the H-2 complex. It has been shown that mice of the 
H-2b and H-2Q haplotypes are high responders but H-2k, H-28 and H-2d 
haplotypes respond poorly to intraperitoneal injections of low doses of 
antigen. Systemic IgA levels after intraperitoneal injection of 
cholergen did not appear to be affected by the H-2 haplotype of the 
host in this study (Elson & Ealding, 1985). 
1.9 Modulation of Immunity by the Biochemical Actions of Cholera 
Toxin 
Cyclic AMP plays an important role in the functions of many cells and 
so it is not surprising that cholera toxin may influence the activity 
of immunological cells by virtue of its effect on cAMP. In particular 
there are many reports of the toxic effects of choleragen affecting 
immunological responses both In vitro and in vivo. These effects would 
appear to be independent of the possible immune response to this 
protein as an antigen. 
Amongst its many actions cholera toxin has been shown to inhibit 
natural killer (NK) activity in mouse and human lymphocytes (Fuse, Sato 
& Kuwata, 1981; Goldfarb & Herberman, 1981; Fuyama, Sendo, Watabe, 
Seiji & Arai, 1981; Fuyama, Naiki & Sendo, 1982) as well as inhibit the 
lectin-induced DNA synthesis In both T and B cells (Sultzer & Craig, 
1973; Holmgren, Lindholm & Unnoth, 1974). It can also inhibit the 
cytotoxic action of immunised mouse spleen cells against an allogenic 
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mastocytoma cell line and the antigen-induced IgE-mediated release of 
histamine from human leukocytes (Lichtenstein, Henney, Bourne & 
Greenough, 1973). 
It has been shown to have both inhibitory and stimulatory effects on 
the PFC response of mice to sheep red blood cells (SRBC) (Northrup & 
Feuci, 1972; Lindholm, Holmgren, Lange & Linnroth, 1976). The 
adjuvant action of CT when administered prior to immunisation was 
thought to be due to inhibition of suppressor cells (Lindholm 
et al, 1976) and the immunosuppression seen when CT is administered 
concurrently with SRBC has been attributed to its action on macrophages 
and helper T cells (Lyons & Friedman, 1978; Kately, Holderbach & 
Friedman, 1978). 
All these effects have been attributed to an increase of the 
intracellular cAW levels of lymphocytes (Lichtenstein et al, 1973; 
Fuyama et al, 1982; Fuse at al, 1981; Holmgren at al, 1974; 
Kateley, Kasarov & Friedman, 1975, Lindholm at al, 1976). It Is 
fair to say that although these biochemical changes have been observed 
a causal relationship between the biochemistry and immune function of 
these cells has not yet been established. 
Teuru and his co-workers demonstrated that cholera toxin could also 
augment the delayed footpad reaction to SRBC in mice when given 
parenterally 1,7 or 10 days before immunisaton (Tsuru, Zinnaka, Nomoto 
& Takeya, 1981). They reasoned that this reaction was not due to 
toxin's effect on adenylate cyclase as the effect could be minimised by 
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a formalin-inactivated cholera toxoid (Tsuru, Namoto, Oka, Kitani, 
Zinnaka & Takeya, 1983). This may well not be the case for two 
reasons, formalinised toxoid may well revert to toxicity in v ivo and, 
secondly, the authors used a hundred fold inc rease in the dose of 
toxoid to achieve this effect. The residual toxicity of such a dose 
may well be enough to stimulate the necessary cANP response. Both 
these properties of toxoids will be di scussed in greater detail in this 
chapter. 
In addition to the modulatory effects of systemic toxin, cholera toxin 
may affect immune responses when administered orally. When fed with 
keyhole limpet haemocyanin (KLH), CT was able to prevent the induction 
of oral tolerance for systemic IgG and simultaneously induce a 
secretory IgA response to KLH. It has been suggested that either the 
binding of CT to the intestinal mucosa, or activation of adenylate 
cyclase or a combination of the two may be responsible for the 
alteration in the regulatory environment that cholera toxin seems to be 
able to induce (Elson & Ealding, 1984b; Lycke & Holmgren, 1986b). It 
was interesting, in the light of this discovery, that the B subunit of 
cholera toxin is capable of inducing increased secretory IgA and serum 
IgG responses to orally administered horseradish peroxidase (HRP), but 
that the HRP must be covalently bound to the B subunit for this to 
occur (McKenzie & Halsey, 1984). Once again, these results have been 
attributed to the lectin-like actions of B subunit but these properties 
have not been causally related. 
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L10 Modulation of Immunity by the Immunological Actions of Cholera 
Toxin 
Choleragen is a highly immunogenic protein and as with other antigens 
may alter the immune response to itself and other antigens by virtue of 
its immunological properties. Yardley and his co-workers (1978) showed 
that combined subcutaneous and intraintestinal immunisaton with cholera 
toxin in rabbits suppressed the local IgA antitoxin response seen after 
intraintestinal immunisation alone. This effect has been confirmed by 
Pierce and Koster (1980) who showed that parenterelly administered 
toxoid could also suppress both primary and secondary mucosal immune 
responses to toxin. As subcutaneous immunisations alone produced 
little IgG or IgA antitoxin in loop fluid (Yardley et al, 1978) it 
is unlikely that this phenomenon was due to the neutralisation of 
antigen by antibody before it could bind to bowel. Studies of the 
effect of antibody on the mucosal immune response would seem to agree 
with this conclusion. Whereas, hyperimmune serum was able to suppress 
primary mucosal response, the development of specific memory and, to 
some extent, the secondary mucosal response, this was not so for 
'primary' immune serum. This 'primary' immune serum was obtained from 
intreperitoneally immunised rats whose mucosal immune response to 
intraduodenal toxin had been suppressed (Pierce, 1980). 
It was suggested that the suppression of secretory IgA antitoxin in 
rabbit was not due to the 'toxigenic' effects of choleragen as it could 
be simulated by moderate doses of a gluteraldehyde-inactivated toxoid 
given by the same route. The authors concluded that the suppressive 
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effect was therefore probably by an 'immunogenic' mechanism (Hamilton 
et a1,1979). This has been confirmed by Koster and Pierce (1983) 
who demonstrated the appearance of nylon wool-nonadherent splenic 
suppressor cells after parenteral immunisation of rats with toxoid. 
The suppressive effect of these cells became greater with time and they 
could be found in the thoracic duct lymph and thymus 2 to 4 months 
after immunisation. 
1.11 The Preparation and Antigenicity of Cholera Toxoids 
Cholera toxin is a potent immunogen but its toxic properties make it 
totally unsuitable as a candidate for a potential vaccine. As a 
result, means have been sought whereby the antigenicity of the protein 
may be preserved but its toxicity eliminated. Three approaches to this 
problem will be considered and the immune responses 'to each type of 
toxoid produced will be discussed. Ideally, a toxoid should be 
immunologically cross-reactive with the parent molecule but without any 
residual toxicity. It will become apparent that only B subunit fulfils 
the latter of these criteria. Nevertheless, the result of any 
detoxificatition procedure will be referred to as a toxoid for the 
purposes of this discussion. 
27 
a) Chemical detoxifications 
It was found that treatment of cholera toxin with formaldehyde in 
vitro erradicated its toxicity. This resulted in a toxoid which 
exhibited little biological activity but that stimulated antitoxic 
antibodies after parenteral immunisation in monkeys. Unfortunately, 
this toxoid was also shown to revert to partial toxicity causing local 
reactions at the site of inoculaton (Northrup & Chisari, 1972). 
Inactivation by ammonium sulphate precipitation of a formal in-treated 
culture medium produced a crude toxoid with some toxin and somatic 
antigen contamination. Alternatively, the culture filtrate could be 
passed down an equine antitoxin-bound sepharose column and the eluate 
neutralised, filter sterilised, incubated with formalin for 21 days, 
dialysed and sterilised once more to produce a purified formalinised 
toxoid. Both these toxoids have been prepared by Dr R0 Thompson of 
the Wellcome Research Laboratories, Kent and have been used extensively 
in animals. 
The purified toxoid was capable of inducing a good systemic antitoxin 
response after subcutaneous administration in rabbits (Peterson, 1979) 
and intraperitoneal immunisation in rats (Pierce, 1980). 
Intraperitoneal immunisation produced mucosal ACC priming in rats 
(Pierce & Gowans, 1975) and stimulated the development of mainly IgG 
but also IgA ACC in the Payer's patches, mesenteric lymph nodes and 
spleens of mice (Fuhrman & Cebra, 1981). Crude toxoid administered 
subcutaneously, stimulated a systemic antitoxin response in dogs (Sinha 
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& Bhaskaran, 1973; Pierce & Reynolds, 1975). In these animals, the 
presence of serum antibody correlated with the appearance of antitoxin 
in their Thiry-Vella loop washings. It has been suggested that under 
these conditions most of the gut antibody is derived from serum (Pierce 
& Reynolds, 1974; Pierce & Reynolds, 1975). Crude toxoid was also able 
to induce a local secretion of dimeric IgA antitoxin when instilled in 
canine Thiry-Vella loops (Pierce & Reynolds, 1975). Furthermore this 
toxoid could also stimulate an ACC response in the jejunum of 
intraduodenally primed rats. 
In contrast, the purified toxoid did not prime for a local humoral 
response in these rats but was as effective as crude toxoid or CT 
itself in intraduodenally boosting a primed animal (Pierce & Gowans, 
1975; Pierce, 1978). 
Chemical detoxification has also been accomplished by treating the 
purified toxin with gluteraldehyde (Rappaport, Bonde, McCann, Rubin & 
Tint, 1974). The resultant toxoid was further treated by 
ultrafiltration to remove any contaminating somatic antigen (Rappaport, 
Pierzchala, Bonde, McCann & Rubin, 1976). This final step eliminated 
the development of systemic vibriocidal antibodies in intramuscularly 
immunised mice but appeared to maintain the antitoxin response in these 
animals. 
Subcutaneously administered toxoid appeared able to produce a good 
systemic IgG response in rabbits concurrent with the appearance of 
small amounts of IgG and IgA antitoxin in the Thiry-Vella loops of 
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these animals (Hamilton et al, 1979). This toxoid appears to stimulate 
very similar systemic antitoxin levels after parenteral " immunisation in 
rabbits to those produced by the formalinised purified toxoid 
(Peterson, 1979). The gluteraldehyde toxoid evoked high titres of 
circulating antitoxin in human volunteers when administered 
perenterally (Peterson, Verway, Craig, Guckian, Williams & Pierce, 
1974) but was also able to produce a systemic humoral response, elicit 
higher rates of seroconversion and stimulate higher geometric mean 
antitoxin titres than saline immunised controls when multiple doses 
were given orally (Levine, Hughes, Young, O'Donnell, Craig, Holley & 
Bergquist, 1978). 
Studies in dogs revealed that although parenterally adminstered toxoid 
primed for both a systemic and mucosal antitoxin response, enteric 
administration of this toxoid failed to induce an ACC response or the 
secretion of antitoxin into the Thiry-Vella loops of these animals 
(Pierce et al, 1978). 
Both the gluteraldehyde- and formalin-treated purified toxoids appeared 
to be poor at priming an immune response, e ither mucosal or systemic, 
when administered enterically compared to the parent toxin. This has 
been attributed both to their inability to bind to gengliosides and 
their failure to activate adenylate cyclase (Pierce, 1978; Pierce et 
al, 1978). 
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b) Production of isolated choleragenoid (B subunit) 
Choleragenoid was originally found to be produced by the Vibrio 
choleree in addition to CT (Finkelstein & LoSpalluto, 1969). It was 
discovered that it could be produced in greater quantities from the 
parent toxin, and that isolated choleragenoid was antigenically 
identical to the toxin but completely devoid of its toxic properties 
(Finkelstein & LoSpalluto, 1970). 
Choleragenoid retains its ability to bind to GM1 gangliosides and 
provokes an ACC response in the jejunal lamina propria after oral 
administration to dogs or intraduodenal injection in rats. In both 
these cases the ACC counts were less than those observed in animals 
immunised with holotoxin (Pierce, Cray & Sacci, 1982; Pierce, Cray, 
Sacci, Craig, Germanier & Firer, 1983). Oral immunisation with B 
subunit produces systemic PFC and antitoxin responses in mice of all 
three classes. It also produces less secretory IgA and less protection 
against toxin-induced fluid secretion than oral immunisation with 
choleragen (Lycke et al, 1983). Feeding choleragenoid fails to 
tolerise the induction of systemic IgG antitoxin by its subsequent 
intraperitoneal administration (Elson & Ealding, 1984b). 
A single dose of B subunit either orally (500 µg) or intramuscularly 
(150 µg) in Bangladeshi volunteers produced a local intestinal 
secretory IgA response. The magnitude of the response was similar by 
both routes but the antitoxin response persisted longer after oral 
immunisation. Levels of antitoxin seen in these volunteers were 
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comparable to 
et al, 1984). 
those observed after clinical infection (Svennerholm 
c) Heat inactivation 
Finkelstein, Fujita and LoSpalluto (1971) described the production of a 
high molecular weight polymer, designated "Procholeragenoid", when 
cholera toxin was heated. It was an intermediate formed optimally by 
heating CT for 5 to 10 minutes at 56 0 C. If the toxin was heated 
further purified B subunit was isolated. This intermediate had 5% of 
choleragen's initial toxicity, by the limit of blueing assay, and was 
found not to revert to toxicity in vivo. 
Workers concerned about the residual toxicity further inactivated this 
polymer by treatment with formalin. Intramuscular immunisation with 
this formalinised procholeragenoid produced good antitoxin titres but 
also a weaker vibriocidal antibody response in rabbits. It also 
produced good titres of neutralising antibodies in Guinea-pigs when 
injected by the same route (Germanier, Rker, Varalley & Inderbitzin, 
1976). This toxoid induced good antitoxin titres after intramuscular 
injection into human volunteers (Germanier, Firer, Varalley & 
Inderbitzin, 1977). 
Unaltered procholeragenoid has also been enterically administered to 
rats and dogs. In rats it produced a marked response after 
intraduodenal immunisation. The magnitude of this response was almost 
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equal to purified toxin but was appreciably reduced by prior incubation 
with GM1 ganglioside or by treatment with formalin. In dogs, 
procholeragenoid administration markedly protected them from the lethal 
diarrhoea following live vibrio challenge and increased the jejunal ACC 
count in these animals (Pierce, Cray, Sacci, Craig, Germanier & 
Fdrer, 1983). 
The residual toxicity of all these toxoids have been compared by the 
limit of bluing assay. Crude formalinised toxoid has the most residual 
toxicity. Purified formalinised toxoid, gluteraldehyde-inactivated 
toxoid and procholeragenoid all had similar toxicities of approximately 
5% of the holotoxin. The residual activity of procholeragenoid could 
be further reduced by formalinisation. Only B subunit is totally non- 
toxic as it does not contain the A subunit necessary for adenylate 
cyclase activation (Pierce, 1978; Pierce et al, 1983) 
L12 Other Factors which may Prevent Cholera, gen-induced Intestinal 
Hypersecretion. 
As can be seen from the foregoing account, many authors have correlated 
the protection observed against CT-induced intestinal secretion (or the 
lethal diarrhoea after live vibrio challenge) with the presence of 
antitoxin. The ability of antitoxin to neutralise the biological 
activities of choleregen (in particular the induction of fluid 
secretion) after periods of incubation has fostered the assumption that 
protection against cholera is mediated by antibody. 
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It is difficult to reconcile this with the observation that 
convalescent volunteers who had antibody titres similar to vaccinated, 
or in some cases unimmunised controls, had significantly greater 
protection against live vibrio challenge (Cash at a1,1974). 
Furthermore, it was observed that there was significant protection 
against live vibrio challenge in immunised dogs over 6 months after 
jejunal ACC were last detectable and serum antitoxin titres were less 
than twice pre-immunisation levels. The authors concluded "it remains 
possible that protection ...... was due to an immune response other 
than, or in addition to, the production and secretion of antitoxin" 
(Pierce at al, 1978). 
More recently it has been shown that protection is greater in toxin- 
immunised dogs (Pierce at at, 1983) or mice (Lange at at, 
1984a) than those receiving enteric B subunit even though both animals 
have equivalent mucosal or systemic antitoxin responses. Furthermore, 
it has been demonstrated that mucous release, toxin binding or toxin 
internalisation is not affected by multiple oral immunisations with 
toxin and the desensitisation of mucosal adenylate cyclase (thought to 
be responsible for this down-regulation of intestinal secretion) is 
unrelated to antibody levels in the intestine, bile or serum of both 
rats and mice. The fluid response to adenylate cyclase stimulation is 
only depressed for 4 to 7 days when it is elicited by prostoglandin El 
but appears to remain Inhibited for more than a month when CT is used 
(Lange at al, 1984b; Lännroth at el, 1984). 
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A protein factor, of molecular weight 30,000, has been isolated from 
the brain, pituitary and intestine of animals orally immunised with 
cholera toxin (Lange & Lännroth, 1984). This factor, which has 
lectin-like properties, is able to prevent intestinal hypersecretion 
only if given shortly before challenge with choleragen. It has been 
found in the bile and breast milk of immunised animals and has been 
thought to have hormone-like actions (Lange & Lännroth, 1984; 
Liinnroth & Lange, 1984; Lange & Linnroth, 1986). Unfortunately, 
the authors have not been able to detect its presence in serum or to 
demonstrate Its ability to desensitise adenylate cyclase. Most 
significantly, animals exhibiting mucosal adenylate cyclase 
desensitisation do so in an antigen-specific manner (Lönnroth 
et al, 1984), and these authors have not attempted to explore the 
specificity of this factor or to explain the mechanism by which a 
putative hormone may exhibit this property. 
Other protective mechanisms may also be responsible for the prevention 
of cholereic diarrhoea. Sprinz (1962) observed that patients suffering 
from cholera exhibited crypt hypertrophy and villous atrophy in 
intestinal biopsies. Increased eosinophil counts have also been 
observed in the intestines of choleragen-fed rats (Lange at al, 
1984b) and both these phenomena are thought to be indicative of aT 
cell-mediated immunological response within the intestinal mucosa 
(Basten & Beeson, 1970; Colley, 1973; reviewed: Ferguson, 1987). 
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In the light of this, it is interesting that Russian workers have 
reported the presence of "specific delayed-type hypersensitivity" in 
the intestine and lymph nodes of previously germ-free rats chronically 
infected with cholera vibrios (Gorskaya, Chakkava, Rubstov & 
Gailonskaya, 1980). Also, other workers have claimed that protection 
from the vibrio is associated with decreased adhesion and colonisation 
and that this is accompanied by an increase in the number of 
intraepithelial lymphocytes (especially "granular" lymphocytes) and the 
number of lymphoid and plasma cells in the lamina propria (Efremov, 
Polotsky, Samiostrelsky, Vasser & Seliverstove, 1982). Finally, nude 
mice do not produce specific IgA when orally immunised with choleragen 
but both specific IgA and protection against toxin-induced 
hypersecretion could be restored by subcutaneous thymus-grafting 
(Lycke, Ericksen & Holmgren, 1987). 
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Chapter 2 
ORAL TOLERANCE TO ENTERIC ANTIGENS 
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2.1 The Immunological Effects of Feeding Antigen 
A number of different immune responses have been reported after the 
enteric administration of antigen. These may affect both local and 
systemic immunity and include energy, tolerance, immunity and 
hypersensitivity. These reactions are not mutually exclusive and may 
occur in the same animal depending on the nature and anatomical 
location of the immune response in question. 
Feeding antigen may induce a systemic humoral immune response and 
circulating antibodies have been found after the ingestion of a number 
of different antigens including bacteria, viruses, contact sensitising 
agents, heterologous red blood cells and food antigens (Waldman & 
Ganguly, 1974; Bradley, Kim & Watson, 1963; Asherson, Zembala, Perera, 
Mayhew & Thomas, 1977; David, 1979; Rothberg, 1969). In addition to 
humoral immunity, feeding may also induce a systemic cell-mediated 
immune reaction (Perrotto, Hang, Isseelbacher & Warren, 1974; Asherson 
et al, 1977). As well as systemic immunity, lumenal exposure to a 
variety of antigens may also result in a local antibody response 
especiall y of the IgA isotype (revie wed, Bienenstock & Befus, 1980). 
Although one result of the enteric encounter with antigen may be the 
induction of specific immunity, an alternative outcome is the induction 
of tolerance. Oral tolerance has been defined as the induction of a 
state of specific systemic immunological hyporesponsiveness following 
the oral administration of antigen and appears to occur more commonly 
than active immunity after feeding. The remainder of this chapter will 
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be addressed to a brief overview of the mucosal downregulation of 
systemic immunity and will include descriptions of the conditions under 
which oral tolerance may be induced, techniques by which it can be 
abrogated and the mechanisms thought to be responsible for its 
occurrence. 
2.2 Oral Tolerance 
One of the earliest descriptions of oral tolerance was by Dakin in 1829 
who described a practice amongst North American Indians of feeding Rhus 
leaves to their young in order to prevent the development of poison ivy 
contact dermatitis later in life. In 1911, Wells studied this 
phenomenon scientifically (Wells, 1911; Wells & Osborne, 1911) and 
since then downregulation of systemic immunity has been shown to occur 
after feeding a wide variety of antigens including contact sensitising 
agents (Chase, 1946; Asherson at a1,1977), protein antigens 
(Thomas & Parrott, 1974; Hanson, Vaz, Maia, Hornbrook, Lynch & Roy, 
1977; Ngan & Kind, 1978) and heterologous red blood cells (Kagnoff, 
1978a; Kagnoff, 1978b; Mattingly & Wakeman, 1978). 
Although oral tolerance may be induced by a wide variety of antigens 
other factors play an important role in its development including the 
doses of antigen used, the frequency of administration and the timing 
of feeding relative to subsequent challenge (reviewed, Bienenstock & 
Befus, 1980). In addition to these, the age at which antigen is first 
encountered also appears to determine whether tolerance ensues. 
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Feeding ovalbumin (OVA) to mice during the neonatal period or at the 
time of weaning fails to induce the systemic tolerance normally 
encountered after such a procedure (Hanson, 1981; Strobel & Ferguson, 
1984). 
The role of the major histocompatibility complex (MHC) in the control 
of immunity is well-established and recent evidence suggests that the 
H-2 locus in mice is important in the induction of tolerance to 
parenterally administered antigen (Lowy, Drebin, Monroe, Granstein & 
Greene, 1984; Robbins, Thomas, Jensen & Kapp, 1984). Stokes and his 
colleagues have already demonstrated that differing strains of mice 
differ in their ability to be tolerised (Stokes, Swarbrick & Soothill, 
1983). Tomasi and his colleagues have confirmed these findings but 
failed to link this difference to the H-2 haplotype of these animals 
(Tomasi, Barr, Challacombe & Curran, 1983). Unfortunately this work 
was not done on congenic strains of mice so that other genetic 
differences may be interfering with the Interpretation of results. 
2.3 Inhibition of Oral Tolerance 
The inhibition of tolerance by pharmacological and immunological 
procedures has allowed workers to examine this Immune process in more 
detail. 
The induction of oral tolerance by feeding OVA has been shown to be 
abrogated by pre-treatment with cyclophosphamide (Hanson & Miller, 
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1982; Mowat, Strobel, Drummond & Ferguson, 1982). It was postulated 
that this phenomonen was related to the effect of cyclophosphamide on 
suppressor T cells (Rbllinghoff, Starzinski-Powitz, Pfizenmaier & 
Wagner, 1977; Schwartz, Askenase & Gershon, 1978). Experiments, 
performed at that time, appeared to rule out the possible effect of 
this drug on the intestinal mucosa as a reason for this alteration in 
the immune response (Sobhon, Wanichanon & Sretarugse, 1977; Mowat 
at al, 1982; Mowat, 1981). 
Experiments using the drug 2'-deoxyguanosine (dGuo) have recently 
confirmed these findings (Mowat, 1986). This drug is converted to 
toxic metabolites by the action of many different purine degradation 
enzymes (Carson, Kaye & Seegmiller, 1977; Cohen, Lee, Dosch & Gelfand, 
1980, Spaapen, Rijkers, Steal, Rijksen, Wadman, Stoop & Zegers, 1984) 
and selectively prevents the generation of suppressor T cells In vivo 
(Dosch, Mensour, Cohen, Shore & Gelfand, 1980; Varey, Lelchuk, 
Hutchings & Cooke, 1983; Brill Van den Akker, Molendijk-Lok, Bianchi & 
Benner, 1984; Brill Van den Akker, Hussarts-Odijk & Benner, 1985). 
Both intestinal epithelial cells and DTH effector cells do not contain 
the necessary kinase enzymes and are resistant to the actions of dGuo 
(Carson et all 1977; Bril at a1,1984; Bril at al, 1985). 
The use of dGuo after feeding OVA also abrogates the induction of 
tolerance and is further compelling evidence for the involvement of 
suppressor T cells in this p henomenon (Mowat, 1986). 
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Pre-treatment of mice with either oestradiol or muramyl-dipeptide (MDP) 
was also able to reverse the usual suppression of serum antibody and 
DTH responses normally observed after feeding OVA (Mowat & Parrott, 
1983; Strobel & Ferguson, 1986). 
Introduction of a graft-versus-host reaction in F, mice once again 
prevented the enteric downregulation of systemic DTH and anti-OVA IgG 
antibody responses. The abrogation of tolerance was associated with an 
augmented ability of spleen cells to present OVA to primed T cells 
while the phagocytic activity of the reticuloendothelial system of 
these animals appeared to remain unaltered (Strobel, Mowat & Ferguson, 
1985). Preliminary experiments performed by Dr Mowat suggest that 
activation of antigen-presenting cells (APC) may also occur following 
pre-treatment of mice with oestrodiol and MDP (personal communication). 
It would appear from this data, that gut-associated APC may well play a 
role in the mucosel regulation of systemic immunity. 
2.4 Mechanisms Responsible for Oral Tolerance 
A number of processes have been implicated in the immunological 
suppression of systemic immunity following feeding. These include both 
serum and cellular fractions which may act independently or in 
combination. 
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These mechanisms have been elicited after feeding a variety of antigens 
and it has become apparent that while some mechanisms may be shared 
others appear peculiar to one particular substance. Some of these 
differences have been attributed to the physical nature of the antigen 
i. e. whether the antigen was particulate or soluble, but most 
particulate antigens would be rendered soluble when administered by 
gavage. The two antigens used most frequently in the study of the 
mechanisms of oral tolerance are sheep red blood cells (SRBC) and OVA 
and this section will primarily include descriptions of the results 
obtained from the use of these. One limitation of this work is that 
these studies use antigens which are relatively large and may be 
expected to contain more than one antigenic epitope. All the immune 
reactions have been measured to the antigen as a whole and so the fine 
regulation of particular idiotypic responses still remains to be 
elucidated. 
Some of the variety of mechanisms involvgd in oral tolerance are 
illustrated by feeding SRBC to mice. The tolerance observed in serum 
antibody and splenic plaque-forming cell (PFC) responses has been 
attributed to circulating antigen-antibody complexes (Andre, 
Heremans, Vaerman & Cambiaso, 1975). Later work, although not 
confirming the tolerance observed with IgG and IgA anti-SRBC PFC 
responses, attributed the downregulation of specific splenic IgM 
responses to anti-idiotypic antibody (Kagnoff, 1978b). Other workers 
have isolated an IgG fraction from the serum of fed animals which 
suppresses anti-SRBC PFC responses in vitro (Chalon, Milne & Vaerman, 
1979). 
43 
In addition to serum-borne suppressive factors, feeding SRBC to mice 
also induces a feedback suppressor pathway where Ly-1+ 23-/I-J+ T cells 
can suppress specific splenic PFC responses by causing normal T cells 
to become suppressor effectors (MacDonald, 1982a; MacDonald, 1982b). 
It is interesting to note that although feeding SRBC may suppress 
specific PFC responses, removal of Peyer's patch suppressor T cells can 
reveal the priming of B cells in the presence of oral tolerance which 
has been induced by feeding ovalbumin (Titus & Chiller, 1981a). Other 
experiments using human gammaglobulin (HGG) have revealed that B cell 
anergy may also occur after feeding (Vives, Parks & Weigle, 1980). 
This serves to emphasise the problems of extrapolating the results 
obtained with one antigen to that obtained from another. 
Feeding SRBC not only tolerises humoral immunity but the induction of 
systemic CMI may also be suppressed. This phenomenon has been ascribed 
to splenic suppressor cells which appear to inhibit the development of 
DTH effector cells (Kagnoff, 1978x). 
Many of the above findings elicited after feeding SRBC have been 
confirmed and extended using the soluble protein, ovalbumin. 
Suppressor T cells that inhibit anti-OVA IgG antibody and IgE antibody 
responses have been demonstrated after feeding. These cells appear 
first in t he Payer's patches (PP) and mig rate from the bowel, appearing 
next in t he mesenteric lymph nodes (MLN) and later in the spleen (Ngan 
& Kind, 1978; Richman, Graeff, Yarchoan & Strober, 1981). A similar 
migration pattern for T suppressor cells (Ts) has also been described 
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after feeding SRBC. T cells capable of suppressing anti-SRBC IgM and 
IgG PFC responses and antigen-specific DTH were detected in the PP and 
MLN of rats within 2 days of feeding. After 4 days of feeding these 
cells were no longer present in the PP or MLN but could be found 
instead in the thymuses and spleens of these animals (Mattingly & 
Waksman, 1978). 
Oral administraton of OVA also induces splenic T cells capable of 
preventing the development of specific DTH effector cells (Miller & 
Hanson, 1979). While it would appear from the foregoing account that 
mucosal regulation of systemic immunity is most commonly accomplished 
by Is, B suppressor cells have been additionally identified as 
responsible for the oral tolerance observed after feeding contact 
sensitivity agents (Asherson et al, 1977). Feeding OVA appears to 
induce Ts for both humoral and cell-mediated immune responses but there 
is evidence to suggest that these regulating mechanisms may operate 
independently. Studies have shown that whereas feeding 2 mg OVA to 
BALB/c mice only tolerises sytemic CMI and IgM anti-OVA antibody 
responses, a larger feed of 25 mg inhibits the development of specific 
systemic IgG and IgM antibody as well as CMI. Furthermore, pre- 
treatment with cyclophosphamide completely abrogates the tolerance 
induced by feeding 2 mg OVA but only partially inhibits the induction 
of tolerance seen after oral administration of the larger dose of 
antigen (Mowat et a1,1982). 
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Further evidence of the separate nature of the regulatory mechanisms 
controlling different limbs of systemic immunity has come from the 
study of 'gut processed' antigen. 'Processing' is the term used to 
describe the ability of the gut to generate a tolerogenic form of 
antigen which is detectable in the serum of mice one hour after 
feeding. These studies have been carried out after feeding OVA, and 
have revealed that the tolerogenic serum fragment is antigen-specific 
but is only capable of inducing tolerance in systemic CMI. Experiments 
using cyclophosphamide suggest that this may be achieved by inducing 
the development of suppressor T cells (Strobel, Mowat, Drummond, 
Pickering & Ferguson, 1983; Bruce & Ferguson, 1986a). Further 
characterisation of the serum tolerogen revealed that it has B cell 
determinants in common with the fed antigen and has a similar molecular 
weight (Bruce & Ferguson, 1986b). This is the first description of the 
transfer of tolerance by serum antigen from protein-fed mice and serves 
to underline the close association between the absorptive and immune 
functions of the intestine. 
Experiments studying the effect of feeding native or denatured OVA have 
served to highlight the dissimilarities that exist between orally- and 
parenterally-induced tolerance (Mowat, 1985). Suppressor T cells are 
believed to recognise intact antigens (Feldmann & Kontiainen, 1976) 
whereas helper T cells respond to determinants within the primary 
structure of protein antigens that have been processed and presented by 
APC. It is therefore surprising that both antigenic forms induced oral 
tolerance which was cross-reactive. Although splenic suppressor T 
cells were only found after feeding the native antigen, it has been 
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shown that pulsed macrophages can induce Ts that cross-react with both 
forms of OVA in vitro (Takatsu & Ishizaka, 1977). 
Earlier studies, however, have inferred that the antigen-presenting 
cell may inhibit the induction of oral tolerance (Mowat & Parrott, 
1983; Strobel et al, 1983; Strobel & Ferguson, 1986). Although the 
APC examined in these studies were isolated from spleens, other workers 
have examined the ability of Peyer's patch accessory cells to present 
antigen. Peyer's patch cells were found to be good stimulators of 
primary and secondary mixed lymphocyte reactions but were poor at 
presenting soluble antigens to sensitised lymph node cells (Tomasi 
et al, 1983). Furthermore, feeding these soluble antigens did not 
induce a T-cell proliferative response in the PP lymphocytes and this 
could not be reversed by drugs shown to be effective against suppressor 
cells. 
Peyer's patches have been shown to contain helper T (Kiyono, Babb, 
Michalek & McGhee, 1980; Richman et al, 1981; Elson & Ealding, 
1984a), suppressor T (Ngan & Kind, 1978; Richman at al, 1981; 
MacDonald, 1983) and even contrasuppressor T cells (Green, Gold, St 
Martin, Gershon & Gershon, 1982) after feeding and it has been assumed 
that the APC present in the PP were responsible for their induction. 
The evidence presented above would suggest that this is not the case 
for the cells involved in oral tolerance. This has been recently 
confirmed by Enders and his colleagues who were able to demonstrate the 
induction of oral tolerance in rats whose PP had been surgically 
removed (Enders, Gottwald & Brendel, 1986). 
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A series of experiments performed by Bland and Warren have suggested an 
alternative site for the presentation of antigen in the 
gastrointestinal tract. Using isolated villous, columnar, epithelial 
cells in short-term cultures they have shown that these cells are 
capable of binding antigen and presenting it to T cells (Bland & 
Warren, 1986a). Rat lymph node cells exposed to antigen and epithelial 
cells were able to mediate antigen-specific suppression of 
proliferative T cell responses. The generation of suppressor activity 
was accompanied by an increase of the expression of suppressor 
phenotype as shown by monoclonal antibodies (Bland & Warren, 1986b). 
Caution must be exercised in the extrapolation of in vitro phenomena to 
the in vivo situation but this work presents an intriguing alternative 
to the PP APC as a source of suppressor T cell induction in oral 
tolerance. 
2.5 Contrasuppreasion and Oral Tolerance 
Challacombe and Tomasi (1980) have demonstrated that feeding either 
ovalbumin or Streptococcus Mans to mice induced specific salivary IgA 
antibodies as well as tolerance in systemic humoral immunity. 
Increased secretory immunity in the presence of systemic tolerance has 
also been shown after intranasal inoculation with poliovirus (Ogre & 
Karzon, 1969). Mice fed OVA were shown to have decreased antigen 
absorption as well as oral tolerance and this was assumed to be 
additional evidence for the presence of mucosal immunity (Swarbrick, 
Stokes & Soothill, 1979). 
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This phenomenon appeared to be explained by a study which demonstrated 
the simultaneous induction of antigen-specific IgA T helper cells and 
IgG T suppressor cells in the PP of mice fed ovalbumin 6 days 
previously (Richman et al, 1981). Similar results were obtained 
after feeding sheep red blood cells (Mattingly, 1983). 
The description of an in vitro contrasuppressor circuit in which a 
Peyer's patch T cell appeared capable of blocking the effects of a 
locally-induced suppressor T cell seemed to provide further evidence of 
a mechanism maintaining local immunity in the presence of concurrent 
systemic tolerance (Green et al, 1982). In this proposed circuit 
an I-J+/Ly-2+ inducer cell found in the PP was thought to interact 
with an I-J+/Ly-1,2+ transducer cell in the spleen to generate an I- 
J+/Ly-1+ contrasuppressor (c/s) effector cell. This c/s effector cell 
was thought to be a resident component of the PP which masked the 
effects of an I-J-/Ly-2+ suppressor effector T cell induced at the same 
time. Thus, suppressor effectors migrating to the spleen would 
tolerise systemic responses but the action of the resident PP c/s cell 
would maintain local immunity (Green & St Martin, 1983). 
Recent experiments have challenged these results. Measurement of 
intestinal antibodies in mice fed KLH showed that there was no local 
immune response in the presence of tolerance. Furthermore, 
simultaneous feeding of CT with KLH both abrogated the induction of 
oral tolerance and stimulated a local response (Elson & Ealding, 1984b; 
Lycke & Holmgren, 1986). This situation seems to be in agreement with 
studies performed in this laboratory which could not detect a mucosal 
49 
DTH response in animals who were orally tolerised. Only procedures 
which abrogated oral tolerance appeared to induce a local DTH response 
(Mowat & Ferguson, 1981; Mowat & Ferguson, 1982b; Mowat et al, 
1982; Mowat & Parrott, 1983; Strobel & Ferguson, 1984). 
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Chapter 3 
SYSTEMIC DELAYED-TYPE HYPERSENSITIVITY 
51 
3.1 Introduction 
Delayed-type hypersensitivity (DTH) represents one of the first 
immunological phenomena to be described (Jenner, 1798; Zinsser, 1925). 
It has been induced in mice using a number of different antigens 
including microbes or their products, heterologous proteins, 
polysaccharides and simple chemical contactants (Crowle, 1962; Asherson 
& Ptak, 1968; Kettman, 1972; Crowle, 1975; Vadas, Miller, Gamble & 
Whitelaw, 1975; Clark & Azar, 1977; Ruddle, 1978; Titus & Chiller, 
1981b). The reaction, which becomes visible 16 to 24 hours after 
antigenic challenge, is specific and is mediated by T lymphocytes - 
antibody and complement not being necessary (Zembala & Asherson, 1973; 
Vedas, Miller, McKenzie, Chism, Shen, Boyse, Gamble & Whitelaw, 1976; 
Moorhead, 1978). 
Hypersensitivity to antigens in mice has been assessed following 
elicitation with specific antigen by measuring swelling in either 
footpad (Kettman, 1972; Clark & Azar, 1977) or ear (Asherson & Ptak, 
1968; Ruddle, 1978) or by the incorporation of radiolabel (Vedas, 
Miller, Gamble & Whitelaw, 1975). The value of these DTH measurements 
is that they represent a means of quantifying this reaction in vivo. 
The DTH lesion has a characteristic histology and time-course and 
although T lymphocytes are fundamental to the phenomenon they are not 
the only cell involved in the ontogeny of this lesion. All these 
points will be considered in greater detail below. 
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3.2 The Development of the Swelling and Histology of the DTH Lesion 
After challenge with specific antigen the earliest change that occurs 
is an immediate swelling response. This localised oedema is most 
marked 2 hours after challenge and has largely disappeared by 4 hours 
after the application of the contact sensitising agent (Van Loveren, 
Meade & Askenase, 1983). 
After approximately 4 to 8 hours small and medium sized lymphocytes 
begin to infiltrate the perivenular and perivenous areas of the 
superficial vascular plexus at the junction of the papillary and 
reticular dermis. In addition some macrophages and basophils can be 
detected at this time but they are small in number. Over the next 
hours and days the mononuclear infiltrate increases progressively 
reaching a maximum at 24 to 48 hours in the mouse and 3 days in man 
(Dvorak, Mihm, Dvorak, Johnson, Manseau, Morgan & Colvin, 1974; Scovern 
& Kantor, 1982). As the lesion matures, the infiltrating lymphocytes 
appear to be larger but fully developed immunoblasts (of the type seen 
in draining lymph nodes) are rare. 
As the mononuclear infiltrate increases and spreads to involve the 
intervascular areas of both the dermis and epidermis the number of 
polymorphmononuclear cells (PMNLs) also increase following the 
distribution of the lymphocytes. By 24 hours there is a dense 
infiltrate of PMNLs both in the dermis and epidermis. These cells 
consist chiefly of basophils but the other leucocytic component depends 
on the means of antigenic challenge. When contact sensitising agents 
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are used eosinophils are the second most frequent PMNL. Neutrophils 
take their place when antigen is intredermally injected (Dvorak 
et al, 1974). 
Electron microscopy has revealed that although there are signs of 
surface activation of tissue mast cells and basophils as early as 6 
hours after challenge, degranulation of these cells does not appear to 
occur until 18 hours after challenge. It should be noted, however, 
that no ultrastructural studies have been performed on DTH lesions 
earlier than 6 hours after challenge. It is also approximately 18 
hours after challenge that ultrastructural changes are occuring in 
endothelial cells of the postcapillary venules of the superficial 
vascular plexus. These include separation of the intercellular 
junctions and thinning of the endothelial cell cytoplasm which allow 
the migration of leucocytes through these cell gaps by diapedesis 
(Dvorak at al, 1974; Dvorak, Mihm & Dvorak, 1976; Askenase, 
Bursztajn, Gershon & Gershon, 1980). 
This increase in vascular permeability assists in the processes 
responsible for the cellular infiltration, increasing dermal and 
epidermal oedema, vascular compaction and fibrin deposition which is 
characteristic of a fully developed DTH lesion and which causes the 
measurable increase in footpad or ear thickness which occurs between 24 
and 72 hours after antigenic challenge depending on the species studied 
(Dvorak at al, 1974). 
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3.3 Cellular Interactions in DTH 
In DTH, local challenge with antigen elicits an antigen-specific 
delayed inflammatory action that depends on the ability of sensitised T 
lymphocytes to recruit non-immune, blood-borne cells into the 
extravascular tissues (Kosunen, Waksman, Flax & Tihen, 1963; Najarian & 
Feldman, 1963; Cohen, McCluskey & Benacerraf, 1967; Asherson & Ptak, 
1968; Lubaroff & Waksman, 1968). It had been held that DTH depended 
solely on the ability of these lymphocytes to release lymphokines and 
sequester circulating leucocytes into the site of antigen challenge but 
there is now some controversy over the mechanism by which circulating 
primed lymphocytes are themselves brought into contact with antigen. 
In particular, the role of the tissue mast cell has recently been the 
subject of conflicting reports. 
T lymphocytes have a central role in DTH reactions. Transfer of DTH to 
heterologous erythrocytes and soluble protein in the mouse is mediated 
by the Lyt-1+ 2-/Ia- subset of circulating T cells (Huber, Devinsky, 
Gershon & Cantor, 1976; Vedas at al, 1976). DTH against allogeneic 
cells and viral antigens can be mediated by an Lyt-1- 23+ subpopulation 
(Smith & Miller, 1979e; Smith & Miller, 1979b; Leung & Ada, 1980). 
Recent reports of mouse cell lines indicate that DTH may be mediated by 
both Lyt-2- and Lyt-2+ cells and that these cells may display 
considerable flexibility in their function (Bianchi, Hooijkaas, 
Benner, Tees, Nordin & Schreier, 1981; Dennert, Weiss & Warner, 1981; 
Weiss & Dennert, 1981; Kaufmann & Hann, 1982; Thomas, Mottram, & 
Miller, 1982; Milon, Marchal, Semen, Truffa-Bachi & Zilberfarb, 1983; 
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Tamura, Chiba, Kojima & Uchida, 1983). 
The first event required for the manifestation of DTH responses is the 
induction of antigen-specific T cells which requires two signals: 
antigens presented in association with the appropriate Class II major 
histocompatability antigens on the macrophage or dendritic cell 
surface, and a nonantigen-specific mediator, with the properties of 
interleukin I, produced by macrophages (Shevach & Rosenthal, 1973; 
Katz, Graves, Dorf, Dimuzio & Benaceraff, 1975; Schwartz, David, Sachs 
& Paul, 1976; Thomas, Yamashita & Shevach, 1977; DeFreites, Chesnut, 
Grey & Chiller, 1983; Jakway & Shevach, 1983). These events may result 
in the expression of interleukin II (IL2) receptor sites on T cells, 
the production of IL2 by T cells and the production of lymphokines 
(Abramson, Brown, Puck & Rich, 1983; DeFreitas et al, 1983). The 
final manifestation of a DTH response is controlled by the Ir-genes of 
the responding animal and by the activity of regulatory suppressor 
cells or mediators (Strassmann, Eshhar & Mozes, 1980a; Strassmann, 
Eshhar & Mozes, 1980b; reviewed: Turk, 1980; reviewed: Geczy; 1984). 
T-T cell interactions may mediate the effector phase of DTH (Strassman 
at al, 1980b; Van Loveren, Kato, Meade, Green, Horowitz, Ptak & 
Askenase, 1984). These interactions may involve the amplification of 
the action of one cell by another or the more efficient distribution of 
a second effector cell due to the action of the first. Furthermore, it 
has been suggested that the second of these two interactions is itself 
mediated via a non-lymphoid cell, the tissue mast cell (Miller & 
Butler, 1983; Van Loveren at at, 1983; Van Loveren at al, 1984). 
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Van Loveren and his colleagues have described an attractive model for 
the initial stage of the DTH reaction which attempts to explain the 
process by which circulating antigen-specific T cells may be brought 
into contact with antigen deposited in the tissues after challenge 
(Askenase & Van Loveren, 1983). 
They have demonstrated an effector T cell which produces a lymphokine 
(PCLF) which is able to transfer, in an antigen-specific non-H2- 
restricted manner, the early swelling phase of DTH. They have also 
shown that this swelling may be inhibited by serotonin antagonists and 
the subsequent late phase of DTH is not present in mast cell-deficient 
mice. They have therefore suggested that serotonin release from PCLF- 
sensitised tissue mast cells (in the presence of antigen) allows the 
ingress of the second DTH effector T cell which then mediates the late- 
phase reaction of DTH (Askenase, Rosenstein & Ptak, 1983; Van Loveren 
et al, 1984; Gershon, Askenase & Gershon, 1975; Schwartz, Askenase 
& Gershon, 1977; Askenase et ei, 1980; Askenase, Van Loveren, 
Kraeuter-Kops, Ron, Meade, Theoharides, Nordlund, Scovern, Gershon & 
Ptak, 1983). 
Recently, however, several authors have reported that although 
serotonin antagonists may inhibit the delayed-phase of the DTH 
reaction, both mast cell-deficient and serotonin-deficient animals are 
capable of expressing normal, or even increased, classical DTH 
reactions (Thomas & Schrader, 1983; Galli & Hammel, 1984). 
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Although this casts doubt on the role of the mast cell in the early 
ingress of DTH effector cells to the site of antigenic challenge, it 
does not exclude the possibility of this phenomenon occurring 
altogether - perhaps mediated by another resident population of cells. 
This is further corroborated by the fact that although PCLF can 
transfer the early phase of DTH it cannot directly sensitise mast cells 
either in vivo or in vitro (Askenase et al, 1983). 
This model still remains the most attractive explanation for the 
efficient approximation of effector T cell and challenge antigen. 
Although some T cell clones may lack the cell surface determinants 
which react with endothelial cells in lymphoid organs and thus have 
abnormal migratory patterns, this model goes some way to explain why 
other clones can transfer DTH when injected locally but are unable to 
do so when given systemically (Bianchi at all 1981; Dennert 
et all 1981; Lin & Askonas, 1981; Weiss & Dennert, 1981; Marchal, 
Seman, Milon, Truffa-Bachi & Zilberfarb, 1982; Minami, Okuda) Sunday & 
Dorf, 1982; Thomas et all 1982; Carroll, Palladino, Oettgen & De 
Sousa, 1983; Gallatin, Weissman & Butcher, 1983; Tamura at all 
1983). 
3.4 The Role of Lymphokines in the inflammatory phase of the DTH 
Reaction 
Since the description of the first lymphokine, MIF in 1966 it is clear 
that these soluble products had a role to play in the expression of 
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DTH. This next section will be a brief review of the effect of these 
substances on the development of the inflammatory phase of the delayed 
skin reaction. 
Before presenting a more detailed discussion of lymphokine function, it 
is as well to highlight some limitations of research in this area. 
Lymphokine activities have generally been derived from supernatants of 
heterogeneous cellular populations. Recent evidence suggests that Lyt- 
2- and Lyt-2+ lymphocytes, B lymphocytes, lymphoid cell lines and even 
non-lymphoid cells can produce lymphokines in addition to the more 
commonly described Lyt-1+ 2- T cells and their often obligatory 
macrophage (Geczy, Farram, Moon, Meyer & McKenzie, 1983; Guerne, Piguet 
& Vassalli, 1983; Bigazzi, Yoshida, Ward & Cohen, 1975; Kuhner, Cantor 
& David, 1980; Landolfo, Herberman & Holden, 1978; Miura, Shimokawa, 
Honda & Hayashi, 1983; Nelson & Leu, 1975; Newman, Gordon, 
Hemmerling, Senik & Bloom, 1978; Sorg & Geczy, 1978; Rosenstreich & 
Wahl, 1979). Studies using T lymphomas and T cell hybridomas have 
shown that they may produce supernatants with multiple lymphokine 
activities and it is still not clear whether a single lymphokine 
molecule may have multiple activities (Farrar, Fuller-Farrar, Simon, 
Hilfinker, Stadler & Farrar, 1980; Higushi, Asada, Kobayashi & Osawa, 
1983; Gemsa, Debatin, Kramer, Kubleka, Deimann, Kees & Krammer, 1983; 
Papageorgiou, Henley & Glade, 1972; Prystowsky, Ely, Beller, Eisenberg, 
Goldman, Goldman, Goldwasser, Ihle, Quintans, Remold, Vogel & Fitch, 
1982; Prystowsky, Ely, Vogel, Goldwasser & Fitch, 1983; Remold, Mednis, 
Kawaguchi, Bersch & Golde, 1983; Schrader & Clark-Lewis, 1981; 
Schreiber, Altman & Katz, 1982; Schreiber, Pace, Russell, Altman & 
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Katz, 1983; Smith, Gilbride & Favata, 1980). Furthermore, several 
molecules may have the same biologic activity and these functions may 
be altered by enzymatic modification (Huff, Uede, Iwata & Ishizaka, 
1983; Männel & Falk, 1983; Nathan, Murray, Wiebe & Rubin, 1983; 
Schreiber et al, 1983). Finally, the study of the molecular 
mechanisms of lymphokine-induced responses is often complicated by the 
heterogeneity of responding cell populations, the complexity and semi- 
quantitive nature of the bioassays and the requirements for second 
signals (Geczy, 1984). 
The processes by which lymphokines may promote the development of the 
inflammatory phase of the DTH reaction may be divided into three areas. 
They may affect the permeability of cutaneous vessels, exert 
chemotactic effects on lymphoid and non-lymphoid cells and inhibit the 
migration of cells away from the site of the DTH lesion. These actions 
may be accomplished both directly and indirectly and have been 
summarised in table 3.1. 
Three lymphokines have been directly implicated in increasing vascular 
permeability. Lymph node permeability factor (LNPF) was the first to 
be described but is present in the extracts from both non-immune 
lymphoid and non-lymphoid cells leaving its role in DTH open to 
question (Walters & Willoughby, 1965; reviewed: Willoughby, 1973). 
Skin reactive factor (SRF) induces skin lesions typical of DTH 3 to 5 
hours after Intradermal injection in Guinea-pigs (Bennett & Bloom, 
1968). This factor is as yet not fully characterised and its effects 
in vivo may be due to a number of mediators in unfractionated 
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supernatants (Morley & Williams, 1973; Pick, Krejci, Cech & Turk, 1969; 
Pick, Krejci & Turk, 1970; Schwartz, Cantanzaro & Leon, 1971; 
Warrington, Buehler & Roberts, 1976; Yoshida & Cohen, 1974). Most 
recently, PCLF, an antigen-specific factor produced by Lyt-1+ 23- 
murine T cells, has been shown to transfer the early swelling phase of 
DTH. This factor which has T cell but no B cell antigenic 
determinants, weighs less than 70,000 daltons and has some biological 
actions similar to IgE (Askenase et al, 1983; Van Loveren 
et al, 1984). Its role in DTH has been discussed earlier in this 
chapter (section 3.3). 
Lymphokines may also produce changes in vascular permeability 
indirectly. Several factors produced as a consequence of coagulation 
cascade activation may also participate in inflammatory reactions. 
Thrombin-activated platelet-derived products may contribute to vascular 
permeability changes in DTH (reviewed: Osler & Siraganian, 1972; Ryan & 
Majno, 1977). Thromboplastic factors, fibrin and fibrinopeptides also 
behave as vasoactive peptides (reviewed: Belew, Gerdin, Porath 
Saldeen, 1978; Jansco, 1961; Ratnoff, 1969). In addition lymphokines 
induce plasminogen-activator from macrophages and so permeability 
changes as a result of plasmin degradation of fibrin are possible 
(Ratnoff, 1969). Plasmin may also induce the formation of the 
vasoactive kinins, C5a and C3a (reviewed: Ryan & Manjo, 1977; Larsen & 
Henson, 1983). Finally, lymphokines may mediate a change in vascular 
permeability through the production of oxygen-free radicals or by the 
Induction of the release of prostaglandin E from macrophages (Johnston, 
Godzik & Cohn, 1978; Nathan, Nogueira, Juangbhanich, Ellis & Cohn, 
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1979; Murray & Cohn, 1980; Hopper & Cahill, 1983; Clement & Leymeyer, 
1983). 
Circulating leukocytes are recruited from the intravascular compartment 
to the site of antigenic challenge. This is the result of local 
generation of lymphocyte-derived chemotactic factors which direct cell 
migration along an increasing concentration gradient of the factor to 
the site (reviewed; Rocklin, Bendtzen & Greineder, 1980; Snyderman & 
Goetzl, 1981). 
The first chemotactic lymphokine was described by Ward and his 
colleagues as chemotactic for macrophages (MCF) (Ward, Remold & David, 
1969). Chemotactic factors for neutrophils, basophils, eosinophils, 
lymphocytes and fibroblasts have been reported (Cohen & Ward, 1971; 
Ward, Unanue, Goralnick & Schreiner, 1979; Postlethwaite, Snyderman & 
Kang, 1976). Recent studies indicate that murine Lyt-1+ 2- T cells 
stimulated with antigen or mitogen produce chemotactic factors for 
lymphocytes and macrophages (Miura, Shimokawa, Honda & Hayashi, 1983; 
Shimokawa, Miura, Hifumi & Hayashi, 1983). In addition, chemotactic 
factors have been extracted from the sites of DTH reactions indicating 
that these factors may be involved in cell recruitment in vivo (Cohen, 
Ward, Yoshida & Burek, 1973; Honda, Miura, Kuratsu & Hayashi, 1982). 
Murine Lyt-l+ 2- T cells and Ia+ accessory cells when stimulated with 
Concanavalin A, periodate or antigen produce macrophage procoagulant- 
inducing factor (MPIF) (Geczy, 1984). MPIF may activate coagulation 
and products of the coagulation sequence may also participate in 
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chemotaxis. Thrombin may be directly chemotactic for monocytes and 
macrophage cell lines, may induce the production of platelet factor 4 
(a powerful chemoattractant for moncytes and neutrophils) or cleave 
fibrinopeptide B from fibrinogen (Deuel, Senior, Chang, Griffin, 
Heinrickson & Kaiser, 1981; Bar-Shavit, Kahn, Fenton & Wilner, 1983). 
Fibrinopeptide B is chemotactic for neutrophils and eosinophils (Kay, 
Pepper & McKenzie, 1974). Other lymphokine-activated enzymes including 
plasminogen activator and kallikrein are chemotactic for monocytes, 
neutrophils and basophils (reviewed: Kay & Kaplan, 1975). Recent 
experiments have shown that aT cell-derived lymphokine which induces 
macrophage aggregation is fibronectin (Godfrey & Purhoit, 1982). 
Fibronectin is chemotectic for fibroblasts and its fragments attract 
monocytes (Prydz & Lyberg, 1980; Norris, Clark, Swigart, Huft, Weston & 
Howell, 1982). 
Following the attraction of mononuclear cells to the site of antigenic 
challenge, the migration inhibition lymphokines presumably retain the 
emigrated cells in the area. The best characterised of these factors 
are migration inhibition factors for macrophages (MIF) and for 
leukocytes (LIF). These lymphokines have been the subject of several 
reviews detailing their production, measurement, chemical 
characteristics and mode of action (David, 1971; Pick, 1979; Rocklin, 
1981; Schrader & Clark-Lewis, 1981). Other lymphokines capable of 
inhibiting the migration of neutrophils (NIF-T), lymphocytes (LMIF) and 
macrophages (MIF and MaggF/fibronectin) have been described (Weissbart, 
Lusis, Kecena, Spolter, Eggena & Golde, 1982; Mowat & Ferguson, 1982a; 
Mowat & Ferguson, 1982b; Godfrey & Purhoit, 1982). Although the 
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mechanism of migration inhibition is still unresolved, recent 
experiments suggest that one mechanism whereby inhibition occurs is by 
activation of the coagulation cascade resulting in the crosslinking of 
surface-bound fibrinogen, thereby immobilising the cells (Hopper, Geczy 
& Davies, 1981). This reaction is mediated by MPIF (Geczy, 1984). 
This section has dealt only with the role of lymphokine in the 
development of the inflammatory phase of the DTH reaction. Lymphokines 
may also be involved with the induction of T cells (as alluded to 
earlier), the deposition of fibrin (which results in the induration 
typical of DTH) and the regulation of the process itself. 
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Factors affecting wtanews vessels 
a. Lymphokines acting directly 
Lymph node permeability factor (LNPF) 
Skin-reactive factor (SRF) 
Antigen-specific factor transferring early swelling response (PCLF) 
b. Lymphokines acting indirectly 
Macrophage procoagulant inducing factor (MPIF) - activation of coagulation: Thrombin-induced platelet activation-vasoactive products 
Vasoactive fibrinopeptides 
Plasmin fibrinolysis: vasoactive fibrinopeptides 
kinins 
C5a, C3a 
Lymphokine-induced (MAF) oxygen-free radical production by macraphages 
Lymphokine-induced (MAF) prostoglandin production by macrophages 
Factors affecting dhesotaxis 
a. Lymphokines acting directly 







b. Lymphokines acting indirectly 
MPIF-induced activation of coagulation: 
Thrombin: chemotactic for macrophages 
Fibrinopeptide B/fibrin: chemotactic for eosinophila and neutrophila Thrombin-induced platelet activation: platelet factor 4, chemotactic for monocytes 
and neutrophils 
Plasminogen activator: chemotactic for monocytes, neutrophils, and basophils pis min- ibrinolysis: fibrinopeptides chemotactic for monocytes, neutrophila, and 
eosinophils 
Fibronectin (MaggF)s chemotactic for fibroblasts 
Fibronectin fragmants: chemotactic for monocytes 
Factors affecting cell migration 
Leukocyte migration inhibition factor (LIF) 
Lymphocyte migration inhibition factor (LMIF) 
Neutrophil migration inhibition factor (NIF-T) 
Macrophage migration inhibition factor (MIF) 
Macrophage procoagulant inducing factor (MPIF) 
Macrophage aggregation factor (MaggF) (Fibronectin) 




MATERIALS AND METHODS 
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4.1 Animals 
Adult BALB/c inbred mice were used normally between the ages of 6 to 12 
weeks. Both sexes of mice were employed but within each separate 
experiment animals of one gender only were used. 
Mixed strain Guinea-pigs and rabbits (Scottish Antibody Production 
Unit) were used as a source of complement. 
All animals, with the exception of the rabbits, were bred and 
maintained in the Animal Unit, Western General Hospital, Edinburgh. 
4.2 Diet 
Animals were maintained on a standard ovalbumin-free rodent diet 
(Labsure CRM (X)) and had access to tap water ad libilum. 
4.3 Anaesthesia 
Procedures such as footpad injection were carried out under light ether 
anaesthesia. Bleeding of mice from axillary vessels was performed 
under heavier ether anaesthesia as this was a pre-terminal event. 
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4.4 Sacrifice of Animals 
Mice were killed by cervical dislocation. 
4.5 Bleeding of Mice 
Small quantities of blood were obtained routinely from the retro- 
orbital plexus under ether anaesthesia using heparinised haematocrit 
tubes (Propper Ltd). In this way, approximately 300 µl could be 
obtained from each mouse at regular intervals. When large quantities 
of blood were required, mice were bled out from the axillary vessels. 
4.6 Removal of Mouse Feet 
Mouse feet were removed for histology immediately after sacrifice. The 
specimens were excised above the ankle joint. 
4.7 Histology 
After removal, mouse feet were immediately placed in 10% phosphate 
buffered formalin. The tissues were left in this fixative for 7 to 10 
days. At the end of this time, two thin longitudinal strips of tissue 
were excised on the medial and lateral aspects of the foot, which 
included the innermost and outermost toes. 
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The specimens were then placed in a neutral EDTA solution to decalcify 
the osseus material. This process took between 4 to 6 weeks and the 
progress was monitored by the radio-opacity of the bones on x-rays. An 
x-ray unit (Watson R600) was used for this purpose. 
When the bones were of the same density as the surrounding soft 
tissues, the specimens were embedded in paraffin wax and longitudinal 
sections of 4 µm thickness were cut. 
Tissues processed in this way were stained with Haematoxylin and Eosin. 
4.8 Cyclopho8pharnide 
Mice were given 100 mg/kg cyclophosphamide (Endoxana WB Ltd) in 
saline, intraperitoneally. 
4.9 Antigens 
Purified cholera toxin (CT) and toxoid (TD) were the antigens most 
frequently used throughout this work. 
Purified cholera toxin was obtained from both the Sigma Chemical 
Company, Dorset, England and from List Biological Laboratories Inc., 
California, USA. 
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The immunopurified formalinised toxoid (lot No: VT2216/7A) was a kind 
gift from Dr R0 Thompson of the Wellcome Research Laboratories, 
Beckenham, Kent. To prepare this toxoid, formalinised vibrio culture 
supernatants were concentrated by ammonium sulphate precipitation. 
This concentrate was dialysed and then applied to an equine antitoxin- 
bound affinity column. This adsorbed toxoid was eluted with acid, 
neutralised and further incubated with formalin to prevent toxic 
reversion. This resultant toxoid was then concentrated and the 
residual formalin removed by ultrafiltration. 
Purified cholera toxin B subunit or CTB (List Biological Laboratories 
Inc. ) and ovalbumin or OVA (chicken egg albumin, Grade V; Sigma 
Chemical Co) were also used. 
4.10 Parenteral Immunisation of Mice 
Mice were immunised for studies of systemic immunity with antigen in 
complete Freund's adjuvant (CFA: H37Ra - Difco Ltd) intradermally into 
one rear footpad. Occasionally, mice were also immunised with antigen 
in incomplete Freund's adjuvant (IFA: 0639-59 - Difco Ltd). 
When lymphocytes were required for assays of CMI, mice were immunised 
with either 1 µg CT, 100 µg OVA or saline in CFA into both rear 
footpads and the draining lymph nodes were subsequently removed. 
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4.11 Oral Immunisation of Mice 
Unanaesthetised mice were fed antigens in a solution of PBS pH 7.6 
containing 6% NaHCO3 (alkaline-buffered saline: ABS) intragastrically 
using a rigid, steel feeding tube with a rounded end. 
4.12 Direct Skin Testing for Systemic DTH 
Mice were tested by measurement of footpad thickness before and 24 
hours after an intradermal injection of antigen in 50 µl of saline, 
using a pair of skin calipers (Pocotest A- Carobronze Ltd). In each 
case, immunised mice were also tested with 50 1A of saline as 
controls. There was normally no net increase in footpad thickness 24 
hours after this control injection. 
4.13 Footpad Challenge with Antigen 
Cholera toxin has been shown to cause oedema after intradermal 
injection into rat (Finkelstein & Hollingsworth, 1970) and mouse 
footpads (Lexomboon, Goth & Finkelstein, 1971). As any extranous 
swelling would interfere with the measurement of systemic DTH, 
intradermal injections of various doses of cholera toxin and toxoid 
were given into the rear footpads of unimmunised mice. The incremental 
change in footpad thickness at 24 hours was compared to that observed 
in saline-inoculated animals. 
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As can be seen from figure 4.1, an injection of saline did not cause 
any footpad swelling. However, all doses of toxin and the highest dose 
of toxoid (50 µg) did (p<0.001 in all cases), although the toxoid 
caused considerably less footpad oedema than the choleragen inoculates 
(p<0.001). 
The two lower doses of toxoid and the unrelated protein antigen, 
ovalbumin, did not significantly alter footpad thickness 24 hours after 
injection. For this reason, 5 µg of toxoid was used to elicit DTH 
responses in toxin- and toxoid-immunised animals. 
4.14 Enzyme-linked Immunosorbent Assays for the Detection of 
Circulating Antibody 
a) IgG anti-cholera toxin ELISA 
EIA microtitration plates (M129A; Dynatech Ltd) were coated at 41, C 
for 16 hours with 5 jig/ml solution of purified cholera toxin in a 
0.05 M carbonate buffer pH 9.6. These plates were then sequentially 
incubated with serum samples or with a hyperimmune mouse serum diluted 
1/200 with serum diluent for 2} hours at roo m temperature, 1/5000 
dilution of alkaline phosphatese-conjugated goat anti-mouse IgG (heavy 
and light chain) affinity-purified IgG antibody (Jackson 
Immunoresearch) in serum diluent for 3} hours at room temperature, 
and finally, p-nitrophenylphosphate substrate (Sigma) in a 10% 
Diethanolamine buffer pH 8.6 for approximately 30 minutes at room 
temperature. 
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The wells were extensively washed between incubations with an isotonic 
saline solution containing 0.5% Tween 20 (Sigma) and 2% horse serum. 
The plates were read in a MR 580 micro ELISA autoreader (Dynatech 
Instruments). Mouse IgG antitoxin levels were recorded as light 
absorbance readings at 405 nm, all results were adjusted by a 
correction factor so that the positive hyperimmune serum raised in 
BALB/c mice gave a value of 1.00. 
b) IgM anti-cholera toxin ELISA 
The same procedure as above was employed with minor modifications. The 
plates were coated as before, but the serum to be assayed was diluted 
1/100. All incubation conditions and times were as above except that 
the detecting antibody used in this ELISA was a 1/2000 dilution of 
alkaline phosphate-conjugated goat anti-mouse µ chain IgG antibody. 
The remaining steps are as described above. 
c) IgA anti-cholera toxin EUSA 
Microtitre plates were coated with a5 µg/ml solution of purified 
toxin in a carbonate buffer for 2 hours at 37 °C and were then 
incubated with a 1/20 dilution of the serum to be tested for 16 hours 
at 4°C. Any bound antibody was detected by incubating the plate 
with a rabbit anti-mouse alpha chain antibody (Lutton Bionetics Inc) at 
a 1/1000 dilution followed by an alkaline phosphatase-conjugated goat 
anti-rabbit IgG antiserum (Northeast Biomedical) also diluted 1/1000. 
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Both these incubations were for 6 hours at room temperature. Substrate 
and washes were as for the other ELISAs. 
d) IgG anti-cholera toxoid ELISA 
EIA plates were coated with a 5 µg/ml solution of cholera toxoid in 
carbonate buffer for 16 hours at 40 C. Sequential incuba tions were 
performed with a 1/200 dilution of mouse serum and a 1/500 dilution of 
alkaline phosphatase-conjugated goat anti- mouse IgG (heavy and light 
chain) affinity purified IgG antibody for 21 and 3j hours, 
respectively, at room temperature. 
e) IgG anti-ovalbumin ELISA 
Ovalbumin was used as the solid phase antigen by coating EIA plates 
with a 10 µg/ml solution in carbonate buffer for 16 hours at 40 C. 
Mouse serum was diluted 1/400 and incubated as above. The remaining 
steps are also as described above. 
Details of these assays are summarised in table 4.1. 
4.15 Preparation of Cell Suspensions 
Spleens and mesenteric and peripheral lymph nodes were removed 
immediately after sacrifice. After washing in RPMI 1640 (Flow Labs) 
they were dissected free of surrounding material and cut into small 
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pieces with scissors. The pieces were then gently pushed through a 
fine gauge wire mesh using the plunger of a5 ml syringe (BD Ltd). The 
resulting cell suspension was washed x3 at 400 g in unaltered RPMI 
1640 for cell transfer experiments and in supplimented medium for 
lymphocyte migration inhibition assays. Cell viability was assessed by 
the Trypan blue exclusion method and was normally greater then 90%. 
4.16 Detection of sensitisation in peripheral lymph nodes by 
lymphocyte migration inhibiton 
Popliteal and inguinal lymph nodes were taken from animals immunised 
bilaterally into the rear footpads with antigen in CFA. After 
processing, cell suspensions were adjusted to 1.5 x 10 a /ml in complete 
RPMI 1640 and 10 µl capillary tubes (Drummond Microcaps) filled with 
the cells. After sealing one end with parafin wax (Cristoseal - 
Hawksley Ltd), these were pelleted at 400 g for 4 minutes and the tubes 
cut just above the cell pellet. The parts containing the cells were 
then placed in wells of migration inhibition plates (Sterilin Ltd), 
being held in place with silicone vacuum grease (Edwards Ltd). The 
wells were then filled with 0.5 ml complete RPMI 1640 alone or medium 
containing various concentrations of antigen, sealed with a coverslip 
and incubated for 21 hours at 370 C. 
After culture, the areas of migration were drawn using a camera lucida 
(Zeiss Ltd) attached to a Zeiss Spectromicroscope and measured by 
planimetry. The results are expressed as a migration index obtained as 
75 
follows: 
MI = Area of migration in wells containing antigen 
Area of migration in medium alone 
A minimum of 6 wells were used for each antigen concentration. 
4.17 Reduction of Toxicity in Guinea-Pig and Rabbit Serum 
2x 10 7 lymphoid cells/ml of complete RPMI 1640 were suspended in 1/10 
dilution of fresh Guniea-pig or rabbit serum and incubated at 371, C 
for 40 minutes. Cells were washed 3 times and viable cells were 
counted using Trypan blue exclusion. 
Both Guinea-pig and rabbit serum are non-specifically toxic to both 
splenic lymphocytes and thymocytes (table 4.2). 
In order to reduce this toxicity, a crude suspension of BALB/c 
thymocytes and spleen cells were suspended in the fresh serum in a 
proportion of 1 part cells to 9 parts serum, by volume. This mixture 
was agitated gently for 1 hour at 40 C. At the end of this time, the 
suspension was centrifuged at 800 g for 10 minutes, the 'absorbed' 
supernatant was decanted and incubated with splenocytes at 3711 C to 
assess residual toxicity. As can be seen from table 4.3, this 
proceedure dramatically reduced the cytotoxicity of the Guinea-pig and 
rabbit serum. 
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4.18 Elimination of T Cells from Cell Suspensions 
2x 10 7 lymphoid cells/ml of complete RPMI 1640 were incubated for 30 
minutes at room temperature in 1/1000 dilution of monoclonal IgM anti- 
Thy-1.2 antiserum (F7D5 - Serotech Ltd). The cells were then washed 3 
times in medium, resuspended in 1/10 dilution of 'absorbed' Guinea-pig 
or rabbit serum as a source of complement and incubated at 370 C for 
40 minutes. Cells were washed 3 times before use. In cytotoxicity 
assays, killing was assessed by Trypan blue exclusion. 
As can be seen in table 4.4, both sources of complement became lethal 
to lymphoid cells when used in conjunction with monoclonal antibody. 
The combination appears to be particularly effective at removing T 
cells as shown by the depletion of thymocytes. 
4.19 Identification of Lymphocyte Classes by an Imnxxnoperoxidese 
Technique 
To identify surface immunoglobulin-positive (slg+) cells, 15 drops of a 
5x 10 5 lymphoid cell suspension in medium were cytocentrifuged at 1000 
RPM for 10 mins. 
The resultant preparation was fixed for 10 minutes in a solution of 
acetone with 0.5% H202- The- slide was washed in phosphate buffered 
saline pH 7.6 and incubated with a 1/10 dilution of horseraddish 
peroxidase-labelled rabbit anti-mouse immunoglobulins (Dako Ltd) for 30 
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minutes at room temperature in a damp box. The slide was washed twice 
in PBS and the peroxidase stain was developed with a filtered 3,4- 
diaminobenzidine solution (DAB: BDH Ltd) for approximately 10 minutes. 
The cells were counterstained with Harris' haematoxylin and the slide 
was coverslipped using a 90% glycerine-in-water mounting medium. Cells 
were examined under an Ortholux microscope (Leitz Ltd) at 400 x 
magnification. 
Thy-1.2-bearing cells were identified indirectly. A cytocentrifuged 
lymphoid cell suspension was prepared as above. The cells were 
incubated with a 1/20 dilution of monoclonal anti-Thy-1.2 for 60 
minutes at room temperature in a damp box. The slides were washed 
twice in PBS and then incubated with a 1/10 dilution of HRP-labelled 
rabbit anti-mouse immunoglobulins. Further steps were as above. The 
proportion of Thy-1.2-positive cells were determined as follows: 
" Thy-1.2-positive =% staining after (anti-Thy-1.2 + anti-mouse Ig) - 
" staining with anti-mouse Ig alone. 
f. 20 Determination of Efficiency of T Cell Elimination from Spleen 
Cell Suspensions 
The above immunoperoxidase technique was used to assess the efficiency 
of absorbed rabbit serum, anti-Thy-1.2 monoclonal antibody or the 
combination of the two at removing the T cell component of splenic 
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lymphocytes. 
Table 4.5 shows that the serum or antibody alone have no effect but the 
combination destroys 98.5% of splenic Thy-1.2-positive cells. 
4.21 Statistics 
Results are expressed ±1 standard deviation, unless otherwise stated. 
Student's t-test was used to compare differences between groups in most 
cases. In experiments including ELISA assays, non-parametric 
distributions were observed and results were compared by Wilcoxon's 
Rank Sum test in addition to the Student t-test. In practice, similar 
significance levels were usually obtained. 
4.22 Solutions and Buffers 
10% phosphate buffered 
formelin: 
(1 litre) 
Neutral EDTA solution: 
(1750 mis) 
Formaldehyde 100 ml 
Distilled water 900 ml 
NaH2PO4.2H20 4g 
Na2HPO4 6.5 g 
Na2 EDTA (BDH Ltd) 250 g 
Distilled water 1750 ml 
pH 7.0 
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Phosphate buffered NaCI 36.0 g 
saline: Anhydrous Na2HPO4 7.49 g 
(5 litres) Anhydrous KH2PO4 2.15 g 
Distilled water 500 ml 
pH 7.6 
10% diethanolamine DEA (diethanolamine: BDH Ltd) 100 ml 
buffer: Distilled water 800 ml 
(900 mis) MgC12.6H20 (BDH Ltd) 0.1015g 
Sodium azide 0.2 g 
pH 8.6 
Tris-HC1 buffers 0.2 M tris [hydroxymethyl] aminomethane 25 mis 
(100 mis) (BDH Ltd) 
0.1 N HC1 75 mis 
3,4-diaminobenzidine DAB (3,4-dieminobenzidine: BDH Ltd) 10 mg 
solution: 30% u/v H0 10 Al 
Tris-HC1 buffer pH 25 ml 
ELISA reagents: 
Carbonate buffer: Carbonate buffer 0.05 M pH 9.6 
(North East Biochemicals Ltd) 
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Washing solution: 0.05% Tween 20 (BDH Ltd) 
in physiological saline 
Serum diluent: 0.05% Tween 20 in 
physiological saline 
0.2% sodium azide (BDH Ltd) 
Complete RPMI 1640 RPMI 1640 (Flow Labs) 100 ml 
medium: Penicillin (5000 u/ml)/Streptomycin 
(5000 jig/ml) (Flow Labs) 2 ml 
Hepes buffer 1M (Flow Labs) 1.5 ml 







Figure 4.1 The non-epecitic footpad a. llirg cvMed by Lhtr deruel injection 
of antigen 
This graph shows the increment in footpad thickness 24 hours after the 
injection of saline or various antigens dissolved in saline. The volume of 
inoculate was 50 N1. The bars represent the mean increment in footpad 
thickness ± standard deviation for each group. 
All results were compared to those obtained from mice injected with saline 
only. 
* p<0.001 
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Table 4.1 Protocols for ELISA assays 
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% Cytotoxicity of lymphoid cells 
Spleen Thymus 
Guinea-pig serum 67.7 56.0 
Rabbit serum 30.3 71.0 
Table 4.2 Cytotoxiclty of fresh Guinea-pig and rabbit sera on various 
lymphoid cells 
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% Cytotoxicity of splenic lymphocytes 
Absorbed Guinea-pig serum 5.0 (0.2 - 9.8) 
Absorbed rabbit serum 2.0 (0.0 - 6.0) 
Table 4.3 Cytotoxicity of 'absorbed' Guinea-pig and rabbit serum to 
splenocytes (mean and range of 3 experiments) 
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Treatment % Cytotoxicity to lymphoid cells 
Peripheral LN Splenic Thymocytes 
cells lymphocytes 
anti-Thy-1.2 abs 
+ Guinea-pig C' 46.0 43.6 95.9 
anti-Thy-1.2 abs 
+ rabbit C' NT 45.4 97.0 
Table 4.4 The effect of anti-Thy-L2 monoclonal antibody in 
combination with two sources of complement on the mortality of various 
lymphoid cell populations. 
NT not tested 
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Treatment % Thy-1.2-positive cells in splenic 
lymphocytes 
None 41.2 
anti-Thy-1.2 alone 40.2 
abs rabbit C' alone 41.8 
anti-Thy-1.2 + abs rabbit Cl 0.6 
Table 4.5 The effect of various incubations of the T cell content of a 
splenic lymphocyte population. 
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Chapter 5 
SYSTEMIC I-UMORAL QTY TO PARENTERAL LY AND ORALLY ADM MTO ED 
CHOLERA TOXIN AND TOXOID 
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5.1 Introduction 
Systemic humoral immunity has been extensively studied in a number of 
animal models following the parenteral administration of cholera toxin 
and toxoid. Both the holotoxin and its immunopurified formalinised 
derivative have been shown to be powerful antigens but generally the 
toxoid has been employed at much higher doses to give equivalent 
results (Peterson, 1979; Fuhrman & Cebra, 1981; Pierce & Gowans, 1975). 
The B subunit is the major antigenic determinant against which 
antitoxin is directed (Pierce, 1978) and so the following experiments 
have employed doses of toxin and toxoid with a similar B subunit 
content so that the relative antigenic potency of these two 
preparations may be more accurately compared. 
Experiments have been designed which examine the systemic antibody 
response to parenterally administered toxin and toxoid, but as it is 
the purpose of this project to also examine the state of cell-mediated 
immunity in these animals, the conditions used to look at humoral 
immunity are also those in which DTH is likely to occur, and will be 
repeated in the following chapter which deals solely with systemic CMI. 
As mentioned above, cholera toxoid is generally used in greater 
quantities than choleragen in order to obtain a similar immune 
response. This requirement is usually explained in terms of poorer 
binding to gangliosides or reduced adenylate cyclase activation 
(Pierce, 1978) but the possibility that formalinisation limits the 
antigenic cross-reactivity between these two proteins has never been 
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examined. To this end, an anti-toxoid ELISA has been developed so that 
both anti-toxoid and antitoxin responses can be measured following the 
administration of these antigens by both of the above routes. 
Animals have also been prefed both toxin and toxoid in order to examine 
the effect of initial enteric exposure on the subsequent development of 
specific systemic antibody responses. 
5.2 Systemic Humoral Immunity to Cholera Toxin 
BALB/c mice were immunised with either saline or 1 µg CT in CFA into 
the hind footpad. Two weeks later the animals were given a second 
intradermal injection of 5 µg TD in saline into the contralateral 
footpad. IgG, IgM and IgA antitoxin antibody levels were measured 7, 
13 and 22 days after the initial injection and comparison was made 
between the two groups of animals. 
IgG antitoxin levels (figure 5.1) were undetectable in saline-primed 
animals at all the times tested. Similarly low IgA antitoxin levels 
were obtained from these animals (figure 5.2). Although positive 
readings were detected from this group when the specific IgM isotype 
was measured, this probably reflects non-specific binding by this class 
of antibody (figure 5.3). When one considers the results of the CT- 
primed animals, IgG antitoxin levels were significantly greater than 
those detected in the saline-immunised controls at all times tested 
(p<0.05 on day 7, p<0.01 on days 13 and 22). The largest difference 
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between the two groups was seen on day 22 of the experiment, eight days 
after the intradermal injection of toxoid. The IgA antitoxin responses 
of the toxin-primed mice were only significantly greater than control 
values (p<0.01) on day 22 of the experiment, that is eight days after 
the toxoid booster injection. Specific IgM antibody was not detected 
as the ELISA absorbance readings did not significantly differ between 
choleregen- and saline-primed animals at any time during the 
experiment. 
5.3 The Influence of Antigen Dose, both Inununisetion and Boosting, on 
the Systemic Antitoxin Antibody Response. 
As can be appreciated from the above results, the greatest levels of 
antitoxin antibody detected in CT-primed animals were found 8 days 
after these mice were given an intradermal booster of toxoid (day 22 of 
the experiment). This time was therefore chosen as the most 
appropriate at which to examine the effects of varying the immunising 
and boosting doses of these two respective substances. Accordingly, 
mice were intradermally primed with either saline or three differing 
doses (0.1 µg, 1.0 µg and 10.0 µg) of CT in CFA. Two weeks later 
these mice were intradermally boosted into the contralateral footpad 
with one of three differing doses of toxoid (0.5 µg, 5.0 µg and 50 
µg). Eight days after this, on day 22 of the experiment, the animals 
were bled and their serum IgG and IgA antitoxin antibody levels were 
measured. 
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Unfortunately there were not enough animals to perform a statistical 
comparison between the groups boosted with 0.5 µg TD but the trends 
observed in the other results also appear to hold true for these 
animals. IgG antitoxin levels were greatest in animals immunised with 
1 or 10 µg CT regardless of the footpad challenge dose of toxoid 
used. The levels observed, in these two groups, did not significantly 
differ from each other but were significantly greater (p<0.05) than 
those measured in animals immunised with 0.1 gg CT which were, in 
turn, significantly greater than the antitoxin responses (p<0.05) of 
saline-immunised controls when challenged with either 5.0 or 50.0 pg 
TD (figure 5.4). 
Results for IgA antitoxin levels were similar in that all toxin-primed 
animals had significantly greater (p<0.05) responses than saline- 
immunised controls. IgA antitoxin antibody levels did not 
significantly differ between groups of toxin-primed animals (figure 
5.5). 
5.4 Comparison of Systemic Antitoxin Humoral Immunity after Toxin or 
Toxoid Immunisation 
As has been mentioned earlier, both cholera toxin and toxoid have been 
shown to be powerful antigens capable of inducing similar antibody 
responses in a variety of animals. Unfortunately, no such comparison 
has been made using equivalent doses of antigen. The major antigenic 
determinants on the holotoxin have been shown to reside on the B 
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subunit, and so the following experiment employed doses of toxin and 
toxoid with a similar B subunit content. As the predominant humoral 
response to parenterally administered toxin is of the IgG isotype, the 
following experiment was confined to assaying this specific class of 
antibody as a measure of the animals' humoral response to priming with 
these two antigens. 
Mice were intradermally primed with either saline, 1 µg CT or 5 µg 
TD in CFA on day 0 of the experiment. As before these animals were 
intradermally boosted with 5 µg TD two weeks later. The mice were 
bled on days 7,13 and 22 of the experiment and the IgG antitoxin 
content of their sera was measured. The results of this experiment are 
shown in figure 5.6. 
Once again, saline-primed animals failed to produce significant IgG 
antitoxin at any time during the experiment. Just as before, the 
toxin-primed animals had significantly higher levels of IgG antitoxin 
antibody (p<0.01) than the saline controls at all times. 
The results of the animals primed with toxoid fell between these two 
extremes. IgG antitoxin levels in toxoid-primed mice did not 
significantly differ from the saline controls until after receiving the 
booster injection (p<0.01 on day 22), but were significantly less than 
specific IgG levels in toxin-primed animals at all times (p<0.05 on day 
7, p<0.01 on days 13 and 22). 
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5.5 Comparison of Antitoxin and Anti-toxoid H noral Immunity after 
Parenteral Immunisation with Toxin or Toxoid 
Toxoid-primed animals may produce poorer antitoxin responses for two 
reasons. Toxoid may be a poorer antigen or anti-toxoid antibody may 
only partially cross-react with the holotoxin. If the toxoid is a 
poorer antigen, then one would expect a lesser humoral response 
regardless of whether antitoxin or anti-toxoid antibody levels were 
measured. However, if the above result represents limited cross- 
reactivity between the two forms of antigen, animals primed and boosted 
and then tested against the same antigenic form should give the highest 
responses, i. e. toxin primed and boosted mice should have the highest 
serum antitoxin antibody levels. 
To examine this, groups of animals were immunised with either 1 µg CT 
or 5 µg TD in CFA as before. Two weeks later half of each group of 
mice received 5 µg TD into the contralateral footpad and half were 
intradermally boosted with 1gg CT in saline. Mice were bled the day 
before and 8 days after recleving booster Injection (days 13 and 22 of 
the experiment). 
Figures 5.7 and 5.8 show the antitoxin and anti-toxoid IgG responses, 
respectively, observed in these animals. Toxin-immunised animals had 
significantly greater (p<0.01) IgG antitoxin responses than mice primed 
with toxoid both before and after boosting. Toxoid was equally 
effective at boosting antitoxin responses as the native holotoxin. 
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After challenge, IgG anti-toxoid levels were not significantly 
different between any of the groups, although the mean absorbance (405 
nm) level was higher in toxoid-primed animals. Similarly, there was no 
statistical difference between the anti-toxoid levels measured in the 
groups before they received their booster injections. However, if 
these day 13 results are pooled (a statistically valid procedure as the 
animals had not been subdivided at this stage), the toxoid-primed 
animals have a significantly increased anti-toxoid response compared 
with the combined results of the two groups of mice primed with toxin 
(p<0.01). 
5.6 Investigation of the Effect of Feeding Choleragen or Toxoid on the 
Subsequent Induction of Systemic Humoral Antitoxin Immunity 
Previous work has shown that one can obtain good antibody responses to 
cholera toxin by priming with antigen in CFA on day 0, boosting with 
toxoid on day 14 and measuring the antitoxin responses on day 22. 
Adding a single antigenic feed to a similar protocol, one week before 
priming (day -7), has been shown to be effective at tolerising both 
systemic CMI and antibody responses to ovalbumin when performed in 
this strain of mice (Mowat et al, 1982). A single feed of either 
choleragen or toxoid was therefore added to the above regime to see if 
either would tolerise systemic antitoxin responses. 
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Animals were fed either alkaline-buffered saline (ABS) alone or ABS 
containing either 1 µg CT or 5 µg TD. Seven days later the animals 
were immunised with 1gg CT in CFA and then boosted with a footpad 
injection of 5 µg toxoid fourteen days after th is. The animals were 
bled for serum IgG and IgA antitoxin estimations 8 days after receiving 
the toxoid booster (day 22 of experiment). 
The serum obtained from the animals on day 22 revealed that neither 
feeding toxin nor toxoid significantly inhibited the induction of an 
IgG or IgA antitoxin response compared with sham-fed controls (figure 
5.9), i. e. oral tolerance was not induced for this antigen. 
5.7 Investigation of the Ontogeny of the Systemic IgG Antitoxin 
Antibody Response after Prefeeding Varying Doses of Choleragen 
In order to ascertain the effect of feeding differing doses of 
choleragen on the induction of systemic immunity, mice were fed either 
0.1,1 or 10 µg CT in ABS as well as ABS alone 7 days before priming 
with an Intradermal injection of 1 µg CT in CFA. Animals were 
boosted with 5 µg TD two weeks after this and antitoxin estimations 
were made on serum obtained on days -1 (pre-immunisation), 7,13 and 22 
of the experiment. The results of this experiment are shown in figure 
5.10. 
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Unfortunately, animals fed 0.1 or 10 µg CT were not bled before 
Immunisation, but IgG antitoxin antibody was not detected in animals 
fed either ABS or 1 µg CT. Seven days after immunisation, there was 
no significant difference in the levels of specific antibody found in 
animals fed either ABS or 0.1 or 1 µg CT. However, the IgG antitoxin 
antibody responses of animals fed 10 µg CT were significantly greater 
than those observed in all other groups at this time (p<0.02). By day 
13, there was no significant difference in the systemic IgG antitoxin 
levels of any these animals and the some was true on day 22 of the 
experiment. 
These results suggest that varying the dose of choleragen fed does not 
induce oral tolerance for antibody but that the oral administration of 
10 µg CT initially appears to induce significantly more priming of 
systemic humoral immunity. 
5.8 Investigation of the Induction of Oral Tolerance for Systemic 
Humoral Anti-toxoid Responses by Feeding Choleragen or Toxoid 
The foregoing experiments have shown that feeding cholera toxin or 
toxoid does not tolerise the induction of systemic antitoxin antibody 
responses. A further experiment was performed to assess the effect of 
prefeeding on the Induction of anti-toxoid humoral immunity. 
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Animals were fed either ABS, 1 µg CT or 5 µg TD one week before 
immunisation. Fed mice were immunised with 5 µg TD in CFA as was a 
group of unfed animals. Other unfed animals were immunised with saline 
in CFA at the same time. After 14 days all animals were intradermally 
boosted with 5 µg TD and serum anti-toxoid levels were measured 8 
days after this. 
The results of this experiment are shown in figure 5.10. They show 
that saline-primed animals gave low IgG anti-toxoid responses even 8 
days after receiving an intradermal booster injection of toxoid. 
Toxoid-primed animals had significantly greater anti-toxoid responses 
(p<0.01). Feeding either ABS, 1 µg CT or 5 µg TD failed to 
tolerise systemic anti-toxoid antibody levels. 
5.9 Summary 
Intradermal immunisation with CT induces significant IgG and IgA 
antitoxin responses especially after boosting with toxoid. Optimal IgG 
and IgA antitoxin responses were obtained after immunisation with 
either 1.0 or 10.0 µg toxin regardless of the booster dose of toxoid 
employed. 
Parenterally administered toxoid also induces significant IgG antitoxin 
levels but these are significantly less than those obtained with the 
holotoxin. Toxoid is as effective as choleragen at boosting antitoxin 
antibody levels but is superior to the native toxin in inducing pre- 
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challenge IgG anti-toxoid responses. It would appear that each antigen 
Is superior at priming for antibodies against Its own antigenic 
determinants but that each are equally capable of boosting primed 
responses regardless of the agent used to stimulate the B cells 
Initially. 
Finally, feeding cholera toxin or toxoid failed to tolerise the 
induction of either antitoxin or anti-toxoid humoral immunity. Work 
performed independently around this time, using a slightly different 
experimental protocol, confirmed the failure of fed choleragen to 
induce oral tolerance for systemic antitoxin antibody responses 
(Ealding & Elson, 1984b). Not only does a single feed of 10 gg CT 
fail to induce oral tolerance but experiments described above suggest 
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Figure 5.1 Systemic 199 antitoxin antibody levels after 1i , da. tion with 
diolrs taoriw 
The above graphs show the serum IgG antitoxin antibody levels obtained from 
mice iwtjnised with either saline (0) or CT (") in CFA. Animals were 
intrsdersally immunised on day 0 and boosted with 5 pg TD in saline on day 
14. Individual animals were bled on day 7,13 and 22 of the experiment and 
their serum was measured in an IgG antitoxin ELISA. The above points 
represent the absorbance readings of these sera in this assay. 
Statistical comparisons were made using the Wilcoxon rank sum test between 
saline- and choleragen-primed animals. 
* p<0.05 
** p<0.01 







DAY OF E(PERIMENT 
Figure 5.2 Systedc IgR antitmcin antibody levels after iýiaatim With 
cholera toxin 
The above graphs show the serum IgA antitoxin antibody levels obtained from 
mice immunised with either saline (0) or CT (0) in CFA. Animals were 
intradermally immunised on day 0 and boosted with 5 pg TD in saline on day 
14. Individual animals were bled on day 7,13 and 22 of the experiment and 
their serum was measured in an IgA antitoxin ELISA. The above points 
represent the absorbance readings of these sera in this assay. 
Statistical comparisons were made using the Wilcoxon rank sum test between 
saline- and choleragen-primed animals. 
* P<0.01 
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DAY OF EXPERIMENT 
Figure 5.3 Systesic Igjl antitoxin antibody levels after Immunization with 
coolers toxin 
The above graph shows the serum IgI antitoxin antibody levels obtained from 
mice immunised with either saline (0) or CT (") in CFA. Animals were 
intradermally immunised on day 0 and boosted with 5 pg TD in saline on day 
14. Individual animals were bled on day 7,13 and 22 of the experiment and 
their serum was measured in an Igo antitoxin ELISA. The above points 
represent the absorbance readings of these sera in this assay. 
Statistical comparisons were made using the Wilcoxon rank sum test between 
saline- and choleragen-primed animals. 
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Figure 5.4 The effect of varying the iamaniestion and boosting domes of 
antigen on the induction of systemic IgG antitoxin antibodies 
The above graph shows the serum IgG antitoxin antibody levels in mice 
immunised with either saline (0 ), 0.1 pg CT (A ), 1.0 pg CT (") or 10.0 
pg CT (A) in CFA. Mice were intradermally immunised on day 0 and boosted 
into the tootped with either 0.5 pg, 5.0 pg or 50.0 pg TD on day 14 of 
the experiment. The points above represent individual antitoxin results 
obtained on day 22 of the experiment. 
Statistical comparison was made between saline- and toxin-immunised animals 
for each dose of toxoid used. 
" p<0.05 
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Figure 5.5 The effect of varying the immueisetion and boosting dose. of 
antigen on the induction of systemic Igl1 antitoxin entibodiea 
The above graph shows the serum IgA antitoxin antibody levels in mice 
immunised with either saline (0 ), 0.1 jig CT (A ), 1.0 jig CT (0) or 10.0 
pg CT (A) in CFA. Mice were intradermally immunised on day 0 and boosted 
into the footpad with either 0.5 Ng, 5.0 pg or 50.0 pg TO on day 14 of 
the experiment. The points above represent individual antitoxin results 
obtained on day 22 of the experiment. 
Statistical comparison was made between saline- and toxin-immunised animals 
for each dose of toxoid used. 
+ p<0.05 




Figure 5.6 The effect of imiiisstion with either cholera toxin or toxoid an 
the induction of apstesiic I¢ antitoxin antibody levels 
The above graph shows the serum IgG antitoxin levels obtained from mice 
immunised with either saline (0 ), 1 pg CT (") or 5 jig TD (f) in CFA. 
Animals were intradermally immunised on day 0 and footpad boosted with 5 pg 
TD on day 14 of the experiment. The points above represent individual 
antitoxin results obtained on days 7,13 and 22 of the experiment. 
Statistical comparison were made between saline- and antigen-immunised animals 
at each time point. 
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* P<0.01 
7 13 22 






IMAiaA CT CT TD TO 
BOOST CT TO CT TO 
Figure 5.7 The influence of ieiising or boosting with either cholereyen or 
toxoid an syste. ic Ig6 ntitoxin antibody reeponees 
This graph shows the systemic IgG antitoxin levels obtained from mice 
immunised with either I pg CT or 5 pg TO in CFA on day 0 and boosted with 
either 1 pg CT or 5 pg 1D on day 14 of the experiment. Individual mice 
were bled on day 13 (0) and day 22 (0) and their sera were measured in an 
IgG antitoxin ELISA. The above points represent the absorbance readings of 
these sere in this assay. 
Statistical comparisons were made between identically boosted groups at the 
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Figure 5.8 The influence of isminising or boosting with either choleragen or 
toxoid an systemic I¢ nti-tcuoid antibody responses 
This graph shows the systemic IgG anti-toxoid levels obtained from mice 
immunised with either 1 jig CT or 5 pg TD in CFA on day 0 and boosted with 
either 1 pg CT or 5 pg TD on day 14 of the experiment. Individual mice 
were bled on day 13 (0) and day 22 (") and their sera were measured in an 
IgG anti-toxoid ELISA. The above points represent the absorbance readings of 
these sera in this assay. 
Statistical comparisons were made between identically boosted groups at the 







Figure 5.9 The effect of prefeeding Choleragen or toxoid on the induction of 
systemic 196 and IgA antitoxin antibodies 
This graph shows the effect of feeding ABS (0 ), 1 pg CT (") or 5 pg TD 
(#) on the induction of systemic IgG and IgA antitoxin after immunisation 
with 1 pg CT in CFA. Animals were fed seven days before immunisation. Mice 
were boosted into the footpad with 5 pg TD two weeks after immunisation and 
were bled for serum antibody measurement 8 days after this injection. The 
above points repesent the absorbance readings of these sera in these isotype- 
specific assays. 







Figure 5.10 The effect of feeding varying doses of choleregen an the 
development of the 190 antitoxin response to a dwleregen ieawnisetion 
This graph shows the IgG antitoxin antibody responses of mice fed either ABS 
(0 ), 0.1 pg CT (" ), 1 jig CT (0) or 10 pg CT (*) seven days before 
intredermal immunisation with 1 pg CT in CFA. The animals were fed on day - 
7, immunised on day 0 and footpad boosted with 5 pg TD on day 14. The 
animals were bled on days -1,7,13 and 22 of the experiment and their sera 
tested in an IgG antitoxin ELISA. The above points represent the absorbance 
of these sera in this assay. 
Stetisical comparison was made between saline- and choleragen-fed animals for 
each time point. 
" p<0.02 
nd not tested 
-1 7 Is 22 
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MANAOSE SAI. CT CT CT CT 
BOOST TO TD TD TO TO 
Pique 5.11 The effect of prefeeding cholera toxin or toxoid on the 
aabaequent induction of syateaic I¢ anti-toxoid reeponees by tomoid 
imwsiiaetion 
Animals were either fed ABS, 1 pg CT or 5 pg TI) seven days before 
immunisation. Fed mice were immunised with 5 jig TO in CFA as was a group of 
unfed animals. Other unfed animals were immunised with saline in CFA at the 
same time. Two weeks later all animals were boosted into the footpad with 5 
jig TD and the serum anti-toxoid levels were measured 8 days after this. 
The points shown above represent individual animal's IgG anti-toxoid antibody 
response and experimental groups were statistically compared to those unfed 





SYSTEMIC CMI TO CHOLERA TOXIN AND TOXOID 
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6.1 Introduction 
Antibody responses to both choleragen and its detoxified derivatives 
have been extensively studied but the possibility of a cell-mediated 
reaction to these antigens has been virtually ignored by comparison. 
Experiments have therefore been designed to investigate the state of 
systemic cell-mediated immunity (CMI) under conditions shown previously 
to induce a specific serum antibody response to both cholera toxin and 
toxoid. 
There have been reports in the literature that suggest that DTH 
reactions have an obligatory early component in which an 'immediate- 
type' swelling occurs (Schwartz, Askenase & Gershon, 1977; Askenase, 
van Loveren, Kraeuter-Kops, Ron et al, 1983). In 1970, Finkelstein and 
Hollingsworth described a bioassay for antitoxic immunity. They showed 
that the footpad oedema normally associated with an intradermal 
injection of cholera toxin could be lessened if the animal had first 
been intravenously immunised with the substance. They also reported 
that an inoculation of formalinised toxoid failed to produce footpad 
oedema. However if the animal had been immunised previously, the 
toxoid then caused an increase in footpad thickness within 30 minutes 
of intradermal administration. This may have been the earliest 
description of DTH to cholera toxin had a later time-point been used to 
measure the increment in footpad thickness. 
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Experiments performed in chapter 4 confirmed some of the findings of 
Finkelstein and Hollingsworth and so experiments were designed to 
investigate this phenomenon more fully. In particular, swelling 
responses were measured 24 hours after antigenic challenge in order to 
establish whether DTH had occurred. 
As in 1970, toxoid was used as the antigen to recall a possible DTH 
reaction because it does not cause footpad oedema which would interfere 
with the interpretation of skin testing. Using the simple protocol 
described in Chapter 5, the responses of mice immunised with antigens 
in CFA were examined. Various parameters of DTH were investigated, 
including the specifici ty, dose-response and time-course of the 
response. The histology of the footpad swelling was also investigated. 
Since much of the work in this thesis will relate to in vivo skin 
testing of animals, it was important to establish the presence of 
systemic immunity by tests other than the careful examination of the 
footpad response. An in vitro assay of lymophocyte migration 
inhibition factors and an adpotive transfer proceedure, both of which 
appear to be T cell-mediated phenomena (Marchal, Milon Hurtrel & 
Lagrange, 1978; Titus & Chiller, 1981b; Scovern & Kantor, 1982; Mowat & 
Ferguson, 1982a), have also been used to investigate the presence of 
systemic CMI in toxin-primed mice. 
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Section A: DTH Responses in Host Animals 
6.2 Systemic DTH Responses to Differing Immunisation Doses of Cholera 
Toxin 
The previous chapter described the systemic antibody responses in 
BALB/c mice immunised with toxin in CFA and boosted intradermally with 
toxoid a few weeks later. This protocol has been adopted in the 
following experiments but the second exposure to antigen has been used 
as a challenge for the presence of DTH. In this way, the activity of 
both effector limbs of the immune response may be assessed in the same 
animal - something completely novel in the study of the immune response 
to choleragen. 
Groups of mice were Intradermally immunised with either saline or 0.1, 
1.0 or 10.0 µg CT in CFA. Three weeks later, these groups were 
subdivided and challenged with either 0.5,5.0 or 50.0 µg TD into the 
contralateral hind footpad. Twenty-four hours later, the increment in 
footpad thickness was measured and the results are displayed 
graphically in figure 6.1. 
A footpad injection of 0.5 or 5.0 µg TD in saline-primed animals 
failed to produce an increase in footpad thickness. However an 
injection of 50.0 µg TD caused a significantly greater amount of non- 
specific footpad sweling in similarly immunised mice (p<0.001 in both 
cases). 
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Regardless of the immunising dose used, toxin-primed mice did not have 
significant antigen-specific footpad swelling when challenged with 
0.5 gg TD suggesting that this is too small a dose to elicit in vivo 
skin reactivity. 
On the other hand, when footpad challenged with 5.0 µg TD, all the 
CT-immunised animals had significantly greater footpad swelling than 
saline-primed controls (p<0.01 for groups immunised with 0.1 and 10.0 
pg CT; p<0.001 for 1 µg CT-immunised animals). Furthermore, the 
group immunised with 1 µg CT in CFA had a significantly greater 
response to that observed in the other two positive groups (p<0.05 and 
p<0.001 compared to groups immunised with 10.0 µg and 0.1 µg CT, 
respectively). 
Despite the considerable non-specific swelling reaction with the 
50.0 gg dose, a further, statistically significant increment in 
footpad thickness could be elicited from animals immunised with 
1.0 µg and 10.0 pg CT (p<0.001 and p<0.002, respectively). Animals 
primed with 0.1 µg CT did not have significantly increased footpad 
responses when compared with mice primed with saline. 
As animals had the largest footpad responses when immunised with 1 µg 
CT and challenged with 5 µg TO, this regime was employed in all the 
following experiments. 
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6.3 The Specificity of Systemic DTH to Choleragen 
The previous section showed that mice immunised and challenged with two 
apparently cross-reactive antigens were capable of giving a positive 
footpad response. Experiments were designed to show that this response 
was specific for toxin-derived antigens. 
Accordingly, groups of mice were immunised with saline, 100 gg OVA or 
1 µg CT in CFA. In addition, a group of mice were also immunised 
with 1µg CT in IFA. 
The mice immunised with saline or OVA in CFA or CT in IFA were footpad 
challenged with 5 µg TD while the animals immunised with choleragen 
in CFA were challenged with either saline or 100 µ g OVA. As a 
positive control, animals primed with CT in CFA were challenged with 
5 µg TO. Animals were challenged either 2 or 3 weeks after 
immunisation. The results of these experiments are shown in figure 
6.2. 
In the groups tested 21 days after immunisation, the animals immunised 
with saline and challenged with toxoid did not have a significantly 
positive response and just as before the toxin-primed, toxoid- 
challenged mice mounted significant DTH swelling (p<0.001). Not 
unsurprisingly, toxin-primed animals challenged with saline failed to 
mount a significant response and did not differ statistically from the 
saline-immunised, toxoid-challenged group of mice. 
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Both the animals immunised with OVA and challenged with TD and the CT- 
primed mice challenged with OVA failed to give a significantly positive 
response. These groups did not significantly differ from the saline- 
primed mice. 
Finally, the group of animals immunised with CT in IFA were able to 
mount a significant DTH response when challenged with toxoid. Although 
the response of these animals was significantly less than the one 
observed in positive controls (p<0.001), it was significantly greater 
at the 5% level than the swelling seen in saline-primed, toxoid- 
challenged controls. 
The trends observed above also hold true for animals challenged two 
weeks after immunisation. Once again, mice immunised with saline and 
challenged with toxoid and toxin-primed animals challenged with saline 
both failed to give significantly positive responses. As before, 
toxin-primed, toxoid-challenged mice gave a good DTH response which was 
significantly greater than the results observed in the above two groups 
(p<0.001). 
The footpad responses observed in the OVA-primed, TD-challenged and the 
CT-primed, OVA-challenged groups did not significantly differ from 
those observed in the saline-primed animals but were significantly less 
than the responses of the positive controls (p<0.001). 
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These results indicate that the footpad swelling response observed in 
CT-primed animals is specific for toxin-derived antigens. Furthermore, 
there appears to be no significant quantitative or qualitative 
difference in the results observed either two or three weeks after 
priming. As the shorter of the two protocols was the more convenient, 
this time interval between immunisation and challenge was adopted for 
almost all the following experiments. 
6.4 Time Course of the DTH Response 
Groups of mice were intradermally immunised with either saline or 
1 µg CT in CFA. Two weeks later, half the toxin-primed mice were 
challenged with 5µg TD and half with saline only. The saline-primed 
mice were footpad challenged with 5µg TD at the same time. Over the 
next 48 hours, these animals' footpads were measured at various 
intervals in order to determine the time-course of the DTH swelling 
response. 
The results of this experiment (figure 6.3) show that the footpad 
swelling response to antigen challenge in immunised mice is biphasic in 
nature. 
The control animals, either mice immunised with CT and challenged with 
saline or immunised with saline and challenged with TD, exhibited 
similar footped responses at all times. Both these groups had swollen 
feet within 30 minutes of the injection of 50 µl of inoculate but 
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this had largely disappeared by 2 hours and was virtually gone at 24 
hours. 
In the responsive animals (immunised and challenged with antigen) the 
DTH curve is different. In the first place, these animals mounted 
significantly greater footpad swelling than controls at all times 
(p<0.001 In all cases except one; p<0.01 between this and the saline- 
primed group, 9 hours after footpad injection). 
The shape of this response curve is also different. The initial peak, 
present at 30 minutes, declined rapidly at first and then gradually 
reached its lowest point 9 hours after injection. By 18 hours, the 
mice footpads were again swollen and reached a second peak at 24 hours. 
The swelling present at both 18 and 24 hours after injection was 
significantly greater than that present at 9 hours (p<0.01 in both 
cases). At 48 hours, the incremental change in footpad thickness had 
once again declined. 
Figure 6.4 shows the composite curve of net footpad swelling when the 
result means of the saline-primed animals was subtracted from the means 
obtained from the positive group. It is now appreciable that it is the 
second phase of the response which is responsible for the largest 
amount of swelling when the administraton of fluid into the footpad is 
taken Into account. 
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6.5 The Histology of the Footpad Response to Choleragen 
DTH reactions have a characteristic histology (Dvorak et al, 1974) and 
experiments were designed to see whether the microscopic appearance of 
the footpad reaction was consistent with earlier descriptions. In 
order to observe the development of the lesion, mice immunised with 
either toxin or toxoid were challenged with 5 µg TD fourteen days 
later. The mice were then sacrificed either at 30 minutes or 2,4,8, 
18 or 24 hours after antigen challenge and the histology of their 
footpads examined. Control animals primed with antigen and challenged 
with saline were also sacrifed as above. The results may be seen in 
figure 6.5. 
The earliest change observed was sub-papillary oedema. This could be 
seen in both antigen- and saline-challenged footpads. This oedema 
settled in control footpads and was not detectable in the sections 
taken at 4 hours. 
In the footpads undergoing DTH, mononuclear cells could be seen within 
the venules of the superficial dermal plexus after 4 hours. 
Perivenular lymphocytes were not obvious at this time. By 8 hours, 
however, the superficial dermal plexus was crammed with mononuclear 
cells, mainly small- to medium-sized lymphocytes. The epidermis and 
deeper dermal layers are relatively free of infiltrate but perivenular 
'cuffs' of lymphocytes were prominent. 
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Later changes, observed 18 to 24 hours after antigenic challenge, were 
typical of a classical DTH reaction, with a promine nt, widespread, 
mononuclear cell infiltrate occurring mainly in the deep dermis. This 
infiltrate consisted not only of lymphocytes but other leucocytes as 
well, the most common being basophils and neutrophils. Macrophages 
were not commonly seen a t any time. 
6.6 The Systemic DTH Response to Cholera Toxoid 
The previous chapter compared the antibody responses of BALB/c mice to 
doses of parenterally administered toxin and toxoid with equivalent B 
subunit content. Using an appropriate dose of toxoid (with a similar B 
subunit content to the optimal DTH priming dose of toxin), the DTH 
responses to this modified antigen were examined. 
Groups of mice were immunised with 5 µg TD in CFA. These animals 
were footpad challenged with either saline, 100 µg OVA or 5 pg TD 
either 14 or 21 days after immunisation. The results of this 
experiment are displayed in figure 6.6. 
Regardless of the time elapsed after priming, challenging toxoid-primed 
animals with either saline or OVA failed to produce a significant 
footpad response. In contrast, challenge with the appropriate antigen 
(5 µg TO), produced a footpad swelling response which was 
significantly greater than that observed in the other two groups 
(p<0.001). 
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6.7 The Effect of Challenging Toxin- and Toxoid-primed Animals with 
Cholera Toxin B Subunit 
Experiments in chapter 5 suggest that cholera toxin and toxoid may not 
be totally immunologically cross-reactive. One reason for the 
similarity in the footpad swelling responses of CT- and TD-primed 
animals may be that only shared determinants are recalled with a toxoid 
challenge. 
In order to investigate this, animals were Intradermally immunised with 
either saline, 1 µg CT or 5 µg TD in CFA. Two weeks later, these 
mice were footpad challenged with either 5 µg TD or 1 gg cholera 
toxin B subunit (CTB) and the increment in footpad thickness measured 
24 hours after this. Using these doses, the TD and CTB challenges had 
an equivalent B subunit content. The result of this experiment is 
shown in figure 6.7. 
A small swelling response was observed in saline-primed animals but 
this was comparable in mice challenged with either TD or CTB. CT- and 
TD- primed animals mounted good DTH responses, of similar magnitude, to 
a toxoid challenge. This response was significantly greater than that 
observed in saline-primed and toxoid-challenged controls (p<0.001, in 
both cases). When footpad challenged with CTB, both CT- and TD-primed 
animals exhibited significantly increased footpad swelling compared 
with saline-primed controls (p<0.02, in both cases). The DTH reaction 
did not significantly differ regardless of the antigen used for 
Immunisation, but was significantly less than that observed in 
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similarly primed but toxoid-challenged counterparts (p<O. 001, in both 
cases). 
This result suggests that both toxin and toxoid are equally good at 
priming for a DTH reaction and that TD is superior to CTB as a recall 
antigen. This finding is in agreement with the observation that TD is 
in a partially aggregated form (Thompson, 1984) and that aggregated 
proteins elicit greater DTH reactions (Titus & Chiller, 1981b). 
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SECTION B: Other Assays of Systemic CMI 
6.8 The Passive Transfer of DTH 
This section will deal with the first corroborative test for the 
presence of systemic CMI. Other workers have shown that the transfer 
of DTH to naive syngeneic recipients is mediated by T cells (see 
chapter 3), the experiments that will be described examine the ability 
of draining lymph node cells from toxin-primed animals to reproduce 
this phenomenon. These cells were obtained under conditions where DTH 
has been shown to exist. 
This section will be subdivided into three parts which will, in turn, 
contain descriptions of experiments to determine the number of cells 
necessary to transfer DTH, the specificity of this phenomenon and the 
phenotype of the cell responsible. 
e: The DTH Responses Transferred by Varying Numbers of Primed 
Lymphocytes 
Draining popliteal and inguinal lymph node cells were obtained from 
animals immunised two weeks earlier with either saline or 1 µg CT in 
CFA and were transferred in varying numbers with 5 µg TD to the 
footpads of naive syngeneic recipient mice. 
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As can be seen from figure 6.8, saline-primed lymph node cells all 
transferred a small swelling response except when 10 8 cells were 
injected. A transfer of 10 5 toxin-primed cells/animal did not produce 
a significant DTH response, but all other toxin-primed inoculates did 
(p<0.001). 108 saline-primed cells caused a large amount of non- 
specific footpad swelling. This was significantly greater than the 
swelling responses seen in all other groups except that transferred by 
the equivalent number of antigen-primed cells (p<0.001). 
10 7 cells was chosen as the optimal dose to employ in further 
experiments as that number provided a good positive response, a low 
background of non-specific swelling and required only a small number of 
donor animals. 
b: The Specificity of the Passive Transfer of DTH 
Groups of mice were intradermally immunised with either saline, 100 
µg OVA or 1 µg CT in CFA. Two weeks later, these animals were 
sacrificed and their draining lymph nodes removed and made into single 
cell suspensions. 
The saline- and OVA- primed cells were mixed with 5 µg TD and the 
toxin-primed cells were mixed with saline or 100 µg OVA prior to 
transfer. Either 5 µg TD or 107 toxin-primed cells alone were 
injected into recipients as negative controls and a combination of the 
two was transferred as a positive control. The increment in the 
recipients' footpad thickness was measured 24 hours after transfer and 
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the results are displayed in figure 6.9. 
Positive control animals receiving toxin-primed cells with toxoid had 
the largest footpad response. This swelling response was significantly 
greater than the responses measured in the other groups (p<0.001). 
The smallest footpad response was seen in those animals given toxoid 
alone. The swelling measured in the other negative control groups, 
recieving either 10 7 saline-primed cells with antigen or 10 7 toxin- 
primed cells alone, was significantly greater (p<0.002) but still much 
less than the positive control. The swelling response measured in the 
remaining two groups did not differ from those seen in the negative 
controls. This confirms the specificity of the DTH response described 
in section 6.3. 
c: The Effect of the Depletion of THY-L2 +ve Cells on the Ability of 
Toxin-primed Lymphocytes to Transfer DTH 
Toxin-primed lymphocytes (10 7 /animal) were treated with either anti- 
THY-1.2 monoclonal antibody, absorbed Guinea-pig serum or a combination 
of the two. Cells which survived this procedure were transferred to 
recipients mixed with 5 µg TD. Toxin-primed cells were transferred 
with antigen as a positive control and either cells or antigen alone 
were transferred as negative comparisons. The results may be seen in 
figure 6.10. 
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Untreated toxin-primed lymphocytes again transferred a good DTH 
response in the presence of toxoid. Treating these lymphocytes with 
either anti-THY-1.2 monoclonal antibody or absorbed Guinea-pig serum 
alone did not alter the ability of these cells to transfer DTH. 
However, when toxin-primed cells were treated with monoclonal antibody 
followed by the absorbed serum, they became incapable of transferring a 
positive reaction (p<0.001). The footpad response that these cells 
caused was not significantly different from the non-specific swelling 
caused by an injection of lymph node cells or antigen alone. 
6.9 The Investigation of Migration Inhibition by Choleragen-primed 
Lymphocytes In Vitro 
The experiment described in this final section is a further attempt to 
substantiate the presence of CMI in toxin-primed animals. It concerns 
the measurement of a lymphocyte migration inhibition factor. This 
factor, produced in vitro, has been shown to correlate well with the 
presence of systemic CMI and is most easily obtained from T cell- 
enriched populations (Mowat & Ferguson, 1982a). 
Draining lymphoid cells from BALB/c mice primed two weeks previously 
with either saline, 100 µg OVA or 1 gg CT in CFA were tested in a 
lymphocyte migration inhibition assay (see chapter 4.16). The 
migration out of capillary tubes of these three differently sensitised 
groups of cells was measured after culture for 21 hours in either 
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medium alone or in the presence of various antigens. Antigens used 
were OVA at concentrations of 1.0 and 0.1 mg/ml and TD at 
concentrations of 1.0,0.1,0.01 and 0.001 µg/ml. The areas of 
migration of these cells were measured by planimetry a nd the results 
are expressed as a migratory index, where uninhibited migration of 
cells in medium alone is given a value of 1.0. The results of this 
experiment may be seen in figure 6.11. 
Lymph node cells from saline-primed animals were able to migrate fully 
in the presence of both toxoid and ovalbumin at the concentrations 
used. OVA-primed cells were inhibited from migrating by medium 
containing OVA at 0.1 mg/ml (p<0.01) but were unaffected by the higher 
concentration of OVA or by toxoid at any concentration. 
Conversely, CT-primed lymphocytes exhibited significant migration 
inhibition at a concentration of 0.01 gg TD/ml (p<0.05). Ovalbumin, 
at both the above concentrations, and the remaining concentrations of 
TD did not significantly affect the migration of these cells. 
6.10 Summary 
Experiments described in this section have shown that mice primed with 
cholera toxin produce an antigen-specific footpad swelling response 24 
hours after intradermal challenge with toxoid. A similar response was 
obtained after immunisation with toxoid. 
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Histological examination of the footpad 24 hours after challenge 
revealed a mononuclear cell infiltrate which consisted mainly of smell 
to medium-sized lymphocytes and, to a lesser degree, basophils and 
neutrophils. These findings are indicative of a DTH reaction. Serial 
measurements of footpad thickness and footpad histology were also 
consistent with the ontogeny of a DTH lesion as reported by other 
workers (Dvorak et al, 1974; Van Loveren et al, 1983) and 
confirms that a DTH reaction does include an early oedematous swelling 
component. 
Both TD and CTB were able to successfully recall DTH responses, 
suggesting that T-cell determinants are shared between choleragen and 
its formalinised toxoid. Furthermore, the greater response observed 
after footpad challenge with TD is additional evidence of its partially 
aggragated nature. 
Toxin-primed lymph node cells were able to inhibit their own migration 
in vitro when cult ured with toxoid and the T cell component of these 
lymphocytes were able to passively transfer DTH to naive syngeneic 
recipients. Both these results confirm that syste mic CMI is primed 
under the same conditions that induce DTH. This is the first 
description of systemic CMI to chol era toxin and shows that it occurs 
as part of an immune response which includes the production of 







Figure 6.1 The effect of varying the doses of prising and challenge antigens 
on the induction of DTH to Choleragen 
This graph shows the DTH responses of mice intradermally immunised with either 
saline (Q) or 0.1 pg (p), 1.0 pg (0) or 10.0 pg (! ß ) CT in CFA. 
Three weeks later, these mice were footpad challenged with either 0.5,5.0 or 
50.0 pg TD. The bars represent the mean increment in footpad thickness *1 
standard deviation 24 hours after footpad challenge. 
Statistical comparison was made between the results obtained for saline-primed 
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Figure 6.2 The antigen-apscificty of the 0TH response to choleragen 
Groups of mice were intradermally ismunised with either saline, 100 pg OVA 
or 1 pg CT in CFA. One group of mice was also immunised with 1 pg CT in 
IFA. Two (D) or three ( ) weeks later, these animals were footpad 
challenged with either 5 pg T0,100 pg OVA or saline as shown above. The 
bare represent the mean increment in footpad thicknesses *1 standard 
deviation measured 24 hours after footpad challenge. 
The results of the other groups were statistically compared to those obtained 
from the saline-primed, TD-challenged animals, either 2 or 3 weeks after 
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Figure 6.3 The footpad aielling response of choleragen. prfaed animals at 
various tine after footpad challenge with toxoid 
This graph shows the DTH responses of mice intradermally immunised with either 
saline (0) or 1 pg CT in CFA. Fourteen days after this, the saline-primed 
animals were intradermally challenged 'with 5 pg TD and CT-primed animals 
were challenged with either 5 jig TD (") or saline (0 ). The incremental 
changes in footpad thickness were measured at various intervals over a 48 
hours period. Each point represents the mean increment in footpad thickness t 
1 standard deviation. 
Statistical comparisons were made between the results obtained for toxin- 











Figure 6.4 The cntoysny of the DTH shelling reýpwi.. In daleragwi-prised 
s d. a1. 
This graph shows the net footpad swelling over a 48 hour period caused by a 
DTH reaction in cholera toxin-primed animals. The line showing net swelling 
_) is obtained 
by subtracting the mean incremental changes in footpad 
thickness caused by an injection of 5 pg TD (ý ) from those caused by a 
saline injection (0) in toxin-primed animals. Each point represents the mean 
increment in footpad thickness +1 standard deviation. 
$ Is 24 32 40 4$ 
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Figure 6.5 The histology of the footpad Welling response in toxin-primed 
animals 




Figure 6.5 The histology of the footpad swelling response in toxin-primed 
animals 
b: Mononuclear cells filling venules of the superficial dermal plexus at 4 
hours after footpad challenge. 
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Figure 6.5 The histology of the tootpsd swelling response in toxin-prised 
animals 
c: Perivenular 'cuffing' with lymphocytes at the dermo-epidermal junction at 8 
hours after intradermal challenge. 
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Figure 6.5 The histology of the footpsd swelling response in toxin-prised 
animals 
d: Profound mononuclear cell infiltrate in the epidermis and deep dermis 24 
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Figure 6.6 The footpad swelling response in animals prised with cholera 
toxoid 
This graph shows the systemic DTH responses observed in mice two (0) or three 
( 0) weeks after being intradermally immunised with 5 pg TD in CFA. These 
animals were footpad challenged with either saline, 100 pg OVA or 5 Vg TD. 
The bars represent the mean increment in footpad thickness *1 standard 
deviation 24 hours after intredermal challenge. 
Statistical comparison was made between the group challenged with saline and 
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Figure 6.7 The effect of a dallo ge with cholera toxin B wcbuiit on the DTH 
reapanses of toxL- and toxoid-pried nice 
This graph shows the DTH responses of mice intradermally immunised with either 
saline, 1 pg CT or 5 pg TD two weeks before footpad challenge with either 
5 pg TD or 1 pg CTB. The bars represent the mean increment in footpad 
thickness 24 hours after footpad challenge. 
Statistical comparisons were made between saline-primed animals and the other 







Figure 6.8 The ability of varying ns ers of toxin-priasd 1y hocytes to 
passively trsnster 0TH 
This graph shows the footpad swelling responses of mice receiving various 
numbers of lymphoid cells plus 5 pg TD into their hind footpads. Donor 
animals were bilaterally intradermally immunised with either saline (O) or 
1 pg CT (0) in CFA. After 2 weeks, their draining lymph nodes were removed 
and made into single cell suspensions. Varying numbers of lymphoid cells from 
each donor group were mixed with antigen and the final volume of 50 p1 of 
inoculate was intradermally injected into the footpads of naive syngeneic 
recipients. The bars represent the mean increment in footpad thickness t1 
standard deviation measured 24 hours after cell transfer. 
Statistical comparisons were made between the saline-primed lymphoid cell 
recipients' responses and the results obtained from those mice receiving 
toxin-primed lymphocytes, for each concentration of cells transferred. 
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Figure 6.9 The specificity of the passive transfer of 0TH 
This graph shows the footpad swelling responses of mice receiving 107 primed 
lymphocytes from animals immunised two weeks earlier with either saline (0), 
1 jig CT ( ) or 100 pg OVA ( ) in CFA. These cells were either 
transferred alone or with 5 pg TD or 100 pg OVA as shown above. One group 
of animals received a footpad inoculate of 5 pg TD alone as a negative 
control. 
Statistical comparison was made between the animals receiving toxoid alone and 








TREATMENT OF CELLS 
Figure 6.10 The effect of depletion of THY-1.2-positive cells on the p. ssive 
transfer of DTH 
This graph shows the footpad swelling responses of mice receiving either 
5 jig TD alone (O) or 107 CT-primed lymphocytes in the presence ( ) or 
absence (®) of 5 jig TD. The toxin-primed cells were either left untreated 
or treated with anti-THY-1.2 monoclonal antibody (McAb), absorbed Guinea-pig 
complement (C') or McAb followed by C'. The bars represent the mean increment 
in footpad thickness t1 standard deviation 24 hours after footpad injection. 
Statisitcal comparisons were made between the experimental groups and those 
animals receiving an injection of 5 pg Tp alone. 
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Figure 6.11 The effect of various antigens on the ability of choleragen- 
prised lymph node cells to inhibit their own migration in vitro 
This figure shows the migratory indices of draining lymph node cells from 
saline- (0), OVA- (M) or CT- (D )primed donors in the presence of either OVA 
or TD at varying concentrations. A migratory index of 1.0 is taken as that 
area occupied by lymphoid cells in antigen-free medium after 21 hours in 
culture at 37 °C. The migratory is calculated according to the formula 
shown in chapter 4.16. 
Statistical comparison is made between the migration observed in antigen-free 
medium and that in the presence of antigen for each population of lymphoid 
cells from the donors described above. 
*p<0.05 
**p<0.01 




ORAL TOLERANCE TO CHOLERA TOXIN OR TOXOID 
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7.1 Introduction 
In the previous chapter it was demonstrated that parenteral 
administration of cholera toxin and toxoid Induces specific systemic 
CMI. Experiments in Chapter 5 demonstrated that under similar 
conditons a specific systemic humoral immune response may be also 
detected. It was also shown that prefeeding choleragen or toxoid 
failed to tolerise the induction of this antitoxin response which is in 
agreement with the findings of Elson and Ealding (1984b). 
This chapter reports the results of studies, performed in parallel with 
those in Chapter 5, that examine the effect of feeding on the induction 
of specific CMI. 
Using the protocol employed in Chapter 5, sytemic CMI was assessed 
after feeding various doses of toxin and toxoid. As mentioned in 
chapter 1, the oral administration of toxin and toxoid produces 
different effects on the induction of systemic antibody and this has 
been attributed to the difference in the biochemical properties of 
these two substances (Pierce, 1978). Prefeeding both choleragen and 
its toxoid allowed the role of these biochemical properties in the 
Induction of oral tolerance to be assessed. 
The specificity of the effect of prefeeding these antigens was once 
again studied by using the unrelated protein, ovalbumin. 
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7.2 The Effect of Feeding Cholera Toxin on the Subsequent Induction of 
Systemic DTH 
In order to investigate the effect of prefeeding choleragen, the 
experimental protocol, illustrated in figure 7.1, was devised. 
Essentially, two groups of animals fed alkaline-buffered saline (ABS) 
were immunised one week later with either 1 pg CT or saline in CFA to 
act as positive and negative controls, respectively. Two other groups 
of mice were fed 1 µg CT and subsequently immunised with either 
1 µg CT or saline in CFA to see whether feeding affected the 
induction of DTH or was able to induce DTH directly. All animals were 
footpad challenged with 5 µg TD two weeks after immunisation. The 
results of this experiment are shown in figure 7.2. 
As might be expected, animals fed ABS and immunised with saline did not 
exhibit significant footpad swelling. The positive control group (fed 
ABS and immunised with CT) gave a good response which was significantly 
greater than that observed in the negative controls (p<0.001). 
Feeding toxin tolerised the induction of DTH, the footpad responses 
being significantly less than that measured in the positive control 
group (p<0.02). However, tolerance was not complete as the DTH 
swelling in this group was still greater than that of negative controls 
(p<0.02). 
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Feeding choleragen did not induce DTH directly as the responses 
observed in this group did not differ statistically from those of the 
negative controls. 
7.3 The Effect of Feeding Cholera Toxoid on the Subsequent Induction 
of DTH 
In order to see whether the biochemical properties of choleragen were 
important in the induction of oral tolerance, the same protocol was 
used here as has been described in section 7.2 with the exception that 
5 µg TD was fed in place of the holotoxin. 
The results of this experiment are shown in figure 7.3. Once again, 
negative controls (fed ABS and immunised with saline) did not exhibit 
DTH but positive controls (fed ABS and immunised with CT) gave a good 
response (p<0.001). 
Feeding toxoid partially tolerised the induction of DTH (p<0.01 
compared with positive controls, p<0.02 compared with negative 
controls) but was unable to induce DTH directly. 
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7.4 The Effect of Feeding Different Doses of Toxin and Toxoid on the 
Subsequent Induction of DTH 
Previous experiments showed that prefeeding either toxin or toxoid was 
able to induce oral tolerance. Experiments with ovalbumin have shown 
this phenomenon to be dose-dependent (Mowat at al, 1986). In order to 
see whether the same applied to these proteins, animals were fed either 
ABS, CT (0.1,1.0 and 10.0 g g) or TD (0.5,5.0 and 50.0 g g) one 
week before intradermal immunisation with 1 µg CT in CFA. Systemic 
DTH responses were assessed 14 days after immunisation. 
The results of this experiment are shown in figure 7.4. Feeding 1.0 or 
10.0 µg CT tolerised the induction of systemic DTH compared with ABS- 
fed controls (p<0.001 and <0.05, respectively). 50 µg and 5.0 µg 
TD administered orally also significantly suppressed the induction of 
subsequent DTH responses (p<0.05 and <0.01, respectively). 
The animals fed either 0.1 µg CT or 0.5 µg TD were not tolerant, 
having DTH responses which were not statistically significantly 
different from ABS-fed controls. 
7.5 The Specificity of Oral Tolerance Induced by Feeding Toxin and 
Toxoid 
This was assessed in two ways. First of all, mice immunised with 
100 Vg OVA in CFA were fed ABS, 1gg CT or 5µg TD one week 
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earlier. Two weeks after immunisation these animals were footpad 
challenged with 100 µg OVA, and their DTH responses were measured 24 
hours later. 
As can be seen in figure 7.5, a pre-feed of either toxin or toxoid did 
not suppress the induction of DTH to OVA compared to that observed in 
sham-fed controls. 
Secondly, animals were fed either 25 mg OVA, 1 µg CT or 5 µg TD one 
week before immunisation with 1 µg CT in CFA. Systemic DTH responses 
were tested two weeks later. 
OVA-fed animals had antitoxin DTH responses which were significantly 
greater than those observed in both the toxin and toxoid-fed mice 
(p<0.001 and <0.05, respectively). These results are displayed 
graphically in figure 7.6. 
7.6 The Effect of Feeding Toxin or Toxoid on the Subsequent Induction 
of Toxoid-primed DTH Responses 
Both choleragen and its toxoid are able to tolerise the induction of 
specific systemic CMI. However, as has been shown in chapter 5, these 
two proteins are not totally immunologically cross-reactive. It was 
decided, therefore, to examine the effects of feeding these antigens on 
the induction of systemic CMI to cholera toxoid. 
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Accordingly, mice were fed either ABS, 1 µg CT or 5 µg TO. One 
week later these mice were immunised with 5 µg TD in CFA along with 
unfed controls. Other unfed mice were immunised with saline in CFA at 
the same time as negative controls. All these animals were footpad 
challenged with 5 µg TD two weeks later. The DTH responses measured 
24 hours after footpad challenge are shown in figure 7.7. 
Once again, negative controls did not exhibit DTH. Feeding ABS did not 
depress DTH responses in toxoid-primed mice compared to unfed positive 
controls. Both these groups had footpad responses which were 
significantly greater than the saline-primed mice (p<0.001, in both 
cases). 
Feeding CT or TD significantly suppressed the induction of DTH (p<0.01 
in both cases) but once again the tolerance was incomplete as these 
responses were significantly greater than those seen In the negative 
controls (p< 0.001 and p<0.01, respectively). 
7.7 Summary 
Feeding either choleragen or Its toxoid inhibits the induction of 
systemic DTH to either of these antigens. This tolerance is Incomplete 
as there is still a residual DTH reaction. This Is in accordance with 
the findings for other antigens. 
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The oral tolerance induced is both 
Feeding OVA failed to suppress sy 
administration of either CT or TD 
systemic DTH to OVA. In addition, 
and toxoid (0.5 g g) fed failed to 
DTH. 
antigen-specific and dose-dependent. 
stemic antitoxin CMI and the oral 
did not tolerise the induction of 
the lowest doses of toxin (0.1 µg) 
suppress the induction of specific 
What appears to be novel in this system is the totally divergent effect 
of enterically applied antigen on the two limbs of systemic immunity. 
A dose of toxin (10 µg) which has been used to induce systemic 
antitoxin is also capable of tolerising systemic DTH. This is the 
first time such an obvious separation in the mucosal regulation of 
different effector mechanisms of systemic immunity has been reported. 
Finally, as both toxin and toxoid are capable of suppressing the 
induction of DTH, it suggests that the ability to induce oral tolerance 
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Figure 7.1 Experimental protocol to examine the effect of prefeeding cholera 
toxin on the induction of systemic DTH 
The shaded mice have been immunised with 1 Ng CT in CFA. The others have 
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Figure 7.2 The effect of feeding choleregan on the induction of systemic 0TH 
This graph shows the DTH responses of mice fed either ABS or 1 jig CT one 
week before intradermal immunisation with either 1 Ng CT or saline in CFA. 
All animals were footpad challenged with 5 pg TD two weeks after 
immunisation. The bars represent the mean increment in footpad thickness *1 
standard deviation 24 hours after footpad challenge. Experimental groups were 
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Figure 7.3 The effect of feeding dalere toxoid an the induction of systemic 
DTH 
This graph shows the DTH responses of mice fed either ABS or 5 pg TD one 
week before intradermal immunisation with either 1 pg CT or saline in CFA. 
All animals were footpad challenged with 5 pg TD two weeks after 
immunisation. The bars represent the mean increment in footpad thickness *1 
standard deviation 24 hours after footpad challenge. Experimental groups were 











Figure 7.4 The effect of feeding various doses of cholera toxin or toxoid on 
the subsequent induction of specific systemic DTH 
This graph shows the DTH responses of mice fed ABS ((3) or various doses of CT 
( ) or TD (®) one week before intradermal immunisation with 1 pg CT in 
CFA. These mice were footpad challenged with 5 pg TD two weeks after 
immunisation. The bars represent the mean increment in footpad thickness *1 
standard deviation 24 hours after footpad challenge. The experimental groups 
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Figure 7.5 The effect of feeding cholera toxin or tocoid an the . thw cent 
induction of systemic DTH to an unrelated protein antigen, ovalbunin 
This graph shows the 0TH responses of mice fed ABS, 1 pg CT or 5 pg TO one 
week before intradermal immunisation with 100 pg OVA in CFA. Two weeks 
after immunisation, the animals were footpad challenged with 100 pg OVA. 
The bare represent the increment in footpad thickness *1 standard deviation 
24 hours after footpad challenge. Experimental groups were compared 
statistically to those mice fed ABS. 
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Figure 7.6 The effect of feeding an unrelated protein mtigen, owlbiin, on 
the subsequent induction of DTH to Choleragen 
This graph shows the DTH responses of mice fed 25 mg OVA, 1 pg CT or 5 pg 
TD one week before intradermal immunisation with 1 pg CT in CFA. Two weeks 
after immunisation, the animals were footpad challenged with 5 pg TD. The 
bare represent the mean increment in footpad thickness *1 standard deviation 
24 hours after footpad challenge. The other experimental groups were compared 
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Figure 7.7 ' The elect of feeding cholera toxin or toxoid on the subsequent 
induction of systoic DTH to cholera toxoid 
This graph shows the DTH responses of mice fed ABS, 1 pg CT or 5 pg TD one 
week before intradermal immunisation with 5 pg TO in CFA. Other unfad 
groups of mice were immunised with either 5 pg TD or saline in CFA, at the 
some time, to act as positive and negative controls, respectively. All 
animals were footpad challenged with 5 jig TO two weeks after immunisation. 
The bars represent the mean increment in footpad thickness +1 standard 
deviation 24 hours after footpad challenge. All results were compared 





TEE EFFECT OF CYCLOPHOSPHAMIDE AND ORALLY-PRIIVED SPLEEN CELLS ON TEE 
EDUCTION OF ORAL TOLERANCE 
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8.1 Introduction 
Cyclophosphamide (CY) is a potent alkylating agent which acts 
principally on cells actively synthesising DNA. CY may have differing 
effects on the immune responses of the host depending on the dose used 
and the timing of administration relative to immunisation (reviewed: 
Mowat, 1981). It would appear however, that T suppresor and B cells 
are more sensitive to its action than helper or cytotoxic T cells 
(Kaufmann, Hahn & Diamantstein, 1980; Shand & Liew, 1980). 
Suppressor T cells are thought to be responsible for the down- 
regulation of CMI responses after feeding OVA (Miller & Hanson, 1979; 
Challacombe & Tomasi, 1980; Titus & Chiller, 1981). The sensitivity of 
murine suppressor T cells to certain doses of CY (Askenase, Hayden & 
Gershon, 1975; Ferguson & Simmons, 1978; Gill & Liew, 1978) has been 
used to elucidate mechanisms responsible for oral tolerance after 
feeding OVA. Pretreatment of BALB/c mice with CY (100 mg/kg) before 
feeding abrogated the induction of tolerance normally observed with 
orally administered OVA (Mowat et al, 1982). CY pretreatment also 
prevented the induction of splenic suppressor cells normally associated 
with feeding OVA (Hanson & Miller, 1982). 
Feeding cholera toxin appears only to tolerise the Induction of the 
cell-mediated limb of systemic immunity but it may well be that 
choleragen induces similar suppressor mechanisms to that found with 
more usual protein antigens. 
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In order to examine this, the ability of CY to abrogate the induction 
of oral tolerance associated with feeding cholera toxin and toxoid was 
tested. The effect of CY pretreatment on the induction of systemic 
humoral immunity was also investigated. Furthermore, transfers of 
spleen ce lls from donors fed either toxin or toxoid were performed to 
elucidate their effects on the systemic immune response of parenterally 
immunised recipients. 
8.2 The Effect of Cyclophosphamide on the Induction of Oral Tolerance 
by Cholera Toxin 
Mice were given an intraperitoneal injection on day -9 of either 
cyclophosphamide (100 mg/kg) or the equivalent volume of saline. Half 
the cyclophosphamide-treated mice were fed 1 µg CT and half were fed 
ABS on day -7. Saline-injected animals were treated in the same way. 
After 7 more days, mice were immunised with CT in CFA and assessed for 
systemic DTH 2 weeks later. On day 22 of the experiment the animals 
were bled and their serum antibody levels measured. The experimental 
protocol may be seen in figure 8.1. 
The effects of cyclophosphemide may be seen in figure 8.2. There was 
no difference in the footpad responses of ABS-fed animals with or 
without cyclophosphamide pretreatments. Feeding toxin significantly 
suppressed subsequent DTH responses (p<0.001). Cyclophosphemide 
pretreatment abrogated the tolerance induced by feeding choleragen. 
The footpad swelling seen in these animals did not significantly differ 
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from that observed in ABS-fed controls. 
The systemic IgG and IgA antitoxin levels of these animals are shown in 
figure 8.3. As noted earlier in chapter 4, feeding toxin fails to 
tolerise serum antibody levels and, furthermore, pretreatment with 
cyclophosphamide does not significantly alter these levels. 
83 The Effect of Cyclophoephamide on oral Tolerance Induced by 
Cholera Toxoid 
The same experimental protocol was employed as described in the 
previous section, except that animals were fed 5 µg toxoid in place 
of toxin. 
Once again, toxoid-fed animals had significantly reduced footpad 
swelling responses (p<0.01). Pretreatment with cyclophosphamide also 
abrogated the induction of tolerance in these animals. The results of 
this experiment are shown in figure 8.4. 
&4 The Effect of Spleen Cells Transferred from Orally Immunised 
Animals on the Induction of Systemic Immunity in Recipients 
Groups of mice were fed 1 µg CT, 5 µg TD or ABS alone. One week 
later these mice were sacrificed and a suspension of their spleens 
intraperitoneally injected into syngeneic recipients. 10 a spleen cells 
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were transferred on the same day as recipients were intradermally 
immunised with CT in CFA. Two weeks later systemic DTH responses were 
assessed as before and 8 days after this (22 days after footpad 
immunisation) the recipient mice were bled and their serum antitoxin 
levels (IgG and IgA) were measured. As a control, animals were sham- 
injected with medium only and immunised, footpad challenged and bled as 
for the spleen cell recipients. 
ABS-fed animals had identical footpad swelling to unfed animals who 
received spleen cells from ABS-fed donors (figure 8.5). Recipients of 
spleen cells fröm either toxin- or toxoid-fed donors had significantly 
suppressed DTH responses (p<0.01 and p<0.05, respectively). 
There was no significant difference between the IgG and IgA serum 
antitoxin levels measured in any of these groups (figure 8.6). 
8.5 Summary 
Cyclophosphamide abrogated the induction of tolerance for systemic DTH 
responses normally observed following feeding cholera toxin or toxoid. 
At a dose of 100 mg/kg cyclphosphamide did not affect serum antitoxin 
levels observed in these animals. 
Tolerance for DTH induction could be transferred by 10 8 spleen cells 
obtained from mice one week after feeding either CT or TD. 
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Transferred spleen cells did not effect the induction of systemic 
humoral antitoxic immunity. 
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Figure 8.1 Experimental protocol to test the effect of pntretinq nice with 
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Figure 8.2 The effect of cyclop o" IF' ide pretrest ent on the induction of 
tolerance associated with feeding diolere toxin 
This graph shows the effect of intraperitoneally administered CY (100 mg/kg) 
on the induction of oral tolerance to cholera toxin. Animals received CY two 
days before being fed 1 pg CT ( ) or ABS (O) and were intradermally 
imsunised with 1 pg CT in CFA one week after feeding. Animals were footpad 
challenged two weeks after immunisation. The bars represent the mean 
increment in footpad thickness *1 standard deviation 24 hours after footpad 
challenge with 5 pg M. Experimental groups were statistically compared to 






Figure 8.3 The effect of cyclophoup ide pretreatment on the induction of 
systemic humoral antitoxin response. 
This graph shows the effect of intraperitoneally administered CY on subsequent 
systemic antitoxin antibody responses. Animals were pretreated with CY two 
days before being fed either 1 pg CT ( ) or ABS (O) and were 
intradermally immunised with 1 pg CT in CFA one week after feeding. Two 
weeks after immunisation, mice were footpad challenged with 5 Ng TD and were 
bled for serum antibody determination 8 days after this. 
The points represent the IgG (circles) or IgA (diamonds) antitoxin levels 
obtained from individual mice expressed as the absorbance at 405 nm in an 
isotype-specific ELISA. 
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Experimental groups were compared statistically to the results from'those mice 








Figure 8.4 The effect of cyclophosphaaide on the induction of oral tolerance 
to cholera toxoid 
This graph shows the effect of intraperitoneally administered CY (100 mg/kg) 
on the induction of oral tolerance to cholera toxoid. CY was administered two 
days before either 5 pg TO (®) or ABS (0) was fed. Seven days after 
feeding, animals were immunised with 1 pg CT in CFA and footpad challenged 
two weeks later with 5 pg TD. The bars represent the mean increment in 
footpad thickness *1 standard deviation 24 hours after footpad challenge. 
Statistical comparison was made between the group that was fed ABS but did not 
recieve CY and the other groups of animals. 
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Figure 8.5 The effect of orally iaatniaed spleen cells on the induction of 
systemic DTH in parenterally isssnised syngeneic recipients 
This graph shows the effect on the induction of DTH of the transfer of 
10 e spleen cells from ABS-, CT- or TD-fed syngenic donors. Donor mice were 
fed either ABS (O ), 1 pg CT ( ) or 5 pg TD (® ). One week later these 
mice were sacrificed, and 10 
s of their spleen cells were injected 
intraperitoneally (ip) into syngeneic recipients. Spleen cell recipients were 
intradermally immunised with 1 pg CT in CFA on the same day as cell 
transfer. Two weeks later they were footpad challenged with 5 pg TD. The 
group of mice that did not receive spleen cells, were given a sham ip 
injection of an equivalent volume of medium only on the day of immunisation 
and were otherwise treated like the other animals. The bars represent the 
mean increment in footpad thickness 24 hours after footpad challenge *1 
standard deviation. 
Results of experimental groups were statistically compared to those obtained 
from the sham-injected animals. 
" P<0.05 
*+ p<0.01 





Figure 8.6 The effect of orally ialuniaad spleen cello on the systric 
humeral naponae induced by the parenteral administration of choleragsn 
This graph shows the serum IgG (circles) and IgA (diamonds) antitoxin antibody 
responses of CT-primed mice who received either a sham ip injection of medium 
or 10 s spleen cells from syngeneic donors fed ABS (O), 1 pg CT (  ) or 
5 pg TD (® ) one week earlier. Recipient animals were intradermally 
iwmunised on the same day as the ip injection and were footpad challenged with 
5 pg two weeks later. Eight days after footpad challenge the animals were 
bled for serum antibody estimations. The points represent the antitoxin 
levels of individual mice expressed as the absorbance at 405 nm in an isotype- 
specific ELISA. 
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Experimental groups were compared to sham injected controls. 




CHARACTERISATION OF THE ORALLY-DVDUCED SIPPRESSOR CELL 
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9.1 Introduction 
The previous chapter has suggested that the mucosal downregulation of 
the induction of systemic CMI is achieved by the induction of 
cyclophosphamide-sensitive suppressor cells. These cells were found in 
the spleen seven days after feeding. Previous work with OVA has 
produced similar findings (Miller & Hanson, 1979; Mowat et 81, 
1982), and so experiments were designed to examine whether other 
similarities exist between the suppressor cells induced by the oral 
administration of these two dissimilar protein antigens. Accordingly, 
several facets of the choleragen-induced splenic suppressor cell were 
examined. 
Feeding OVA results in a THY-1 +ve suppessor cell which inhibits the 
Induction of systemic CMI. Depletion of this population of cells from 
the spleens of toxin-fed animals was performed to see if this abrogated 
the ability of these cells to transfer oral tolerance to recipient 
mice. 
Earlier studies have shown that after feeding both soluble and 
particulate antigens, suppressor cells may be found in the Peyer's 
patch (PP)9 mesenteric lymph node (MLN), spleen and thymus. Transfer 
of lymphoid cells from these tissues various times after feeding 
antigens have suggested that orally-induced suppressor cells appear 
first in the PP and then subsequently migrate to MLN, spleen and thymus 
(Ngan & Kind, 1978; Mattingly & Waksmen, 1978; Richman at al, 
1981). Cell transfer protocols with cells obtained from MLN and spleen 
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were used to examine whether similar migration patterns applied to the 
suppressor cells induced by feeding toxin. 
Finally, the suppressor cell induced by feeding OVA or SRBC has been 
shown to inhibit the afferent limb of cell-mediated immunity (Kagnoff 
1978a; Miller & Hanson, 1979). Transfer protocols of splenic cells 
from CT-fed donor to recipients on the same day as or various days 
after immunisation was undertaken to see whether these lymphocytes 
functioned in the same manner. 
All these experiments were performed to see if the mucosal regulation 
of systemic CMI is achieved by a common mechanism despite the 
differences in the control of humoral immunity that are apparent after 
feeding dissimilar protein antigens. 
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As A PHENOTYPIC STUDY OF THE SPLENIC SIPPRESSOR CELL 
9.2 The Effect of Depletion of Thy-L2 +ve Celia on the Suppressive 
Function of Toxin-primed Spleen Cell Suspensions 
Donor mice were fed 1 µg CT or ABS alone. One week later, the 
animals were sac rificed and their spleens were made into a cell 
suspension. The toxin-primed spleen cells were either left untreated 
or treated with absorbed rabbit complement (ARC), anti-Thy-1.2 
monoclonal antibody (McAb), or McAb f ollowed by ARC. The procedure of 
cell depletion is as described in Chapter 4.18. 
10 8 control splenocytes (donors fed ABS) along with the treated and 
untreated CT-primed spleen cells were transferred intraperitoneally to 
syngeneic recipients. Recipient animals were immunised with 1 µg CT 
in CFA, on the same day as cell transfer, and then footpad challenged 2 
weeks later with 5 µg TD in saline. The increment in footpad 
thickness was measured 24 hours aft er footpad challenge. 
Untreated toxin-primed spleen cells were able to transfer significant 
suppression of the induction of systemic DTH compared to spleen cells 
from ABS-fed donors (p<0.01). Treating toxin-primed cells with either 
McAb or ARC alone did not alter their ability to transfer suppression 
as both of these cell populations were able to convey significant 
tolerance (p<0.05 and p<0.01, respectively). 
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Treatment of toxin-primed spleen cells with the McAb followed by ARC 
abrogated their ability to suppress the induction of systemic DTH. The 
DTH responses of recipients of Thy-1.2-depleted toxin-primed spleen 
cells were not significantly different from those seen in animals 
receiving control cells. The response observed in this group was, 
however, significantly greater than those observed in the recipients of 
untreated toxin-primed cells (p<0.01), McAb-treated cells (p<0.05) and 
ARC-treated cells (p<0.01). The results of this experiment may be seen 
in figure 9.1. 
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Bs STWY (IF THE MIGRATION PATTERN OF THE ORAU-Y-KXICM 
CELL 
9.3 The Effect of Transferring MLN and Spleen Cells Various Days after 
Feeding ABS or CT on the Induction of Specific DTH in Syngeneic 
Recipients 
Groups of BALB/c mice were fed either ABS or 1 µg CT. Either three 
or seven days after feeding, these animals were sacrificed and their 
MLNs and spleens removed. 10 cells from each separate lymphoid source 
were transferred intraperitoneally into syngeneic recipients on the 
same day as they were immunised with 1 µg CT in CFA. Two weeks 
later, the recipient animals were footpad challenged with 5 µg TD in 
saline and the increment in footpad thickness was measured one day 
after this. This experimental protocol is shown diagrammatically in 
figure 9.2. The results of this experiment are shown in figures 9.3 
and 9.4. 
Neither the MLN nor the spleen cells transferred from CT-fed donors 
significantly suppressed the induction of DTH when removed 3 days after 
feeding. It is worth noting, that of the 8 animals that received CT- 
primed MLN cells, 4 exhibited statistically significantly reduced DTH 
responses compared to control animals by some 74% (p<0.001). However, 
the remaining 4 animals in this group failed to respond in this way to 
their MLN inoculate with DTH results 
"that were similar to, or even 
greater than, the mean control response. It is this divergence which 
is responsible for the large standard deviation seen in these results. 
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Similarly curious results were obtained when this experiment was 
repeated twice more. 
MLN and spleen cells removed from donor animals 7 days after feeding 
toxin both transferred significant inhibition compared to ABS-fed 
control cells (p<0.05 in both cases)(see figure 9.4). 
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Cs THE K43DE OF ACTION OF TEE ORALLY-POlCED SPLONC SIPPRESSOR CELL 
9.4 The Effect of Transferring CT- and TD-primed Spleen Cells on or 
after the Day of Immunisation on their Ability to Convey Suppression to 
Syngeneic Recipients 
Donor animals were fed either ABS, 1 gg CT or 5 µg TD and 
sacrificed one week later and their spleens removed. 10 s spleen cells 
were then transferred intraperitoneally to syngeneic recipients. The 
'recipients were immunised with 1 µg CT in CFA and were given the 
spleen cells either on the same day as immunisation or 3 or 6 days 
afterwards. All recipient animals were footpad challenged with 5 Vg 
TD two weeks after immunisation and the increment in footpad thickness 
was measured 24 hours after this. This experimental protocol is 
illustrated in figure 9.5. 
Toxin-primed cells were able to produce significant suppression when 
transferred on the same day or 3 days after immunisation (p<0.001 and 
p<0.05, respectively). However, the DTH responses of recipients were 
not significantly different from controls receiving cells from ABS-fed 
donors when the cell transfer was 6 days after immunisation. These 
results can be seen in figure 9.6. 
Figure 9.7 shows the results of the experiments using toxoid-primed 
cells. As with CT-primed cells, TD-primed spleen cells transferred 
tolerance to syngeneic recipients when given intraperitoneelly on the 
same day as or 3 days after immunisation (p<0.05 and p<O. 01, 
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respectively). However, when these cells were transferred 6 days after 
immunisation they failed to suppress the induction of systemic DTH. 
9.5 The Effect of Feeding Toxin or Toxoid on the Function of DTH 
Effector Cells 
The previous experiment suggested that orally-induced suppressor cells 
were only ef fective in the prevention of the induction of DTH. Their 
inability to suppress DTH when transferred 6 days after immunisation 
implied that they inhibit the afferent limb of the CMI response. In 
order to con firm this an experiment was designed whereby primed DTH 
effector cells were transferred into orally-primed animals. 
Animals were fed either ABS, 1 µg CT or 5 µg TD and one week later 
were given a footpad injection of 107 CT-primed cells plus 5 µg TD. 
As a control, ABS-fed animals were inoculted with only 5 µg TD or 
10 7 primed lymph node cells into their footpads. The increment in 
footpad thickness was measured 24 hours after footpad injection. The 
primed DTH effector cells were obtained from the draining lymph node 
cells of animals intradermally primed with 1 µg CT in CFA two weeks 
earlier. 
The results shown in figure 9.8 show that neither 1 µg CT or 5 µg 
TD suppressed the DTH transferred by primed effector cells in the 
presence of antigen. The control animals receiving either 10 7 lymph 
node cells or 5 µg TD alone did have significantly less footpad 
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swelling than the similarly fed group of animals receiving a 
combination of the two (p<0.001 in both cases). 
9.6 Summary 
The results of these experiments suggest that the cell transferring 
oral tolerance is Thy-1.2 +ve and is therefore presumably aT cell. 
This cell appears to be present in the MLN as well as the spleen 7 days 
after feeding, however, the data concerning its presence or absence in 
the MLN 3 days after feeding is inconclusive. It would seem that the 
cell has not yet reached the spleen after 3 days. 
Spleen cell transfer experiments indicated that the suppressor cell was 
only capable of inhibiting the induction of DTH effector cells. 
Feeding mice with either CT or TD one week earlier (which allows 
sufficient time for the induction of both MLN and splenic suppressor 
cells) failed to inhibit the adoptive transfer of DTH by mature 
effector cells which would -seem to confirm that the suppressor cell 








TREATMENT OF CELLS 
Figure 9.1 The effect of depletion of Thy-1.2 +ve eplenic lymphocytes an the 
ability of those cells to transfer oral tolerance 
This graph shows the DTH responses of mice receiving spleen cells from CT- 
( ) or ABS-fed (Q) donors on the same day as they were intradermally 
immunised with 1 pg CT in CFA. These animals were intradermally footpad 
challenged with 5 pg TD in saline two weeks later and the increment in 
footpad thickness 24 hours after this. 
Spleen cells were obtained from donors fed 1 week previously and were 
transferred to recipients intraperitoneally. Two groups of mice received 
either 108 untreated ABS- or CT-fed spleen cells respectively. As further 
controls two groups received 10S spleen cells from CT-fed donors treated with 
either absorbed rabbit complement (ARC) or anti-Thy-1.2 monoclonal antibody 
(McAb) alone and the experimental group received the cells that remained after 
108 CT-fed splenocytes had been treated with first McAb and then ARC. 
The bars represent the mean increment in footpad thickness *1 standard 
deviation 24 hours after footpad challenge. Statistical comparison was made 
between the group receiving ABS-fed splenocytes and the others. 
* p<0.05 
** p<o. 01 
-- McAb C" McAb+C' 
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Figure 9.3 The effect of the transfer of ILN or spleen cells obtained 3 days 
after feeding CT or ABS on the induction of specific DTH in syngweic 
recipients 
Groups of mice were fed either ABS (0) or 1 pg CT (U). Three days later 
these animals were sacrificed and a suspension of 10 HLN or spleen cells were 
transferred intraperitoneally to syngeneic recipients. The recipient mice 
were immunised intradermally with 1 pg CT in CFA on the day of transfer and 
footpad challenged with 5 pg TD in saline two weeks after this. This 
protocol is illustrated diagrammatically in figure 9.2. The bare shown 
represent the mean increment in footpad thickness :1 standard deviation 
measured 24 hours after footpad challenge. 
Statistical comparison was made between recipients of antigen-fed cells and 
















Figure 9.4 The effect of the transfer of lt. N or upieen cells obtained 7 days 
after feeding CT or ABS on the induction of specific 0TH in myngsaeic 
recipients 
Groups of mice were fed either ABS (O) or 1 pg CT (  ). One week later 
these animals were sacrificed and a suspension of 10 MLN or spleen cells were 
transferred intraperitoneally to syngeneic recipients. The recipient mice 
were immunised intradermally with 1 pg CT in CFA on the day of transfer and 
footpad challenged with 5 Ng T) in saline two weeks after this. This 
protocol is illustrated diagrammatically in figure 9.2. The bars shown 
represent the mean increment in footpad thickness t1 standard deviation 
measured 24 hours after footpad challenge. 
Statistical comparison was made between recipients of antigen-fed cells and 
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Figure 9.5 Experimental protocol to saeesa the ende of action of the aplenic 
suppressor cell 
The shaded mice denote the day of experiment that the spleen cells were 
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Figure 9.6 The effect of the transfer of 108 CT-fed spleen cellg, an or after 
the day of ieainiatian an the subsequent develgp t of systemic 0TH 
This graph shows the DTH responses of mice receiving 108 spleen cells 
intraperitoneally from CT- (B>) or ABS-fed (0) donors on the same day as (day 
0) or 3 or 6 days after immunisation. These mice were immunised with 1 pg 
CT in CFA and footpad challenged two weeks after this with 5 pg TD in 
saline. This protocol is show diagrammatically in figure 9.5. The bare 
represent the mean increment in footpad thickness t1 standard deviation 24 
hours after footpad challenge. 
Statisitical comparison was made between the recipients of the two types of 
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Figure 9.7 The effect of the transfer of 108 TD-fed spleen cells on or after 
the day of immunisation on the subsequent development of systemic DTH 
This graph shows the DTH responses of mice receiving 108 spleen cells 
intraperitoneally from TD- (®) or ABS-fed (0) donors on the same day as (day 
0) or 3 or 6 days after immunisation. These mice were immunised with 1 pg 
CT in CFA and footpad challenged two weeks after this with 5 pg TD in 
saline. This protocol is shown diagrammatically in figure 9.5. The bars 
represent the mean increment in footpad thickness ±1 standard deviation 24 
hours after footpad challenge. 
Statistical comparison was made between the recipients of the two types of 










Figure 9.9 The effect of prior oral edWkinietretion of CT or TD on the pesaive 
trwafer of DTH by primed effector cells 
This graph shows the DTH responses observed in groups of BALB/c mice fed 
either ABS (13), 1 pg CT ( ) or 5 pg TD (®). One week later these 
animals received 107 draining lymph node cells from toxin-primed donors in the 
presence of 5 jig M. Draining lymphocytes were obtained from syngeneic 
donors immunised intradermally with 1 pg CT in CFA two weeks earlier. 
ABS-fed mice also received either 5 pg TO or 107 lymph node cells alone, as 
controls. The bars shown represent the mean increment in footpad thickness 
1 standard deviation measured 24 hours after the intradermal injection of 
cells or toxoid or both. Statistical comparison was made between the results 
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Chapter 10 
11-E E EM OF SERLM O]JICIID C NE FAR AFTER FEEDIG OV THE 9. jENT 
INDUCTION OF SYSTEMIC DTH 
189 
10.1 Introduction 
Serum collected from mice fed OVA one hour previously has been shown to 
transfer suppression for the induction of antigen-specific DTH 
responses in syngeneic recipients. Tolerance for systemic antibody 
cannot be transferred in this way. 
As the suppression transferred by serum may be abrogated by the 
pretreatment of the recipient but not the donor with CY, it has been 
postulated that serum transfer induces tolerance by the induction of a 
T suppressor cell (Strobel et ail, 1983). 
Analysis of this serum, reveals that a protein fragment bearing 
determinants for anti-OVA antibody and having the same or approximately 
the same molecular weight as the native antigen is responsible for this 
phenomenon (Bruce & Ferguson, 1986a; Bruce & Ferguson, 1986b). A CY- 
sensitive splenic T suppressor cell capable of inhibiting the induction 
of DTH following OVA feeding has been described previously (Miller & 
Hanson, 1979; Hanson & Miller, 1982). It is possible that the 
tolerogenic serum fraction described above induces this cell. 
The OVA-specific suppressor T cell described above has characteristics 
in common with the splenic suppressor cell induced by feeding cholera 
toxin described in the previous chapters. Serum obtained one hour 
after feeding choleragen was therefore examined for its capacity to 
transfer tolerance. Furthermore, experiments employing either CY or 
cell transfer protocols were used to investigate the capacity of this 
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serum tolerogen to induce the splenic suppressor cell described 
earlier. 
10.2 The Effect of Serum Transfer on Systemic DTH Responses 
A protocol was devised to see if serum obtained one hour after feeding 
toxin could suppress systemic DTH responses as has been observed with 
ovalbumin. Donor mice were fed either 1 µg CT or ABS alone. One 
hour later, the mice were bled out and their serum was separated and 
pooled. Groups of syngeneic recipients were injected intraperitoneally 
with 0.8 mls of toxin-fed serum, ABS-fed serum or an equal volume of 
saline as a sham control. One week later, all groups were 
intradermally immunised with 1 µg CT in CFA and were challenged with 
5 µg TD into the contralateral rear footpad 14 days after this. The 
increment in footpad thickness was measured 24 hours later. 
The results of this experiment are shown in figure 10.1. Mice 
receiving serum from ABS-fed donors had similar DTH responses to those 
receiving a sham intraperitoneal injection of saline. Serum obtained 
from animals fed CT one hour previously was able to significantly 
suppress the induction of DTH after intraperitoneal transfer (p<0.01). 
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10.3 The Effect of Serum Tolerogen on the Splenic Suppressor Cell 
Work with ovalbumin has suggested that gut processed antigen induces a 
specific suppressor cell for DTH responses. Such a cell has been found 
in the spleens of toxin-fed animals, so experiments were designed to 
see if serum obtained one hour after feeding toxin could induce this 
splenic lymphocyte. 
The experimental protocol is shown diagrammatically in figure 10.2. 
Mice were fed either 1gg CT of ABS alone. One hour later these mice 
were bled out and their serum was pooled. 0.8 mis of ABS- or toxin-fed 
serum were each injected into two groups of animals. The first group 
of animals received the appro priate serum intraperitoneally and 7 days 
later were immunised as before. 
The second group of serum recipients were intermediate hosts. These 
mice were intraperitoneally injected with 0.8 mis of the appropriate 
serum, 7 days later they were sacrificed and their spleens removed. 
JOB spleen cells were then intraperitoneally transferred to a third set 
of animals who were immunised on the same day as cell transfer. All 
mice were footpad challenged two weeks after immunisation and the 
increment in footpad thickness noted after 24 hours. 
The results of this experiment are displayed in figure 10.3. Splenic 
lymphocytes from ABS-fed serum recipients do not alter the systemic DTH 
responses significantly when compared with the responses of animals 
receiving ABS-fed serum directly. As in the previous experiment, 
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toxin-fed serum was able to significantly suppress the induction of 
systemic DTH (p<0.001). However, toxin-fed serum did not Induce 
suppressor cells in the spleens of recipient mice after 7 days. The 
DTH responses in these spleen cell recipients were not significantly 
different from those observed in ABS-fed serum recipients. 
10.4 The Effect of Cyclophosphamide on Serum-induced Tolerance 
As the serum tolerogen did not induce the splenic suppressor cell 
normally found after feeding cholera toxin, an experiment was performed 
to see if this serum transfer phenomenon was sensitive to 
cyclophosphamide as has been reported for ovalbumin. 
In these experiments groups of mice received an intraperitoneal 
injection of either cyclophosphamide (100 mg/kg) or saline. Two days 
later these mice received another intraperitoneal injection - 0.8 mis 
of either ABS- or CT-fed serum. Seven days after serum transfer the 
mice wer e immunised and subsequently footpad challenged as has been 
described earlier. 
Earlier experiments have shown that cyclophosphmide alone does not 
alter the DTH responses in saline fed mice. It is not suprising, 
therefore, that the results, displayed in figure 10.4, show that toxin- 
fed serum significantly suppresses the induction of DTH compared with 
responses observed in cyclophosphamide-pretreated ABS-fed serum 
recipients (p<0.002). The tolerance observed in toxin-fed serum 
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recipients is abrogated by pretreatment with cyclophosphamide. 
10.5 Summary 
Serum collected one hour after feeding BALB/c mice with cholera toxin 
was able to suppress the induction of DTH when transferred 
intraperitoneally to syngeneic recipients. This phenomenon was 
abrogated by pretreatment of the recipients with cyclophosphamide (100 
mg/kg) two days before serum transfer. 
This serum fragment did not appear to induce the splenic suppressor 
normally found one week after feeding cholera toxin to BALB/c mice. 
However, further experiments are required to establish this with 
certainty and to define the alternate mechanism(s) by which the serum 
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This graph shows the 0TH responses of three groups of mice intradermslly 
immunised with 1 pg CT In CFA one week after an intraperitoneal injection of 
saline or serum from syngeneic mice fed either ABS (O) or 1 pg CT (U) one 
hour previously. Immunised mice were footpad challenged with 5 pg TO two 
weeks later. The above bars represent the wean increment in footpad thickness 
*1 standard deviation observed 24 hours after footpad challenge. Results 
were compared to those obtained from the nice receiving the sham 
intrsperitonesl injection of saline. 
* p<0.01 
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Figure 10.3 Experint to assess the cgmity of choler. gsn-tsd serum to 
induce a gplenic sWresIor cell 
The above graph shows the DTH responses of groups of mice receiving either 
spleen cells fron serum recipients of serum itself fron ASS- (O) or CT-fed 
(0) donors. Serum was transferred one hour after feeding. Animals receiving 
serum were immunised one week later, spleen cell donors received serum at the 
same time but their aplenocytes were transferred one week later to recipient 
mice. These mice were intraderaally immunised on the same day as cell 
transfer. This regime ensured that all recipient groups were immunised on the 
same day and footpad challenged two weeks later. A diagrammatic 
representation of this protocol may be seen in figure 10.2. The bars 
represent the mean increment in 
footpad thickness *1 standard deviation, 24 
hours after footpad challenge. 
Experimental results are compared to those obtained in mice receiving serum 








Figure 10.4 The effect of c1 soepb ide co the tole ice tre srerred by 
dgleregan-fed eeri 
This graph shows the DTH responses of nice pretreated with cyclophosphamide 
(100 mg/kg) or given a sham injection of saline two days before receiving an 
intraperitoneal injection of serum from syngeneic donors fed ABS (D) or CT 
( 0) one hour previously. These mice were immunised with CT in CFA one week 
after receiving serum and were footpad challenged two weeks after 
immunisation. The bars represent the mean increment in footpad thickness *1 
standard deviation, 24 hours after footpad challenge. 
Experimental results are compared to those obtained from cyclophoaphamide- 








The objective of this thesis has been to study the systemic immune 
response of BALB/c mice to cholera toxin and to examine the 
consequences for this response when the antigen was prefed. This 
objective has been achieved. I have been able to show that a cell- 
mediated immune response is induced by a parenteral immunisation of 
toxin in addition to the production of specific antitoxin antibodies. 
Studies in which choleragen was prefed have confirmed that this antigen 
does not induce oral tolerance for systemic antibody. However, these 
experiments did reveal that choleragen suppresses the induction of 
systemic cell-mediated immunity. Further investigation revealed that 
cyclophosphamide pretreatment reversed the induction of tolerance and 
cell tansfer studies showed that feeding induced a splenic suppressor 
cell. 
There is evidence that choleragen can modulate immune responses by Its 
biochemical properties as well as by virtue of Its antigenicity 
(chapter 1). In order to examine whether the above observations were 
due to its inherent 'toxicity', a toxoid was substituted for the toxin 
in several experiments. These studies revealed that the toxoid was 
inferior at priming for antitoxin antibody responses but that some of 
this effect was due to limited cross-reactivity of these two antigens. 
However, both these proteins were equally effective at boosting 
antitoxin antibody responses, priming for systemic DTH and inducing 
oral tolerance. 
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Further investigation of the nature of the toxin-induced splenic 
suppressor cell revealed that it had many of the characteristics of 
suppressor cells induced by feeding other more classical enteric 
protein antigens. The role of the gut in immunologically 'processing' 
antigen was also examined by serum transfer and showed that a great 
similarity exists between the handling of different protein antigens. 
Furthermore, this work suggests that several mechanisms participate in 
the induction of oral tolerance for systemic CMI. 
Each of these findings will be discussed in turn, beginning with the 
systemic immune responses to parenterally administered choleragen. 
1L2 Systemic Antibody Levels in Parenterally Primed Mice 
Systemic antibodies to cholera toxin have been discovered after 
specific priming of mice (Svennerholm at all 1980; Lycke at all 
1983; Elson & Ealding, 1984a; Elson & Ealding, 1985), rats (Lange 
at al, 1984b), rabbits (Peterson, 1979; Yardley at all 1978; 
Hamilton et all 1979) and dogs (Pierce at al, 1978; Pierce 
at all 1982). IgG and IgA antitoxin antibody levels have been most 
frequently measured but specific IgM has also been detected. This 
study has confirmed some of these findings In that parenteral 
immunisation with choleragen has been shown to Induce systemic IgG and 
IgA antibodies. However, circulating IgM antitoxin antibodies were not 
consistently present. There are several possible reasons for this 
which lie both in the particular assay used and the phenomenon of IgM 
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production in vivo. 
ELISA assays were used to measure specific antibody levels in this 
study. ELISA is a technique commonly employed to assay levels of 
specific antibody and has been frequently used to measure anti- 
choleragen antibody levels in both humans and animals (Holmgren & 
Svennerholm, 1973; Svennerholm & Holmgren, 1978; Young at al, 
1980). This particular assay was set up using a hyperimmune serum 
raised in adult BALB/c mice. This serum contained significant amounts 
of all the three principal isotypes of antitoxin and was used as the 
positive standard against which experimental sera were evaluated. 
While the other two assays worked consistently, the IgM antitoxin ELISA 
did not regularly detect significant levels in specifically immunised 
animals. Background absorbance levels were higher in this assay than 
in the other two. It appeared that the isotype-specific antiserum was 
able to non-specifically bind to the toxin-coated plates despite 
blocking with protein. The conjugate only bound non-specifically to 
toxin-coated wells. This phenomenon was also observed when an anti- 
mouse immunoglobulin antiserum (Miles Ltd) was used In this assay. IgM 
is not the predominant isotype In the antitoxin response and thus has 
to compete in this assay for binding spaces with more numerous and 
perhaps more avid antibodies of other classes. It is possible that 
under these circumstances not enough specific IgM antitoxin Is bound to 
fall within the detectable range of the ELISA system. 
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There are other reasons why low levels of specific IgM may be observed 
in these animals. There are no studies of the isotypic response to 
different doses of parenteral choleragen but virtually all the studies 
examining the humoral immune response to choleragen in mice have used 
10 µg toxin either orally or parenterally (Svennerholm at al, 
1980; Elson & Ealding, 1984a; Elson & Ealding, 1984b; Lycke at al, 
1985; Lycke & Holmgren, 1986a). Furthermore, workers raising anti- 
choleragen monoclonal antibodies of the IgM isotype found that large 
doses of toxin (50 µg) were needed and that clones were detected 4 
days after immunisation (Remmers, Colwell & Goldsby, 1982). Therefore, 
another explanation may be that the dose of antigen used was too small 
and the timepoint examined (7 days) too late to either stimulate or 
detect significant IgM antitoxin responses. 
A number of workers have compared the antigenicity of formalinised 
toxoid to that of the holotoxin (Pierce & Gowans, 1975; Pierce, 1978; 
Peterson, 1979; Pierce, 1980; Fuhrman & Cebra, 1981). Varying 
conclusions have been drawn from these studies, but none of these 
papers have used these two substances in comparable amounts. 
Comparative experiments using these two proteins at the mucosal surface 
have always attributed differences in immune response to the particular 
biochemical properties of the toxin (binding to cell surface 
gangliosides and adenylate cyclase activation) (Pierce, 1978; Pierce at 
al, 1978; Lycke & Holmgren, 1986x) but more subtle changes in 
antigenicity due to the detoxification procedure have never been 
examined. The majority of antibodies raised by immunisation with the 
holotoxin are directed against B subunit determinants (Holmgren & 
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Svennerholm, 1979; Svennerholm, Holmgren, Black, Levine & Merson, 1980; 
Lindholm, Holmgren, Wilkstrom, Karlsson, Andersson & Lycke, 1983). 
It is for that reason that B subunit is generally thought of as being 
the immunodominant portion of choleragen (Holmgren & Svennerholm, 
1983). Experiments described in chapter 5 have therefore employed 
doses of toxin and toxoid with a similar B subunit content. 
The results obtained show that toxin is superior to toxoid at priming 
for an antitoxin response, but that both substances are equally 
efficient at recalling an anamnestic response especially of the IgG 
isotype. Boosting of a specific IgG response has been shown to be aT 
cell phenomenon (Schrader, 1975; Okumura, Metzler, Tsu, Herzenberg & 
Herzenberg, 1976) and it is therefore possible that this result 
reflects cross-reactivity at the T cell level whereas B cell 
determinants are not shared between these two substances. An anti- 
toxoid ELISA was therefore developed in order to examine whether 
differences exist in the response to both forms of this antigen. The 
ELISA used solid M129A microtitre plates in place of the flexible M 29 
plates used in the method of Cruce and his colleagues (Cruce, Wachsmuth 
& Feeley, 1983). In contrast to their findings we found that solid 
plates were able to bind sufficient antigen and gave more consistent 
results than the flexible plates. 
Results from this assay were intriguing, the toxoid-primed animals had 
significantly higher levels of circulating IgG anti-toxoid than animals 
Immunised with choleragen. However this difference was not as great as 
in the reverse situation and significance was only found when all the 
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prechallenge animals were compared (i. e. those destined for challenge 
with either toxin or toxoid). This is a fair statistical comparison to 
make as the original two groups had not been further subdivided at this 
stage of the experiment. This difference was not maintained after the 
second antigenic challenge where all groups gave statistically similar 
results. It could be that although there are specific differences in 
the antigenic determinants on these two substances only shared 
determinants are 'helped' by specific T cells. The antitoxin results 
suggest that some antigenic determinants have been lost from the 
holotoxin during the process of formalinisation. 
Formalinisation has been used for the conversion of toxins to toxolds 
for some time. Formaldehyde has been shown to effect a reductive 
alkylation of lysine (Pancake & Nathenson, 1973) and tyrosine residues 
(Habeeb, 1969). The effect of such changes on antigenicity is variable 
with some authors reporting decreases in antigenicity (Bradley & 
Barnes, 1972; Pancake & Nathenson, 1973; Gatti, Ostborn & Fagraeus, 
1974; Pierce, 1978; Peterson, 1979) and others reporting no change 
(Jacobs & Sommers, 1939; Grasset & Zoutendyk, 1933; Zinsser & 
Cetteneda, 1931; Pappenheimer Jr, 1938; Hewitt, 1930; Bradley & Barnes, 
1972; Habeeb, 1969) or even increased reactivity (Warren, Spero & 
Metzger, 1973). Crude formaldehyde is able to polymerise antigens and 
the observed difference in responses has been attributed both to 
polymerisation (Warren et al, 1973) and the alteration of lysine- 
containing B cell determinants (Pancake & Nathenson, 1973). While all 
the foregoing studies have measured the humoral immune response to 
formelinised antigenic determinants, the T cell response to such 
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antigens has only recently been critically evaluated. Some work 
employing cellular antigens is relevant to the consideration of this 
point. 
Elegant studies using formalin-fixed target cells have shown that 
chemical treatment removes the determinants recognised by the majority 
of anti-H-2 monoclonal antibodies. However, these cells are still 
capable of stimulating the appropriate response from H-2-specific 
cytotoxic T lymphocytes. Work with mutant cell lines has shown that 
target cells must possess a lysine residue within the B cell 
determinant for formalinisation to prevent the binding of monoclonal 
antisera (Hua, Langlet, Bufferne & Schmitt-Verhulst, 1985). These 
studies clearly demonstrate that formalinisation can selectively alter 
the ability of B cells and antibodies to recognise specific 
determinants and suggests that It may be this phenomenon which Is 
responsible for the observed differences in Immunogenicity between 
toxin and toxoid (especially when assayed against the holotoxin) rather 
than the biochemical properties of choleragen. 
1L3 Systemic Cell-Mediated Immunity in Parenterally Primed Mice 
It is common for antigens to induce both humoral and cell-mediated 
Immune responses. Experime nts described in chapter 6 have established 
that choleragen is capable of inducing systemic CMI under conditions 
where specific IgG and IgA have also been shown to exist (chapter 5). 
This is the first description of CMI to choleragen. 
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DTH was assessed by direct skin testing whereby the incremental change 
in footpad thickness 24 hours after intradermal challenge with antigen 
is measured using engineers' calipers. This is a reliable and well- 
established method for quantifying DTH responses in experimental 
animals (Kettman, 1972; Clark & Azar, 1977; Titus & Chiller, 1981b). 
However, the assay as used in this project had two drawbacks. Firstly, 
preliminary results (chapter 4) showed that an intradermal injection of 
choleragen causes a large amount of non-specific footpad oedema. They 
also showed that toxoid, in amounts up to 5 µg, did not, both of 
which are in agreement with earlier studies (Finkelstein & 
Hollingsworth, 1970; Lexomboon at al, 1971). As the non-specific 
oedema would interfere with the measurement of DTH, toxoid was chosen 
as the challenge antigen regardless of the immunising protein. This 
meant that differential responses to a challenge with the two forms of 
cross-reacting antigen could not be assessed. This was not felt to be 
of major importance as other studies have confirmed that 
formalinisation does not appear to alter T cell reactivity (Hue at al, 
1985) and that limited studies in which animals were challenged with 
purified B subunit gave similar responses in both choleragen- and 
toxoid-primed mice. 
The second problem in this assay was the wide scatter of results 
obtained from mice that had been identically treated i. e. the intra- 
group variation was large and this resulted in large standard 
deviations about the mean. This was not due to poor technique because 
repeating this assay on OVA-primed and challenged animals gave results 
which agreed well with those obtained by other workers in our 
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laboratory. The possible reasons for this variation are two-fold. 
Toxoid (like toxin) has a limited shelf-life. The DTH responses 
obtained one or two months after being kept at 4 to 8OC were not as 
great as was obtained when the preparation was 'fresh'. As the toxoid 
was a gift, in limited supply and could not be frozen to maintain 
antigenicity, extra internal controls were always included. Secondly, 
this formalinised immunopurified toxoid has been shown to have a small 
amount of residual toxicity in the limit of bluing essay (Pierce, 
1978). Furthermore, other formalinised cholera toxoids have been shown 
tö revert to toxicity in vivo (Northrup & Chiseri, 1972) and it might 
be this that is responsible for the observed mouse-to-mouse variation. 
The DTH skin test confirmed that toxin-primed mice gave positive 
responses both 24 and 48 hours after specific antigen challenge. 
Histological examination of the lesions induced showed a gradual 
accumulation of mononuclear cells. Initially, these were lymphocytes 
but basophils and neutophils were additonally involved at later 
timepoints. These findings are also consistent with earlier 
descriptions of DTH (Dvorak at a1,1974; Scovern & Kantor, 1982; 
Pellitier, Forget, Bourassa & Skamene, 1984). In addition to the later 
swelling response, an 'immediate-type' oedematous response was also 
observed. This is in agreement with the findings of other workers (Van 
Loveren at 81,1983) who have suggested that the early swelling is 
an obligatory component of the DTH response brought about by the 
release of serotonin from tissue mast cells specifically armed with aT 
cell factor (Askenase at al, 1983a; Askenase at al, 1983b; Askenase & 
Van Loveren, 1983; Van Loveren at a1,1984). There are studies 
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which have shown DTH to occur in mast cell-deficient mice but these 
have not examined whether this early swelling component still occurs 
(Thomas & Schrader, 1983; Gall! & Hammel, 1984). The necessity or 
exact nature of this phenomenon has yet to be established but these 
experiments do confirm its existence. 
Dose-response studies have shown that optimal DTH is induced by priming 
with 1 µg of choleragen, whereas other work suggests that priming of 
specific antibodies is better with 10 µg of toxin. Work with cloned 
T cells has shown that they can both passively transfer DTH and provide 
help for specific antibody production (Bianchi at al, 1981; Dennert 
at al, 1981; Milon et al, 1983). Earlier studies In SRBC- 
primed animals revealed that low doses of antigen preferentially 
induced DTH whereas higher doses primed most favourably for specific 
humoral immunity. It was suggested that the T cell mediating both 
these functions may be specifically trapped in the spleen by B cells 
induced by the larger doses of antigen (Milon et a1,1983). 
The foregoing experiments were specifically designed to look at the 
activation of T cells by choleragen. DTH is an established measure of 
T cell reactivity but other facets of T cell activation were also 
assessed. 
Antigen administered intradermally into the hind footpad has been shown 
to drain to the popliteal and inguinal lymph nodes of the recipient 
(Hall, 1985). Draining lymph node cells from choleragen-primed mice 
were shown to have reduced migration when cultured in the presence of 
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cholera toxoid at a concentration of 0.01 µg/ml. Antigen 
concentrations both ten-fold higher and lower failed to induce 
migration inhibition in these cells and cells from saline- or OVA- 
primed donors were not inhibited by any of the concentrations of toxoid 
in culture. This method is a modification of the technique described 
by Mowat and Ferguson (1982a) and has been used to assess the cell- 
mediated immune response of mesenteric lymph node cells after the 
enteric administration of antigen (Mowat & Ferguson, 1982b; Mowat, 
1986). The assay was originally described using the peripheral 
draining lymph node cells from mice primed intradermally with ovalbumin 
and experiments performed in this thesis have confirmed that OVA-primed 
cells exhibit migration inhibition only in the presence of specific 
antigen. Although best seen in T cell-enriched populations the 
phenomenon could also be observed with T cell-depleted lymphocyte 
preparations but T cell contamination could not be ruled out as a 
possible source of error (Mowat & Ferguson, 1982a). 
Lymphocytes have been shown to release many soluble products capable of 
inhibiting the migration of a number of differing cells including 
macrophages, lymphocytes and neutrophils (David, 1972; Pick, 1979; 
Rocklin at all 1980; Schrader & Clark-Lewis, 1981; Weissbart at all 
1982; Godfrey & Purholt, 1982). Lymphoid cells from a number of 
tissues have been used in direct migration inhibition assays including 
spleen (Rich & Lewis, 1932; Carpenter, Berseles & Ganghan, 1968; 
Likhite, Haasz, Algom & Richter, 1972; Hughes, Preece & Light, 1980), 
thymus (Bakker, Englehart, Mulder & Hoedemaeker, 1975; Hughes at all 
1980), tonsil (Mazuran, Rebetic, Sabioncello & Dekaris, 1979) and lymph 
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nodes (Thor & Dray, 1968; Likhite et a1,1972). Migration 
inhibition has also been described in peripheral blood lymphocytes 
(Kowalczyk & Zembala, 1978; Bradsher, Sutcliffe & Alford, 1979). 
Positive results in these assays have been correlated with the presence 
of 0TH in vivo (Thor & Dra y, 1968; Likhite et al, 1972; Mazuran 
et ei, 1979; Hughes et al, 1980) and other measures of CMI 
(Kowalczyk & Zembala, 1978; Bradsher et al, 1979). Although other 
workers have shown that immune complexes may inhibit cell migration in 
vitro (Bloom & Bennett, 1966; Carpenter et al, 1968), Mowat and 
Ferguson (1982a) have shown that their migration Inhibition assay 
closely paralleled DTH in vivo and was unaffected by the level of 
humoral immunity. 
Finally, the corner stone of CMI has been the description of immune 
responses that could be transferred wi th cells but not serum. Many 
authors have been able to transfer DTH to naive syngeneic recipients 
using primed lymphoid cells (Marchal at all 1978; Titus & Chiller, 
1981b; Scovern & Kantor, 1982; Mil on at all 1983; Van Loveren 
at al, 1984). These experiments have established that T cells 
transfer this reaction. Work with T cell clones has further confirmed 
the lineage of the DTH effector cell. It has also revealed that some 
of these clones are only capable of transferring a DTH reaction if 
injected locally in the presence of antigen (Bianchi at al, 1981; 
Dennert et al, 1981; Lin & Askonas, 1981; Weiss & Dennert, 1981; 
Marchal et all 1982; Minami at al, 1982; Thomas at all 
1982; Carroll et all 1983; Gallatin at all 1983; Tamura 
at al, 1983). 
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The local passive transfer of DTH using primed lymphoid cells admixed 
with antigen has been used successfully to demonstrate the presence of 
CMI to bacteria (Lin & Askonas, 1981; Kaufmann & Hahn, 1982), contact 
sensitising agents (Thomas at all 1982; Van Loveren at all 
1984), heterologous red blood cells (Marchal at all 1978; Bianchi 
at all 1981; Marchal at all 1982; Milon at all 1983), and 
protein antigens (Scovern & Kantor, 1982). Cells transferring DTH have 
been obtained from mucosal as well as peripheral lymphoid tissues 
(Shields & Parrott, 1985). In all cases the effector cells have been 
shown to be THY-1 positive. This technique has the obvious advantage 
that it does not require the immune cells to migrate to the site of 
antigenic challenge and that it appears to require fewer primed 
lymphocytes than passively sensitising the whole animal intravenously. 
For these two reasons the passive transfer of DTH was used as a measure 
of CMI in toxin-primed animals. Draining lymph node cells, obtained 
from mice primed with toxin, were able to transfer DTH to naive 
syngeneic recipients in the presence of specific antigen. Depletion of 
the Thy-1.2 positive lymphocytes from this population abrogated their 
ability to transfer DTH and confirmed the T cell lineage of these 
effector cells. 
1L4 Systemic Immunity after Prefeeding with Antigen 
Previous studies have demonstrated that the induction of systemic 
Immunity may be inhibited by prefeeding with a number of protein 
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antigens (Vaz, Maia, Hanson & Lynch, 1977; Ngan & Kind, 1978; Richman, 
Chiller, Brown, Hanson & Vaz, 1978; Swarbrick at all 1979; 
Challacombe & Tomasi, 1980; Titus & Chiller, 1981a; Mowat at ei, 
1982). Few of these studies have examined the consequences of feeding 
on both cell-mediated and humoral limbs of the effector response. A 
protocol which does is the one routinely employed in this laboratory to 
assess the effect of feeding OVA (Mowat at all 1982; Mowat & 
Parrott, 1983; Mowat, 1985; Strobel at all 1985; Mowat, 1986). 
This was adopted as it also allowed a more direct comparison of the 
responses to choleragen and the more frequently studied enteric 
antigen, OVA. BALB/c mice have been shown, by a number of workers, to 
be a strain capable of exhibiting oral tolerance (Mowat at all 
1982; Mowat & Parrott, 1983; Strobel & Ferguson, 1984; Mowat, 1985) and 
have been used in the examination of the murine response to orally and 
parenterally administered choleragen (Remmers at all 1982; Robb, 
Nichols, Whoriskey & Murphy, 1982; Lindholm at all 1983; Lycke 
at all 1987) and so were a natural choice for these experiments. 
A single feed of either 1 or 10 µg of cholera toxin was able to 
tolerise the induction of systemic CMI but had no effect on the 
subsequent induction of systemic antitoxin levels by parenteral 
immunisation. A smaller feed of choleragen (0.1 µ g) failed to 
tolerise the induction of either limb of the immune response. Several 
workers have shown that the induction of oral tolerance is dose- 
dependent and it is usually the higher doses of antigen which 
successfully induce tolerance (Asherson, Zembala, Thomas & Perera, 
1980; Mowat, Thomas, MacKenzie & Parrott, 1986). The inability of 
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choleragen to induce oral tolerance for specific antitoxin responses 
has been reported independently by other workers (Svennerholm 
et al, 1980; Elson & Ealding, 1984b; Lycke & Holmgren, 1986a). 
Indeed, earlier studies have shown that feeding cholera toxin can prime 
for both local and systemic antitoxin responses (Lange & Holmgren, 
1978; Pierce, 1978; Svennerholm et al, 1980; Lange et al, 
1984a; Elson & Ealding, 1984a). Unfortunately, pre-parenteral 
immunisation bleeds were not performed routinely on the above animals, 
but the IgG antitoxin levels obtained 7 days after parenteral 
immunisation were consistently and statistically significantly higher 
in those animals which had been fed 10 µg choleragen (chapter 5). By 
day 22 of the experiment there was no difference in the antitoxin 
levels in any of the groups. This is consistent with the findings of 
Lange & Holmgren (1978) who observed that antitoxin levels were similar 
in animals who had received between 2 and 5 boosters with toxin and 
that further significant elevation in specific antibody levels required 
additional exposure to antigen. 
Experiments using other proteins have shown that different immune 
effector mechanisms have differing susceptibilities to the induction of 
oral tolerance. Mowat and his co-workers have shown that feeding 5 mg 
OVA tolerised the induction of both specific DTH and IgM antibody 
levels whereas higher doses of fed OVA (25 mg) were required to 
additionally tolerise specific IgG antibody levels (Mowat at al, 
1982). Furthermore, studies in which mice were pretreated with 
cyclophosphamide revealed control mechanisms with different 
sensitivities to this drug (Mowat at al, 1982). It has been 
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inferred from these results that each effector limb of systemic 
immunity is under the control of separate mechanisms. Several workers 
have suggested that such regulation is accomplished by T cells and have 
been able to demonstrate B cell priming in anima ls who had been 
tolerised by the oral administration of OVA (Titus & Chiller, 1981a; 
Mowat at al, 1986). Experiments in which human gammeglobulin has 
been fed has revealed that B cell energy may also occur (Vives 
et al, 1980). 
A possible explanation for this clearly divergent response to the oral 
administration of choleragen may lie in its 'toxic' biochemical 
properties. Choleragen has been shown to alter the activity of 
lymphocytes in vitro (Lichtenstein at al, 1973; Holmgren at al, 
1974; Kateley at al, 1975; Lindholm at air 1976; Fuse 
at air 1981; Fuyama at al, 1982) and both suppress (Northrup & 
Fauci, 1972; Yardley at al, 1978; Hamilton at al, 1979; Pierce 
& Koster, 1980; Koster & Pierce, 1983; Fuse at al, 1981; Goldfarb & 
Herberman, 1981; Fuyama at air 1981; Fuyama at al, 1982) and 
enhance (Lindholm at al, 1976; Tsuru at al, 1981; Tsuru 
at air 1983; Lycke & Holmgren, 1986) immune responses to related 
and unrelated antigens in vivo. It may be that the suppressor cells 
which are induced by feeding protein antigens and have been shown to 
control both antibody levels and plaque-forming cell responses (Hanson 
at al, 1977; Ngan & Kind, 1978; Richman at al, 1978; 
Challacombe & Tomasi, 1980; Titus & Chiller, 1981; Cowdery & Johlin, 
1984) are more sensitive to the actions of choleragen than those which 
regulate the induction of specific NTH. 
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In order to examine the relevance of the biochemical properties of 
choleragen, experiments were performed whereby cholera toxoid was fed 
which lacked both the ability to bind to gangliosides and activate 
adenylate cyclase. Feeding a dose of toxoid with an equivalent B 
subunit content to that of the fed choleragen had similar effects on 
oral tolerance. The two highest doses of toxoid (5 and 50 µg) 
suppressed the induction of DTH but not specific antibody responses and 
the lowest dose fed (0.5 µg) suppresed neither. It would seem 
therefore that the inability to induce tolerance for antibody is an 
Inherent antigenic property of these preparations. However the same 
may not be true for the ability of these preparations to stimulate 
antibody when administered enterically. 
These two preparations differ in their ability to stimulate both local 
and systemic specific humoral responses when fed. The holotoxin 
stimulates several orders of magnitude more antitoxin-containing cells 
and it has been suggested that this difference is a reflection of the 
'toxic' actions of choleragen (Pierce, 1978). Some evidence for this 
has been accrued by feeding other proteins simultaneously with 
choleragen. When cholera toxin is fed at the same time as keyhole 
limpet haemocyanin (KLH), it both abrogates the systemic tolerance for 
antibody usually observed and induces a local humoral immune response 
to KLH (Elson & Ealding, 1984b; Lycke & Holmgren, 1986a). There is no 
difference between the effect of feeding KLH alone or in the presence 
of purified cholera B subunit on anti-KLH responses (Lycke & Holmgren, 
1986a). Feeding horseraddish peroxidase (HRP) does not induce a local 
or systemic antibody response, but both may be Induced if HRP is 
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covalently linked to choleragenoid (McKensie & Halsey, 1984). Both 
binding and enzymatic actions of choleragen may therefore play a role 
in the enteric priming of mucosally-associated B cells. This is 
further supported by the observation that isolated B subunit is a much 
more powerful oral immunogen than the formalinised toxoid (Pierce, 
1978) but is still inferior to the native holotoxin at inducing local 
antitoxin-containing cells (Pierce at al, 1983). Procholeragenoid, 
a high molecular weight, heat-aggregated polymer of choleragen which 
has less than 5% of the residual toxicity of the holotoxin, is equally 
as good as choleragen and better than isolated B subunit at stimulating 
local ACC responses (Pierce et al 1983). This is in agreement with 
experiments which demonstrated that small amounts of orally 
administered choleragen (100 ng) had adjuvant properties. When fed 
simultaneously with either KLH or isolated B subunit it stimulated 
enhanced local antibody production to them even though this dose was 
insufficient to provoke an antibody response to itself (Lycke & 
Holmgren, 1986a). It is of interest that although choleragen and 
cholera toxoid differ in their ability to prime for antibody, they are 
both equally capable of boosting specific humoral immune responses when 
applied enterically 
(Pierce, 1978) suggesting that this phenomenon may 
be mediated by T cells. 
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11.5 Cellular Suppressor Mechanisms Induced by Feeding Choleragen 
A single feed of choleragen has been shown to tolerise systemic DTH. 
Feeding other protein antigens has also resulted in the suppression of 
systemic CMI (Miller & Hanson, 1979; Challacombe & Tomasi, 1980; Titus 
& Chiller, 1981a; Mowat et al, 1982) and this has been most 
frequently associated with the induction of suppressor cells (Miller & 
Hanson, 1979; Challacombe & Tomasi, 1980; Mowat et e1,1982; Mowat, 
1986). Some of the evidence for suppressor cell involvement in oral 
tolerance has indirectly come from the use of pharmacological agents 
(Mowat et al, 1982; Mowat, 1986). 
Preliminary experiments (chapter 8) investigated the sensitivity of 
oral tolerance to pretreatment with cyclophosphamide. Cyclophosphamide 
(CY) is an alkylating agent used in cancer chemotherapy. It has been 
shown to reverse the tolerance resultant from suppressor cell 
activation (Sy, Miller & Claman, 1977; Turk, Parker, Poulter, 1972) and 
when used within the dose range of 20 to 200 mg/kg has been found to 
Inhibit short-lived suppressor cells affecting DTH responses (Attallah, 
Ahmed & Sell, 1979; Diamantstein, Klos, Hahn & Kaufmann, 1981). 
Pretreatment with CY (100 mg/kg) two days before feeding has been found 
to abrogate the induction of tolerance by OVA (Mowat et al, 1982). 
CY has the potential to damage the intestinal mucosa (Sobhon at al, 
1977) but studies have shown that this dose of CY has minimal effects 
on the integrity of the gut mucosa (Ecknauer & L. ährs, 1976; Hartwich, 
Weisshaar & Domschke, 1978; Mowat, 1981) and experiments which have 
examined the tolerogenic properties of absorbed antigen have shown it 
218 
to be unchanged by this procedure (Mowat, 1981; Strobel at al, 
1983). Using the protocol described above, I found that 
cyclophosphamide abrogated the induction of tolerance by choleragen. 
This suggested that suppressor cells may also be implicated in oral 
tolerance to choleragen and so a cell transfer protocol was employed to 
examine this further. 
Spleen cells were obtained from donors fed cholera toxin (1 µg) one 
week previously and were transferred intraperitoneally to syngeneic 
recipients on the same day as they were parenterally immunised with 
choleragen in adjuvant. One hundred million viable spleen cells were 
transferred as this was the average content of an adult BALB/c mouse 
spleen. The intraperitoneal route of transfer was preferred over the 
intravenous one as it gave the same results in preliminary experiments 
but abolished the loss of animals through pulmonary embolism. 
Spleen cells from toxin-fed donors were able to suppress the induction 
of DTH as did cells from animals fed cholera toxoid (5 µg). Splenic 
suppressor cells capable of inhibiting CMI have also been demonstrated 
after feeding OVA (Miller & Hanson, 1979), SRBC (Kagnoff, 1978e) and 
contact sensitising agents (Asherson et 819 1980). The similarity 
between the mechanism controlling DTH after feeding choleragen and 
other protein antigens was remarkable considering the unique action of 
the holotoxin on the humoral immune response when administered 
enterically. Experiments were designed (chapter 9) to investigate the 
phenotype, migration and mode of action of these cells to see if any 
further similarities were apparent. 
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Suppressor cells induced by feeding antigen are usually of T cell 
lineage (Mattingly & Waksman, 1978; Ngan & Kind, 1978; Richman 
at al, 1978; Miller & Hanson, 1979; Asherson at al, 1980; 
MacDonald, 1982a; MacDonald, 1982b; Silverman, Perl, Fitch & Rothberg, 
1983; Mowat et al, 1986). However, suppressor B cells have also 
been found after the enteric administration of contact sensitising 
agents (Asherson et al, 197 7; Asherson, Perera, Thomas & Zembala, 
1979). Treatment of spleen cells from choleragen-fed donors with anti- 
THY-1.2 monoclonal antibody and complement abrogated their ability to 
inhibit the induction of DTH confirming that these cells were also T 
lymphocytes. 
Suppressor cells have been found to migrate from the PP to MLN and then 
to the spleen after feeding OVA (Ngan & Kind, 1978; Richman et al, 
1981). A similar pattern of migration was found after feeding SRBC but 
the thymus was colonised in addition to the spleen (Mattingly & 
Waksman, 1978). Experiments were designed to study this phenomenon in 
choleragen-fed animals and migration was followed using functional 
characteristics; in other words, the capacity of different lymphoid 
tissues to transfer suppression was examined at various times after 
feeding. 
Suppressor activity was present in both the spleen and MLN one week 
after feeding. Spleen cells did not transfer suppression when obtained 
3 days after feeding but the results for MLN cells at this time were 
curious. Although the experiment was repeated 3 times, the same result 
was obtained in that half the toxin-fed MLN recipients had tolerant DTH 
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responses (<50% of control respnses) and half remained unsuppressed by 
the cell transfer. These results occurred despite pooling and mixing 
donor cells. Suppressed and unsuppressed responses did not occur 
sequentially (suggesting that mixing was adequate) and transferred 
cells were always greater than 95% viable. These cells were 
transferred intraperitoneally for the reasons given before and this 
unusual but repeatable result may reflect a defect in their capacity to 
migrate at this stage of their ontogeny. The experiment would need to 
be repeated using the intravenous route of transfer but there are 
several examples of effective T cells which fail to function until 
experimentally located at the site of antigen challenge (Weiss & 
Dennert, 1981; Lin & Askonas, 1981; Kaufmann & Hahn, 1982; Minami 
at at, 1982; Van Loveren at al, 1984). It may also be that 3 
days is not the most appropriate time after feeding to examine the MLN 
for the presence of suppressor cells. No conclusive evidence for a 
migration of cells regulating DTH has been accrued from these 
experiments and further timepoints and other lymphoid cells (PP and 
thoracic duct lymph) need to be examined. However, antitoxin- 
containing and regulatory cells have been shown to disseminate 
throughout the MALT in toxin-fed rats (Pierce & Gowans, 1975; Pierce & 
Cray Jr, 1981) and helper T cells for IgA and IgG have been found in 
the PP, MLN and spleen of mice fed choleragen (Elson & Ealding, 1984a). 
Suppressor cells have been demonstrated which work either on the 
afferent or efferent limbs of the effector T cell response (Zembala & 
Asherson, 1973b; Asherson & Zembala, 1974; Asherson et e1,1977; 
Kagnoff, 1978a; Miller, Sy & Claman, 1978a; Miller, Sy & Claman, 1978b; 
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Miller & Hanson, 1979; Perera & Asherson, 1981; Battisto, Beckman & 
Yen-Lieberman, 1985). In additon to their functional characteristics, 
these suppressor cells have other distinct properties which allow their 
separation. Suppressor cells (Ts aff) working on the afferent limb of 
the T cell response appear to be sensitive to CY and resistant to adult 
thymectomy (Asherson et al, 1980; Thomas, Watkins & Asherson, 1981) 
which is the opposite to that found for suppressors (Ts eff) of T 
effector cells (Asherson at ei, 1980). Although a Ts eff has been 
found which is sensitve to CY (Gill & Liew, 1978), this may reflect the 
sensitivity of a second auxilliary T cell which is necessary for the 
normal operation of the first (Sy, Miller, Moorhead & Claman, 1979; 
Asherson et al, 1980). It might be supposed, from the results of 
cyclophosphamide pretreatment, that the choleragen-Induced suppressor 
cells may work by inhibiting the afferent limb of DTH and experiments 
were designed to examine this. 
Spleen cells, obtained seven days after feeding, were transferred to 
recipients either on the same day as or 3 or 6 days after immunisation. 
If the suppressor cells inhibited the mature DTH effector T cell it 
would be expected that similar suppression would be observed at all of 
these timepoints. However, if the orally-primed lymphocytes were only 
effective at preventing the induction of DTH effector cells, it would 
be expected that the observed suppression would decline the later the 
transfer was performed after immunisation. The results of this 
experiment showed that the suppression declined the longer after 
immunisation the cells were transferred. Significant suppression 
occurred when toxin- or toxoid-primed cells were transferred on the 
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same day as or 3 days after immunisation. There was no significant 
suppression when either cell was injected after 6 days. 
In order to confirm these findings, mice which had been fed either 
antigen or ABS seven days previously were given a footpad inoculate of 
mature toxin-primed DTH effector cells and toxoid. There were no 
differences in the DTH responses observed in animals which were sham 
fed or which received enteric choleragen or toxoid. This would appear 
to confirm the action of these orally-induced suppressor cells on the 
afferent limb of DTH. Such suppressor cells have been found in the 
spleens of animals fed either contact sensitising agents, SRBC or OVA 
(Asherson et al, 1977; Kagnoff, 1978a; Miller & Hanson, 1979). It 
is interesting to note that recent experiments have revealed that 
animals which are fed OVA after being parenterally immunised also have 
suppressed DTH responses. In this model spleen cells obtained from 
these animals were also ineffective at transferring tolerance (Lamont, 
Bruce, Watret & Ferguson, 1987). It would therefore appear that 
several mechanisms are active in the control of systemic DTH. 
11.6 Serum Tolerogen after Feeding Cholera Toxin 
The work in this thesis has highlighted the divergence in the mucosal 
regulation of the two effector limbs of the systemic immune response to 
choleragen. Not only does feeding not induce oral tolerance for 
antibody but B cell priming (Lange & Holmgren, 1978; Pierce, 1978; 
Svennerholm et al, 1980; Lyck e& Holmgren, 1986a; Lycke & Holmgren, 
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1986b) and antigen-specific IgG and IgA helper T cell activity have 
been demonstrated (Elson & Ealding, 1984a). On the other hand, 
experiments described earlier have shown that oral tolerance for 
systemic DTH may be induced and is associated with the appearance of 
CY-sensitive T suppressor cells. While some of these differences may 
reflect the particular sensitivities of immune regulatory cells to the 
'toxic' actions of this protein antigen (Pierce, 1978; Elson & Ealding, 
1984b; Lycke & Holmgren, 1986a), some may also be explained by a 
differential response of these cells to 'intestinally processed' 
antigen. 
Intestinal processing is the term used to describe the alterations that 
occur in antigenicity of foodstuffs consequent on their passage through 
the gastrointestinal tract. One approach to the study of gut-processed 
antigen has been its collection in the serum of fed animals within a 
short time of feeding and its transfer to recipients whose functional 
responses are then studied (Strobel at al, 1983). 
Other facets of oral tolerance have also been studied using serum 
transfer protocols. However, serum transfer studies have been 
uniformly unsuccessful in tolerising systemic antibody when collected 
between 1 hour or 14 days after feeding (Kagnoff, 1978b; Hanson 
et a1,1979; Strobel at al, 1983; Bruce & Ferguson, 1986a). 
Tolerance for DTH, on the other hand, has been successfully transferred 
by serum from mice given a single feed of OVA (Strobel et al, 1983; 
Bruce & Ferguson, 1986a). 
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Using the protocol devised in this laboratory by these workers, the 
effect of gut processing on choleragen was studied. Serum was 
collected and pooled one hour after feeding 1 µg choleragen to BALB/c 
mice and was transferred to syngeneic recipients who were parenterally 
immunised one week later. The development of specific antitoxin 
antibody and DTH responses were measured as before. Eight hundred 
microlitres of serum were transferred as this was felt to be 
representative of the circulating serum volume of an adult mouse. 
Serum obtained as above was capable of inducing specific suppression of 
DTH but had no effect on systemic antibody. This is in agreement with 
results obtained after feeding OVA (Strobel et al, 1983; Bruce & 
Ferguson, 1986a). 
Experiments in which tolerance has been transferred by serum collected 
from mice after several feeds of particulate antigen has shown that the 
serum contains either antibodies (Kagnoff, 1978b) which were thought to 
be anti-idiotypic in specificity (Kagnoff, 1980) or immune complexes 
(Andre et ad, 1975). Serum in the above experiment was not 
examined for specific antibody or immune complexes for several reasons. 
No specific antibodies were detected in serum obtained one hour after 
feeding OVA (Bruce & Ferguson, 1986x) or one week after its transfer to 
recipients (Strobel et al, 1983). Furthermore it was felt 
extremely unlikely that a naive animal could mount a specific immune 
response of detectable magnitude to choleragen in one hour. Earlier 
experiments (chapter 5) in which serum had been examined for the 
presence of specific antibody one week after feeding 1 gg cholera 
toxin had failed to detect levels which were significantly different 
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from sham-fed controls. 
The serum fragment obtained after feeding OVA induced tolerance which 
was sensitive to CY. Treatment of donors did not alter intestinal 
epithelial cell structure (Ecknauer & Lährs, 1976; Hartwich 
et al, 1978; Mowat, 1981) or affect their ability either to take up 
antigen or generate serum tolerogen (Mowat, 1981; Strobel at el, 
1983) but treatment of recipients abrogated the induction of oral 
tolerance by serum transfer (Strobel at el, 1983; Bruce & Ferguson, 
1986a). Pretreatment of recipients with cyclophosphamide (100 mg/kg) 
also abrogated the induction of tolerance with serum from choleragen- 
fed donors (chapter 10). 
The inference from work with cyclophosphamide and OVA was that the 
serum tolerogen induced a distinct class of suppressor cell which did 
not act on antibody responses 
(Bruce, 1985) and this appeared to be 
substantiated by the report of the induction of DTH suppressor cells 
after feeding OVA 
(Miller & Hanson, 1979) and the description of a 
mouse suppressor cell for DTH which did not affect plaque-forming cell 
responses (Whisler & Strobo, 1978). It might be expected from the 
foregoing account that the suppressor T cell induced by feeding 
choleragen (chapters 8& 9) results from activation by the serum 
tolerogen above. In order to test this, serum obtained from toxin-fed 
mice was pooled and transferred to recipient animals. The recipients 
were left for 7 days and then half were Immunised and challenged as 
before and half were sacrificed. Spleen cells were obtained from the 
sacrificed serum recipients and transferred intraperitoneally to 
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another set of syngeneic mice who were parenterally immunised at the 
same time. Once immunised, these cell recipients were treated 
identically to the surviving serum tolerogen recipients. In this way 
the quality of the serum tolerogen could be assured while testing Its 
ability to induce suppressor cells. These experimental mice were 
accompanied by the appropriate sham-fed controls (chapter 10). Results 
showed that animals who received spleen cells from serum recipients of 
toxin-fed donors were not tolerised, yet the toxin-fed serum was able 
to tolerise recipients. This suggests that the splenic suppressor cell 
described earlier is not induced by the serum tolerogen obtained after 
feeding cholera toxin although further work Is required to confirm 
this. 
The apparent dissociation between the presence of serum tolerogen and 
the induction of splenic suppressor T cells does not rule out the 
possibility that the post-prandial serum fragment does Induce a 
suppressor cell. Certainly the ability of CY to prevent the transfer 
of tolerance to recipients would be an argument in its favour. Other 
sites of migration for orally-induced suppressor cells such as PP, MLN 
or thymus (Mattingly & Wakeman, 1978; Ngan & Kind, 1978; Richman 
et eI, 1981; MacDonald, 1982a, MacDonald 1982b) have not yet been 
examined and the possibilty of a circulating suppressor cell which 
migrates to the site of antigenic challenge has not been excluded. 
Indeed, both resident and circulating lymphocytes which act together in 
a synergistic fashion to produce antitoxin have been described after 
the oral administration of choleragen. It was postulated that the B 
cells disseminate from the site of initial exposure to more distant 
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regions of the MALT and then become resident. The circulating 
lymphocytes, thought most likely to be T cells, migrate continuously 
until recruited to the site of antigen challenge (Pierce & Gowens, 
1975; Pierce & Cray Jr, 1981). 
Further characterisation of the serum tolerogen in OVA-fed mice 
revealed that the fragment was in the molecular weight range of native 
OVA and had B cell determinants in common with the native protein 
(Bruce & Ferguson, 1986b). This serum fragment did not appear to be 
either deaggregated, denatured or native as Injections of all three of 
these preparations in the quantity found after feeding did not 
reproduce the effects of the gut processed antigen (Bruce & Ferguson, 
1986a). It has been postulated that the 'processed' OVA may be able to 
stimulate Ts directly as earlier work has shown that both B lymphocytes 
and T suppressor cells respond preferentially to tertiary antigenic 
structures (Feldmann & Kontiainen, 1976; Endres & Grey, 1980a; Endres & 
Grey, 1980b; Chesnut, Endres & Grey, 1980; Chesnut & Grey, 1985). 
Helper T cells, however, have been shown to respond to short lengths of 
protein primary structure presented in the context of class II MHC 
antigens (Ishizaka, Okudaira & King, 1975; Takatsu & Ishizaka, 1975; 
Chesnut at al, 1980; Unanue, Beller, Lu & Allen, 1984). 
Experiments have shown that procedures which Increase macrophage 
function are associated with the abrogation of oral tolerance and this 
has been taken as additional support for the above hypothesis (Mowat & 
Parrott, 1983; Strobel at al, 1985; Strobel & Ferguson, 1986). 
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Superficially, the experimental findings of this thesis would appear to 
be in conflict with the above hypothesis. The two forms of the toxin 
antigen (holotoxin and formalinised toxoid) do not appear to be equally 
efficient at priming for antibody responses. Anti-toxoid and antitoxin 
ELISA results suggest that this may be due to partial cross-reactivity 
between these two antigenic forms. However, these two proteins are 
equally good at boosting specific IgG antibody responses, shown to be 
mediated by antigen-specific T helper cells (Okumura at al, 1975; 
Schrader at al, 1976), and are equally good at stimulating 0TH 
responses. It would not be unreasonable to suggest from the foregoing 
account that these two antigenic forms have an identical primary 
structure and are therefore totally cross-reactive at the T helper/DTH 
effector T cell level. Indeed work using cells generated from single 
clones has suggested that for the murine immune response they may be 
one and the same thing (Bianchi at a1,1981; Milon at al, 1983). 
It would appear from the results on specific antibody responses that 
choleragen and the toxoid have different tertiary structures. It might 
also be expected, that if orally-induced suppressor T cells recognise 
tertiary structures of protein antigens, these two antigenic forms 
would not be equally efficient at inducing oral tolerance and that the 
tolerance so induced would not be immunologically cross-reactive. In 
fact, the reverse has been the case in that both choleragen and toxoid 
are equally capable of tolerising systemic DTH Induced by either 
protein. While it is clear that formalinisation effects a reductive 
alkylation of tyrosine and lysine residues and alters the antigenicity 
of proteins for B cells (Habeeb, 1969; Pancake & Nathenson, 1973; 
Peterson, 1979) it does not necessarily alter tertiary structures 
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recognised by T cells. Indeed, Hue and his colleagues demonstrated 
that formaldehyde treatment of cytotoxic target cells inhibited the 
binding of H-2-specific monoclonal antibodies but did not affect the 
ability of H-2-specific cytotoxic T cells to lyse them (Hue at al, 
1985). Work with mutant targets has shown that the cytotoxic clones 
used above respond to conformation-dependent determinants Involving 
contributions from both the alpha 1 and alpha 2 domains of 
H-2Kb (Sherman, 1982) and this suggests that formaldehyde treatment may 
only selectively destroy B cell determinants leaving T cell 
conformational determinants, such as seen by suppressor T cells, 
relatively intact. 
Other studies using native and denatured OVA have shown that these two 
forms of the antigen produced different effects when administered 
intravenously but produced totally cross-reactive tolerance when fed 
(Mowat, 1985). In addition to highlighting the difference between 
'classical' and oral tolerance this also would appear to suggest that 
tertiary antigenic structure may not be of importance in the induction 
of mucosally-associated suppressor mechanisms. Recent evidence 
suggests that accessory cells may be important in the induction of 
suppressor cells 
(Usui, Aoki, Sunshine & Dorf, 1984) and workers have 
demonstrated OVA-pulsed macrophages that induce suppressor cells which 
are reactive to both native and denatured forms of the antigen (Takatsu 
& Ishizaka, 1977). Interestingly, feeding native OVA was associated 
with the induction of splenic suppressor cells which induced tolerance 
to either antigenic form. The denatured protein also Induced tolerance 
to both forms of antigen but wes not associated with the induction of 
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splenic suppressor cells (Mowat, 1985). This would appear to be yet 
further evidence to suggest that several systems control the induction 
of systemic DTH. 
The study of the nature of gut-processed antigen is thus of fundamental 
importance in the understanding of oral tolerance. There are several 
approaches to this problem, some authors have examined the biochemical 
properties of fed antigen and tried to modify native proteins to 
reproduce the effect phenomenologically (Mowat, 1985; Bruce & Ferguson, 
1986a; Bruce & Ferguson, 1986b). Other workers have characterised 
suppressor and helper epitopes on proteins with a known sequence and 
have immunised mice with these epitopes in order to uncover the 
hierarchy in which they are recognised in responder and non-responder 
strains (Oki & Sercarz, 1985; Krzych, Fowler & Sercarz, 1985). This 
approach has not yet been used in the study of oral tolerance but it 
appears to be a promising technique. 
I am currently pursuing a different course by raising a series of 
monoclonal antibodies to choleragen and examining the presence or 
absence of antigenic epitopes on fed or native toxin. Furthermore, by 
raising anti-iditoypic antibodies to promising epitopes one may able to 
examine the precise na ture of this process more fully. 
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1L7 Areas for Further Investigation 
This thesis has highlighted two further areas of cholera immunity that 
warrant further investigation. 
This thesis has been the first to demonstrate choleragen's ability to 
stimulate cell-mediated immunity. While the presence of systemic CMI 
is of great interest in examining the processes of oral tolerance, it 
would be more appropriate, in view of the nature of this disease, to 
examine the state of cellular immunity within the intestinal mucosa. 
Now that several techniques exist to measure systemic CMI, it should 
be possible to employ these and other established morphometric and 
histological analyses of mucosal parameters (Ferguson & Parrott, 1973; 
MacDonald & Ferguson, 1977; Marsh, 1980; Marsh, 1981; Mowat & Ferguson, 
1982c) to study the presence of mucosal CMI in choleragen-fed animals. 
Furthermore, studies have shown that other mechanisms not related to 
specific antibody production may be responsible for protection against 
toxin-induced diarrhoea (Pierce et a1,1978; Pierce et al, 
1983; Lange et 81,1984a; Lange et el, 1984b; Lännroth 
et el, 1984). Workers have attributed this protection to the 
presence of a hormone-like factor which has been isolated from brain, 
pituitary and intestinal tissue 
(Lbnnroth & Lange, 1984; Lange & 
Lännroth, 1984; Lange & Lännroth, 1986) unfortunately they have not 
been able to demonstrate its presence in the circulation or explain the 
mechanism by which it exhibits antigen specificity (Lange et al, 
1984b; Linnroth et al, 1984). There Is evidence to suggest that 
local CMI may be induced in animals who are chronic carriers of the 
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cholera vibrio (Gorskaya et al, 1980; Efremov at al, 1982). In 
addition, the protection afforded by multiple feeds of choleragen is 
antigen-specific and is associated with the presence of various T-cell 
dependent phenomena (Lange at al, 1984b; Ldnnroth at al, 1984). CMI 
reactions occurring within the mucosa have been shown to alter a number 
of physiological processes within the gastrointestinal tract (Ferguson 
& Parrott, 1973; MacDonald & Ferguson, 1977; Castro, 1982; Mowat & 
Ferguson, 1982c; Ferguson, 1987). Therefore a project is underway to 
study the ability of orally administered choleragen to induce local CMI 
and whether specific mucosal CMI is involved in the downregulation of 
the enterocyte's sensitivity to choleragen-induced adenylate cyclase 
activation. 
There are many circumstances in which it would be of benefit to 
investigate the primary mucosal immune response to neoantigens in 
humans. At present it is difficult to accrue direct evidence of 
abnormalities of immune function within the gastrointestinal tract. 
Indirect evidence is normally obtained from morphometric, histological 
or immunohistochemical analyses of biopsy specimens, analysis of 
circulating antibody levels and specificites or skin test responses. 
It would be preferrable to study gut immune function directly and one 
approach would be the use of test antigens. These materials could then 
be fed and the resulting im mune responses could be measured in terms of 
specifically reactive cells and/or by the presence of products of a 
specific immune response. In order to be a successful candidate as a 
test antigen a substance would have to be immunogenic, non-toxic and 
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whose specifically-induced reactive cells or immune products could be 
easily measured. The B subunit of choleragen is such an antigen and 
this has been the rationale for characterising the mucosal regulation 
of the systemic immune response to the holotoxin In the first place. 
If a model for the effect of feeding choleragen can be established and 
cells and other products, which have been stimulated enterically, can 
be detected peripherally then the basis exists for similar critical 
analysis of gastrointestinal immune function in man. Many of these 
criteria have been satisfied for choleragenold In that both local and 
systemic antibodies directed against the B subunit have been detected 
after feeding (Svennerholm, Sack, Holmgren & Bardhan, 19821 
Svennerholm, Gothefors, Sack, Bardhan & Holmgren, 1984) and circulating 
lymphocytes capable of producing IgA antitoxin after short term culture 
have been isolated from the peripheral bloodstream after enteric 
administration of antigen 
(Lycke at al, 1985). These results have been 
obtained from both humans and mice illustrating how closely, to date, 
the murine model has resembled the immune responses observed in the 
human. Experiments performed in this thesis suggest that cells 
controlling systemic CMI disseminate from the Intestine after feeding 
choleragen, so the possibility exists that either regulatory or 
effector cells of CMI or both may also be found in peripheral blood of 
subjects fed choleragen. Further work on the migration of regulatory 
cells from GALT is therefore needed. There is the posaibilty that, 
unlike for humoral immunity, different cellular Immune responses may 
occur locally from those observed systemically after feeding 
choleragen. It would therefore be necessary to examine whether this 
divergence exists and to see to what extent the reactions of peripheral 
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blood lymphocytes reflect the immune response at different anatomical 
locations throughout the immune system. 
1L8 Conclusion 
This work represents a comprehensive Investigation of the systemic 
Immune effector response to parenterally administered cholera toxin and 
one of its detoxified derivatives. It has demonstrated that choleragen 
is able to modulate the induction of specific systemic Immunity when 
prefed. While feeding this antigen induces systemic antibodies, it 
also tolerises the induction of DTH. Although atypical in many 
respects, choleragen would appear to behave like other, more classical, 
enteric protein antigens with respect to the induction of oral 
tolerance for systemic DTH. 
These results have important implications. It is now clear that 
mucosal immune effector mechanisms, other than antibodies, must be 
considered as candidates for the protective process which prevents 
cholereic diarrhoea. The totally divergent effect of this antigen on 
the regulation of systemic immunity now allows us to carefully dissect 
both the physiology and anatomical location of antigen presentation 
within the gastrointestinal tract. It is apparent from other studies 
that rodents and humans respond with remarkable similarity to 
choleragen and its associated antigens, therefore finally, and perhaps 
most importantly, this project has laid the foundation for the specific 
analysis of oral tolerance and mucosal immunity in humans without the 
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need for invasive procedures. 
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